Novel strategies for spinal cord injury repair by Pomeshchik, Yuriy
Publications of the University of Eastern Finland
Dissertations in Health Sciences
isbn 978-952-61-1629-7
Publications of the University of Eastern Finland
Dissertations in Health Sciences
d
issertatio
n
s | 259 | Y
u
r
iy P
o
m
esh
ch
ik
 | N
ovel strategies for sp
in
al cord in
ju
ry rep
air
Yuriy Pomeshchik
Novel strategies for spinal cord 
injury repair Yuriy Pomeshchik
Novel strategies for spinal 
cord injury repair
Spinal cord injury (SCI) is a 
catastrophic condition resulting 
in loss of sensation, motor, and 
autonomic function. There is no 
effective therapy for SCI. This thesis 
demonstrates that interleukin-33 is a 
promising novel therapeutic approach 
for acute SCI. Special attention is 
paid to the protective role of the 
transcription factor Nrf2 in SCI. 
The thesis also evaluates potential 
therapeutic avenues in the utilization 
of Nrf2 gene transfer and stem cell 
therapy for SCI.
 
 
 
 
 
 
YURIY POMESHCHIK 
 
 
 
Novel strategies for spinal cord injury repair 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
To be presented by permission of the Faculty of Health Sciences, University of Eastern Finland  
for public examination in Medistudia Auditorium (MS300), Kuopio,  
on Friday, December 5th 2014, at 14.00 
 
 
Publications of the University of Eastern Finland 
Dissertations in Health Sciences  
Number 259 
 
 
Department of Neurobiology, A. I. Virtanen Institute for Molecular Sciences, 
Faculty of Health Sciences,  
University of Eastern Finland 
Kuopio 
2014 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Grano Oy 
Kuopio, 2014 
 
Series Editors:  
Professor Veli-Matti Kosma, M.D., Ph.D. 
Institute of Clinical Medicine, Pathology 
Faculty of Health Sciences 
 
Professor Hannele Turunen, Ph.D. 
Department of Nursing Science 
Faculty of Health Sciences 
 
Professor Olli Gröhn, Ph.D. 
A.I. Virtanen Institute for Molecular Sciences 
Faculty of Health Sciences 
 
Professor Kai Kaarniranta, M.D., Ph.D. 
Institute of Clinical Medicine, Ophthalmology 
Faculty of Health Sciences 
 
Lecturer Veli-Pekka Ranta, Ph.D. (pharmacy) 
School of Pharmacy 
Faculty of Health Sciences 
 
Distributor:  
University of Eastern Finland 
Kuopio Campus Library 
P.O.Box 1627 
FI-70211 Kuopio, Finland 
http://www.uef.fi/kirjasto 
 
ISBN (print): 978-952-61-1629-7  
ISBN (pdf): 978-952-61-1630-3 
ISSN (print): 1798-5706 
ISSN (pdf): 1798-5714 
ISSN-L: 1798-5706
III 
 
 
 
Author’s address: Department of Neurobiology 
A.I. Virtanen Institute for Molecular Sciences 
University of Eastern Finland 
70211 Kuopio 
KUOPIO 
FINLAND 
 
Supervisors: Professor Jari Koistinaho, M.D., Ph.D. 
Department of Neurobiology 
A.I. Virtanen Institute for Molecular Sciences 
University of Eastern Finland 
KUOPIO 
FINLAND 
 
Adjunct Professor Tarja Malm, Ph.D. 
Department of Neurobiology 
A.I. Virtanen Institute for Molecular Sciences 
University of Eastern Finland 
KUOPIO 
FINLAND 
 
Adjunct Professor Katja Kanninen, Ph.D. 
Department of Neurobiology 
A.I. Virtanen Institute for Molecular Sciences 
University of Eastern Finland 
KUOPIO 
FINLAND 
 
 
Reviewers: Professor Carine Ali, Ph.D.  
UMR-S INSERM U919 
Serine Proteases and Pathophysiology of the Neurovascular Unit 
GIP Cyceron  
CAEN Cedex  
FRANCE 
 
Adjunct Professor Henri Huttunen, Ph.D. 
Neuroscience Center 
University of Helsinki 
HELSINKI 
FINLAND 
 
Opponent: Professor Alfredo Gorio, M.D, Ph.D. 
Department of Health Sciences  
Faculty of Medicine  
University of Milan 
MILAN 
ITALY  
IV 
 
 
 
  
V 
 
 
 
Yuriy Pomeshchik 
Novel strategies for spinal cord injury repair, 114 p. 
University of Eastern Finland, Faculty of Health Sciences, 2014 
Publications of the University of Eastern Finland. Dissertations in Health Sciences. Number 259. 2014. 114 p. 
 
ISBN (print): 978-952-61-1629-7 
ISBN (pdf): 978-952-61-1630-3 
ISSN (print): 1798-5706 
ISSN (pdf): 1798-5714 
ISSN-L: 1798-5706 
 
ABSTRACT 
 
Traumatic spinal cord injury (SCI) is a catastrophic condition affecting primarily young 
males. The insult to the spinal cord results in functional impairment and loss of sensation 
and autonomic function below the injury level, often leaving patients bound to a 
wheelchair. Treatment options for SCI are limited to high doses of methylprednisolone 
(MP), the side effects of which overpower relatively modest neurological improvements. 
SCI is biphasic in nature with the primary trauma triggering the multicomponent 
secondary injury cascade that greatly augments initial damage. While the primary damage 
is irreversible the secondary injury is an attractive target for therapeutic interventions. 
Oxidative stress and inflammation are interrelated key components of the secondary injury 
cascade. The transcription factor nuclear factor (erythroid-derived 2)-like 2 (Nrf2) is 
important for endogenous protection from oxidative stress, whereas interleukin-33 (IL-33) 
has potential to modulate adaptive and innate immunity. Induced pluripotent stem cells 
(iPSCs) lack many drawbacks of other stem cell types and are a novel, promising cell source 
for SCI regeneration. In the present study we aimed to investigate whether Nrf2 gene 
transfer, pharmacological IL-33 treatment and iPSCs transplantations alleviate secondary 
injury and improve functional recovery after contusion SCI.  
Our results demonstrated the sustained nature of Nrf2 and IL-33 activation after 
contusion SCI. We identified astrocytes as the main reservoir of intracellular IL-33. Using 
mice deficient for Nrf2 we confirmed the essential role of Nrf2 in SCI pathophysiology and 
discovered new mechanisms of Nrf2-mediated protection. Transfer of the Nrf2 gene into 
the spinal cord with a lentivirus vector resulted in overexpression of Nrf2 in astrocytes and 
neurons. Gene therapy resulted in a number of side effects and did not provide extra 
benefit over natural Nrf2 induction. In contrast, recombinant IL-33 showed great promise 
as a novel treatment for SCI. IL-33 modulated inflammation in the spinal cord and in the 
periphery, leading to attenuated secondary injury and improved functional recovery. 
Despite iPSC therapy being safe and transplanted cells having had the potential to 
differentiate into neurons in vivo they neither survived nor improved functional recovery 
when transplanted into contused spinal cord. Scarce survival of transplanted cells may be 
attributed to insufficient levels of immunosuppression provided by monotherapy with 
calcineurin inhibitor Tacrolimus.   
The results of this thesis provided new insights into the complex pathophysiology of 
secondary damage after traumatic SCI and highlighted the importance of its proper 
regulation. Modulation of the inflammatory response with IL-33 treatment represents a 
promising therapeutic approach for patients with acute contusion SCI. Although Nrf2 gene 
transfer and iPSCs transplantation did not provide the expected benefits, our results are 
important for the further, successful development of these treatments in the future. 
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TIIVISTELMÄ 
 
Traumaattinen selkäydinvaurio on laaja-alainen kehon toimintaa vaikeuttava vamma, 
jonka riskiryhmään kuuluvat nuoret miehet. Selkäydinvaurio johtaa toiminta- ja 
liikuntakyvyn menetykseen ja autonomisen hermoston toiminnan häiriöihin. Koska 
selkäydinvammoihin ei ole olemassa tehokasta hoitoa, on uusien hoitomuotojen 
kehittämisen tarve suuri.  
Selkäydinvaurion jälkeiset sekundaariset patologiat, kuten tulehdusreaktio ja 
hapettumisvauriot voimistavat selkäydinvamman aiheuttamaa ensivauriota.  
Nrf2-transkriptiotekijä säätelee tärkeää solujen puolustuskokonaisuutta, joka koostuu 
sadoista hapettumisvaurioilta suojaavista geeneistä. Interleukiini-33 (IL-33) on elimistön 
oma sytokiini, joka säätelee immuunivastetta. Indusoidut pluripotentit (iPSCs) kantasolut 
ovat erilaistuneista soluista ohjelmoituja kantasoluja, joilla on kyky erilaistua miksi tahansa 
elimistön soluksi. Niiden käyttöön liittyvien vähäisten eettisten ongelmien ja olemattomien 
yhteensopivuusongelmien vuoksi iPSC-solut ovat mullistaneet kantasoluterapian. 
Tämän työn tavoitteena oli tutkia kolmea uutta hoitomuotoa, joiden ajateltiin 
vaikuttavan selkäydinvaurion sekundaarista patologiaa lieventävästi ja toiminnallista 
palautumista edistävästi: Nrf2 geeniterapia, IL-33 hoito ja kantasoluterapia. 
Tutkimustulokset osoittavat, että lentivirusvälitteinen Nrf2-geeninsiirto hiirten 
selkäytimeen ei vähennä selkäydinvammaan liittyviä oireita. Sen sijaan Nrf2-tekijän 
poistaminen lisää selkäydinvammaan liittyvää toiminnallista heikentymistä, osoittaen siten 
Nrf2-tekijän olevan erittäin tärkeä selkäydinvauriosta toipumisessa.   
IL-33-hoidolla aikaansaatiin tehokas, solujen luonnollista tulehdusvastetta säätelevä 
hoitovaste selkäydinvauriossa. Hoito vähensi selkäydinvamman jälkeistä sekundaarista 
patologiaa ja paransi vaurioon liittyvää toiminnallista heikentymistä hiirissä. 
Lääkinnällinen immuunivasteen heikentäminen ei parantanut ihmisperäisten 
kantasolujen selviytymistä hiiren vaurioituneessa selkäytimessä. Siten soluterapia ihmisen 
iPSC-soluista erilaistetuilla aivosoluilla ei lievittänyt selkäydinvaurioon liittyvää 
toiminnallista heikentymistä hiirissä. Tutkimustulokset korostavat immuunivasteen 
huomioimisen tärkeyttä kantasoluterapiassa. 
Tämän väitöskirjatutkimuksen perusteella todettiin, että sekundaarista patologiaa 
säätelevä IL-33-terapia on uusi ja lupaava hoitomuoto selkäydinvauriossa. Lisäksi 
havainnot kantasoluterapian ja Nrf2-tekijän vaikutuksista lisäävät ymmärrystämme näihin 
kohdistuvien terapiamuotojen edellytyksistä ja tulevat tulevaisuudessa lisäämään uusien, 
tehokkaiden hoitomuotojen kehittämisen mahdollisuuksia selkäydinvauriossa. 
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 1 Introduction 
The oldest known trauma textbook in history, the Edwin Smith papyrus (1700 BCE), 
described spinal cord injury (SCI) as a ‘’medical condition that cannot be healed” (van 
Middendorp et al., 2010). Now, more than 3700 years later, despite enormous progress in 
clinical medicine and preclinical research, damage from SCI is largely irreversible and SCI 
remains a catastrophic condition for which treatment is mostly palliative (Kwon et al., 2013; 
Mothe and Tator, 2013; Varma et al., 2013; Silva et al., 2014).  
SCI is a sudden and unexpected condition affecting primarily young males and resulting 
in early invalidization. Motor function impairments up to tetraplegia (Figure 1) and/or loss 
of sensation and autonomic function developing after SCI seriously diminish the quality of 
life of injured individual and lead to social isolation (Rooney et al., 2009; Chen Y et al., 2013). 
Currently the management of acute SCI involves surgical decompression followed by 
physical therapy and rehabilitation. Pharmacological interventions are limited to high 
doses of synthetic glycocorticoid methylprednisolone (MP) (Hurlbert et al., 2013; Varma et 
al., 2013). However, the advantages of high-dose MP for SCI treatment are very 
controversial due to serious adverse effects and relatively modest neurological 
improvements (Bracken et al., 1990; Hurlbert et al., 2013). Therefore, there is urgent need to 
explore new therapeutic strategies for restoring the neurological function after SCI and also 
to expand the knowledge on the cellular and molecular mechanisms of this devastating 
condition.   
 
Figure 1. Extent of injury due to damage of specific spinal segments (modified from Thuret et 
al., 2006).   
 
Primary mechanical injury destroys glial and neural elements and triggers the secondary 
injury cascade that induces the delayed death of cells surviving after initial trauma. 
Secondary injury greatly increases the neurological deficit and complicates the restoration 
of spinal cord function (Tator, 1995; Kwon et al., 2004; Oudega, 2013). Multiple mechanisms 
participate in the complex secondary injury cascade and amplify the initial damage. 
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Oxidative stress and the inflammatory response are well-established critical components of 
the secondary injury cascade and probably occupy a central place in pathophysiology of the 
secondary damage. Importantly, these processes are closely interrelated and augment each 
other (Rowland et al., 2008).  
Oxidative stress resulting from the excessive production of reactive oxygen species (ROS) 
and exhaustion of the endogenous antioxidant system (Halliwell et al., 2007) induces a 
number of detrimental processes such as lipid peroxidation, protein oxidation, and DNA 
damage (Smith et al., 2013). At the front line of defence against oxidative stress is the 
transcription factor nuclear factor (erythroid-derived 2)-like 2 (Nrf2). Under oxidative and 
electrophilic stresses, Nrf2 dissociates from its cytosolic negative regulator Kelch-like ECH-
associated protein 1 (Keap1) and translocates to the nucleus to induce gene expression of 
hundreds cytoprotective genes that contain an antioxidant response element (ARE) in their 
promoter region (Itoh et al., 1997, 1999, 2010; Kobayashi and Yamamoto, 2006; Baird and 
Dinkova-Kostova, 2011). Therefore, activation of the Nrf2-ARE pathway represents an 
endogenous compensatory response to oxidative stress in order to restore impaired redox 
balance (Zhang et al., 2013). While the importance of the Nrf2-ARE system has been proven 
in brain injury models such as stroke and traumatic brain injury (TBI) (Chen and Regan, 
2007; Tanaka et al., 2011; Shang et al., 2013), the contribution of Nrf2-ARE in protection 
from SCI is scarcely investigated and mainly limited to compression SCI model (Mao et al., 
2010, 2011, 2012), warranting the need for comprehensive research of Nrf2 functions in 
more relevant SCI models.  
Gene therapy approaches hold great promise for the treatment of different incurable 
diseases. Gene transfer with viral vectors allows the delivery of therapeutic genes to target 
cells. While gene therapy has already entered into clinical trials for several 
neurodegenerative diseases (Mandel, 2010; LeWitt et al., 2011; Palfi et al., 2014) its 
advantages are largely unexplored in SCI models. Gene delivery of transcription factors is 
especially attractive as it enables simultaneous induction or repression of several genes 
sharing a common regulatory pathway. Therefore, Nrf2 gene transfer after SCI may 
provide induction of numerous cytoprotective genes helping the cells to cope with 
secondary injury.  
Various cells types and mediators participate in the highly complex inflammatory 
response after SCI (Rowland et al., 2008; Plemel et al., 2014). Primary injury disrupts the 
blood-spinal barrier (BSB) and triggers the release of pro-inflammatory mediators from the 
activated resident central nervous system (CNS) cells, resulting in influx of neutrophils, 
monocytes and lymphocytes from the blood stream (Hausmann, 2003; Pineau and Lacroix, 
2007; Donnelly and Popovich, 2008; Beck et al., 2010). For a long time inflammation has 
been considered to be absolutely deleterious for regeneration and functional recovery 
(Taoka et al., 1997; Popovich et al., 1999; Young, 2002). However, gradually it became clear 
that immune cells are highly heterogeneous and not all immune subsets are detrimental for 
SCI recovery. Some are even beneficial and essential. The scarce effect of traditional anti-
inflammatory drugs further supported the view that abolishing inflammation is not a 
feasible therapeutic strategy for SCI. Instead, immunomodulatory therapy that promotes 
the skewing of pro-inflammatory cells into an anti-inflammatory phenotype is believed to 
allow the harnessing of beneficial components of inflammation and facilitation of functional 
recovery (Rossignol et al., 2007; David et al., 2012; Plemel et al., 2014). Interleukin-33 (IL-33), 
a member of the IL-1 cytokine family, is known to possess immunomodulatory properties 
and therefore represents an attractive tool for SCI repair.    
Stem cell -based approach for SCI repair emerged in the middle of 1990s. Since that time 
various types of cells have been tested in preclinical studies and some even moved to the 
clinical trial phase (Fehlings and Vawda, 2011; Mothe and Tator, 2012, 2013; Silva et al., 
2014). Transplanted stem cells are believed to replace damaged neuronal and glial cells, 
provide trophic support for the surviving cells, facilitate remyelination and create an 
environment favorable for regeneration (Fehlings and Vawda, 2011; Mothe and Tator, 2012, 
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2013). Inherently specified to differentiate along the neural lineage neural stem/progenitor 
cells (NS/PCs) may be derived from the adult and fetal CNS, pluripotent embryonic stem 
cells (ESCs) or induced pluripotent stem cells (iPSCs). While autologous derivation of adult 
CNS-derived NS/PCs is almost impossible in clinical settings (Fehlings and Vawda, 2011; 
Faulkner et al., 2014) and the use of ESCs-derived NS/PCs is very limited by ethical, safety 
(potential tumorigenesis) and immunological (allogeneic nature) reasons (Mothe and Tator, 
2013), iPSC-NS/PCs derived directly from a patient’s own somatic cells almost do not have 
these limitations (Fehlings and Vawda, 2011; Kramer et al., 2013; Nakamura and Okano, 
2013). The existing preclinical studies estimating the efficiency of iPSC-derived NS/PCs 
provided very promising preliminary results. However, they mainly utilized 
immunodeficient rodents to avoid the host immune response (Nori et al., 2011; Fujimoto et 
al., 2012; Lu et al., 2014; Sareen et al., 2014), which is not very relevant to clinical settings. 
 This study was carried out to estimate the effect of three novel therapeutic strategies on 
recovery from contusion SCI. First, we employed a gene therapy approach to deliver 
transcription factor Nrf2 into contused mouse spinal cord with the aim of boosting Nrf2-
ARE pathway and enhancing endogenous defence in response to secondary injury. Prior to 
Nrf2 gene transfer we evaluated whether the Nrf2-ARE pathway responds to SCI and 
determined the magnitude and duration of this response. Furthermore, we investigated the 
role of the Nrf2-ARE system in secondary injury using mice deficient for the Nrf2 gene. 
Next, utilizing a pharmacological approach we assessed whether IL-33, a member of the IL-
1 family, is able to beneficially modulate the inflammatory response after SCI by reducing 
secondary injury and promoting functional recovery. Both peripheral and central 
mechanisms of IL-33 action after contusion SCI were identified. Finally, we assessed the 
potential of human iPSC-derived NPCs subacutely transplanted into contused spinal cord 
to survive and promote functional recovery when pharmacological immunosuppression 
was used to avoid the host immune response. 
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2 Review of the literature 
2.1 SPINAL CORD INJURY (SCI) 
2.1.1 Definition and epidemiology of SCI 
SCI is defined as any traumatic injury to the spinal cord. It demolishes neural and glial 
cells and interrupts pathways connecting the brain and the rest of the body. Disruption of 
nerve connections results in sensory loss, paralysis and loss of autonomic function (Rooney 
et al., 2009; Nutt et al., 2013; Olson, 2013). 
Although reliable information on the epidemiology for traumatic SCI is unavailable for 
many countries, it is clear that incidence, prevalence, and injury etiology vary considerably 
from region to region (Burns and O'Connell, 2012). Worldwide, about 2.5 million people 
suffer from SCI, with more than 130,000 new cases reported each year (Thuret et al., 2006; 
Rossignol et al., 2007). In the United States, the incidence of SCI is approximately 40 cases 
per million individuals per year (Rosner et al., 2012), whereas the number of people who 
currently suffer from SCI is estimated to be around 253,000, with 11,000-12,000 new cases 
occurring every year (Rosner et al., 2012; Silva et al., 2014). Importantly, this amount does 
not include injuries that result in death prior to hospitalization and therefore the incidence 
of SCI is underestimated (Rosner et al., 2012). In Finland the incidence of SCI is about 14 
cases per million individuals per year (Ahoniemi et al., 2008), resulting in about 60–70 new 
cases per year (Ahoniemi et al., 2011).  
The leading cause of SCI is traffic accidents, causing up to 30-50% of all injuries. Among 
other reasons are falls, penetrating bullet wounds and other forms of violence, sport, and 
work-related accidents (Sekhon and Fehlings, 2001; Rosner et al., 2012; Chen et al., 2013; 
Silva et al., 2014). Interestingly, in Finland during 1976-2005 the majority of SCI cases were 
the result of falls (41,2%), whereas traffic accidents (39,5%) were only the second leading 
cause (Ahoniemi et al., 2011).  
Approximately 80% of all SCI occur among males and the most common age of SCI is 
between the ages of 16 and 30 years (Chen et al., 2013). This young onset of lifelong 
invalidization results in particularly high personal and economic costs (Rosner et al., 2012). 
In the late 1990s the total direct costs of treating individuals with SCI exceeded $7 billion 
per year in the United States only (McDonald and Sadowsky, 2002).  
Although the life expectancy after SCI is good overall, such important handicaps as 
paralysis, sensory loss, pain, pressure sores, urinary and other infections seriously diminish 
the quality of life for SCI patients (Rossignol et al., 2007).  
2.1.2 Classification of SCI  
SCI may be neurologically complete or incomplete based on sacral sparing, which is 
defined as the presence of sensory or motor function in the most caudal sacral segments as 
determined by the neurological examination. The presence of any sensory and/or motor 
function below the neurological level that includes the lowest sacral segments, S4-S5, 
indicates that the injury is incomplete. If no sensory and motor function is preserved in 
these most caudal sacral segments the injury is defined as complete (Waters et al., 1991; 
Kirshblum et al., 2011).  
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2.2 THE CONCEPT OF PRIMARY AND SECONDARY INJURY 
Understanding the biochemical and cellular events composing SCI pathophysiology is 
extremely important for the development of effective therapeutic interventions. SCI 
pathogenesis is best described as a biphasic process consisting of an initial primary and a 
progressive secondary phase of injury (Tator, 1995; Kwon et al., 2004; Rowland et al., 2008; 
Oyinbo, 2011; Silva et al., 2014). 
2.2.1 Primary injury 
Although tumor growth or other disorders can lead to SCI, the initial mechanical damage 
more often is the result of a) contusion or compression by a blunt force, b) laceration or 
transection of the spinal cord caused by a sharp penetrating force, c) infarct which can be 
caused by a vascular insult (DeVivo et al., 2002; Silva et al., 2014). While the transection or 
full disrupture of the anatomical continuity of the spinal cord occurs relatively rarely 
(Rowland et al., 2008), the most common form of acute SCI in humans is a compressive-
contusive trauma. In this type of injury displaced bone fragments exert force on the spinal 
cord, leading to immediate mechanical damage, which is often followed by persistent 
compression (Sekhon and Fehlings, 2001; DeVivo et al., 2002; Mekhail et al., 2012). 
 Primary damage is defined as the immediate effect of an injury to the spinal cord. 
Regardless of the cause, the initial impact leads to rapid cell necrosis in the immediate 
vicinity of the injury site, especially in the central gray matter. The death of endothelial cells 
and disruption of local blood vessels result in an intraparenchymal hemorrhage, BSB-
dysfunction, and compromised oxygen and nutrient supply to the damaged area and its 
surroundings. Local neurons, astrocytes, oligodendrocytes and endothelial cells die due 
either to direct mechanical damage to the cell membranes or ischemia developing after the 
disruption of microvessels (Hausmann, 2003; Kwon et al., 2004; Hagg and Oudega, 2006; 
Rowland et al., 2008; Ek et al., 2010; Oyinbo, 2011). Immediately after impact the activation 
of microglia, the resident immune cells of the CNS (Yang et al., 2004; Donnelly and 
Popovich, 2008), and upregulation of tumor necrosis factor (TNF) and IL1-β are observed 
(Yang et al., 2004; Pineau and Lacroix, 2007). Activation of microglial cells has been 
detected around damaged axons as early as 30 minutes after human SCI. However, no 
influx of neutrophils and macrophages were observed at this timepoint (Yang et al., 2004).  
In addition, the levels of extracellular glutamate reach excitotoxic levels already within 
minutes after injury (Wrathall et al., 1996). Vascular damage and developing inflammation 
lead to edema or swelling of spinal cord tissue soon after initial impact (Hagg and Oudega, 
2006; Rowland et al., 2008). The primary phase lasts approximately 2 hours and results in 
instant impairment or even loss of functions at and below the level of injury (Norenberg et 
al., 2004; Hagg and Oudega, 2006).   
Soon the primary damage is followed by spreading of secondary tissue damage from the 
injury core both horizontally into white matter and rostro-caudally into the gray matter, 
aggravating the spinal cord pathology (Tator, 1995; Kwon et al., 2004; Oyinbo, 2011; 
Oudega, 2013). This secondary injury occurs within minutes to weeks after initial impact 
and induces delayed damage and death to cells that survive the original trauma (Oyinbo, 
2011; Silva et al., 2014). As the result of secondary injury the area of primary damage 
enlarges significantly. 
Due to unexpectedness and short duration the primary injury to the spinal cord cannot 
be prevented or treated and therefore, treatment strategies are directed mainly to 
combating secondary injury mechanisms (Kwon et al., 2004; Stirling and Yong, 2008; 
Stirling et al., 2009; Fehlings and Nguyen, 2010; Oyinbo, 2011; Raslan and Nemecek, 2012). 
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2.2.2 Secondary injury 
More than 100 years ago it was for the first time noted that secondary damage occurs 
after SCI. These observations were based on the fact that inflammatory fluid removal 
improved neurological functions in injured dogs (Allen, 1911). The observed improvement 
was associated with the presence of a harmful agent in the inflammatory fluid, exacerbating 
damage to the spinal cord (Allen, 1914).  
As of today, more than 25 different secondary mechanisms have been described (Oyinbo, 
2011). Importantly, these processes are interrelated and often positively influence one 
another to promote secondary damage. The most significant of them are vascular 
disturbances, ionic balance disturbances and excitoxicity, free radical formation and lipid 
peroxidation, inflammation, astroglial scar formation and demyelination.  
2.3 VASCULAR EVENTS AFTER SCI 
Vascular disruption, hemorrhage and ischemia are some of the most important aspects 
of the secondary injury cascade (Tator and Fehlings, 1991; Mautes et al., 2000b; Kwon et al., 
2004; Oudega, 2012).  
Within several hours after initial impact microvascular damage increases and spreads in 
all directions. Thus, intraparenchymal hemorrhage is initially localized in the highly 
vascularized gray matter and subsequently expands into the adjacent white matter (Noble 
and Wrathall, 1989; Tator and Koyanagi, 1997; Mautes et al., 2000b). Blood itself is harmful 
for the nervous tissue probably due to hemoglobin, which contains iron (Sadrzadeh et al., 
1987). Recently, iron accumulating in macrophages due to phagocytosis of red blood cells 
was identified as one of the main reasons leading to polarization of macrophages to pro-
inflammatory M1 phenotype and determining their chronic persistence in the injured spinal 
cord (Kroner et al., 2014). Secondly, in areas surrounding hemorrhages the blood supply is 
usually compromised, resulting in different grades of ischemia. Vasogenic edema, 
vasospasm, direct compression by adjacent tissue and thrombosis all may contribute to the 
posttraumatic ischemia (Tator and Fehlings, 1991; Mautes et al., 2000b). Ischemia, in turn, 
leads to a sharp decrease in oxygen and glucose required for cell metabolism with the 
subsequent accumulation of cytotoxic proteolytic enzymes and ROS resulting in cell death 
and tissue loss (Hagg and Oudega, 2006; Oudega, 2012). Importantly, the restoration of 
blood supply and return of oxygen to ischemic tissues causes an increase in free radicals 
and ROS, contributing to additional tissue damage known as reperfusion injury (Oudega, 
2012). 
Damage of blood vessels also leads to accumulation of interstitial fluid. Lack of drainage 
of interstitial fluid causes edema or swelling, resulting in the additional compression of 
nervous tissue (Oudega, 2012). Compression may additionally aggravate ischemia (Hagg 
and Oudega, 2006). 
Another feature of vascular disturbances in the secondary injury phase is the breakdown 
of the BSB leading to the influx of blood cells, including neutrophils, T-lymphocytes and 
macrophages, which in their own way contribute to secondary damage (Popovich, 2000; 
Hausmann, 2003; Profyris et al., 2004; Hagg and Oudega, 2006; Donnelly and Popovich, 
2008). In the secondary injury phase, a number of inflammatory mediators are capable of 
altering BSB permeability. The cytokines TNF and IL-1β, free radicals, and histamine are 
known to induce BSB damage in spinal cord (Schnell et al., 1999; Donnelly and Popovich, 
2008; Rowland et al., 2008). In addition, the important roles of endothelin-1 and matrix 
metalloproteinase-9 (MMP-9) in BSB dysfunction after SCI have been reported (Mautes et 
al., 2000b; Noble et al., 2002). BSB permeability typically peaks at 24 hours following injury 
and lasts at least for 2-4 weeks (Noble and Wrathall, 1989; Popovich et al., 1996; Mautes et 
al., 2000b). 
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2.4 ELECTROLYTE IMBALANCE AND EXCITOTOXICITY AFTER SCI 
Ionic imbalance and excitotoxicity are closely related processes contributing to the 
propagation of secondary injury after SCI (Rowland et al., 2008). The SCI-induced damage 
of plasma membranes leads to the disruption of physiological ion balance resulting in 
intracellular calcium and sodium rise (Hamann and Shi, 2009). An additional contribution 
to the rise in intracellular calcium is provided by glutamate excitotoxicity (Kwon et al., 2004; 
Hamann and Shi, 2009). Glutamate, the most prevalent excitatory neurotransmitter in the 
CNS (Choi, 1992; Kwon et al., 2004; Oyinbo, 2011), is released and accumulates rapidly 
within and around the injury site in response to ischemia and membrane depolarization 
(Wrathall et al., 1996; McAdoo et al., 1999). The increased extracellular glutamate levels lead 
to excessive stimulation of glutamate receptors, such as N-methyl-D-aspartate (NMDA) 
and alpha-amino-3-hydroxy-5-methyl-isoxazolepropionate (AMPA)/kainate receptors 
through which ions, and particularly calcium and sodium, pass. Therefore, excessive 
activation of these receptors leads to the uncontrolled influx of extracellular calcium and 
sodium into the cell (Choi, 1992; Fehlings and Agrawal, 1995; Agrawal and Fehlings, 1996, 
1997; Kwon et al., 2004). Calcium influx, in turn, leads to release of intracellular calcium 
stores (Sattler and Tymianski, 2000). Other factors contributing to calcium overload after 
SCI are free radicals and oxidative stress (Xiong et al., 2007) resulting in inhibition of two 
enzymes extremely sensitive to free radical damage, Ca2+-ATPase and Na+/K+-ATPase. 
These enzymes are responsible for regulation of ionic homeostasis (Rohn et al., 1996; Hall, 
2011). The rise in intracellular calcium causes the activation of proteases such as calpains, 
resulting in degradation of cytoskeletal proteins. In addition, high levels of intracellular 
calcium activate caspases and phospholipases, cause mitochondrial dysfunction and 
increased generation of ROS, ultimately leading to apoptotic death of the cells (Lu et al., 
2000; Kwon et al., 2004; Park et al., 2004; Hamann and Shi, 2009).  
2.5 OXIDATIVE STRESS AFTER SCI 
Oxidative stress is a well-established critical component of the secondary SCI damage 
contributing to axonal disruption and the death of neuronal and glial cells (Hall and 
Braughler, 1989; Hamann et al., 2008; Rowland et al., 2008; Hamann and Shi, 2009; Hall, 
2011; Jia et al., 2012). Recent clinical observations confirmed that SCI patients display 
increased oxidative stress and reduced antioxidant defence for at least one year after injury 
(Bastani et al., 2012). 
2.5.1 Free radical production and their detrimental effects in SCI 
Compared to other organs the CNS, including spinal cord, is particularly susceptible to 
oxidative stress and free radical damage due to its active oxygen metabolism and low 
antioxidant capacity (LeBel and Bondy, 1991; Andersen, 2004; Sayre et al., 2008; Li et al., 
2013; Singhal et al., 2013). Moreover, the cell membranes in brain and spinal cord are highly 
rich in polyunsaturated fatty acids, such as linoleic acid and arachidonic acid, which are 
most vulnerable to oxidation (Mautes et al., 2000a; Sayre et al., 2008; Hamann and Shi, 2009; 
Singhal et al., 2013). 
Free radicals, including ROS and reactive nitrogen species (RNS), are molecules that 
contain one or several unpaired electrons, making them highly reactive. Molecular oxygen 
has two unpaired electrons. The addition of one electron to molecular oxygen leads to 
formation of superoxide. If two electrons are transferred, the product is hydrogen peroxide. 
Although hydrogen peroxide is not a free radical, it is still a damaging ROS as it is able to 
penetrate biological membranes. Transferring a third electron to hydrogen peroxide 
produces a highly reactive hydroxyl radical. When superoxide interacts with nitric oxide it 
produces a highly reactive free radical called peroxynitrite. The oxidation process caused 
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by free radicals geometrically generates more ROS that promote the reaction across the cell 
surface (Lewen et al., 2000; Kwon et al., 2004; Jia et al., 2012) 
There are several reasons leading to free radical production and oxidative stress in the 
secondary injury phase. ROS are rapidly generated in spinal cord tissue during ischemia 
and also upon subsequent reperfusion (Sakamoto et al., 1991; Mautes et al., 2000a; Oudega, 
2012). Among other reasons are mitochondrial dysfunction, glutamate-mediated increase of 
intracellular calcium, release of iron from storage proteins due to acidosis, and liberation of 
catalytically active metal ions due to hemoglobin degradation following hemorrhage. 
Phagocytic cells, such as activated microglia and infiltrating neutrophils and macrophages 
provide additional sources of ROS (Mautes et al., 2000a; Hausmann, 2003; Bao et al., 2004; 
Xiong et al., 2007; Hamann and Shi, 2009; Hall, 2011; Jia et al., 2012).  
Although the generation of ROS under physiological conditions is important for normal 
cellular redox reactions, the imbalance between ROS formation and antioxidant defence 
system under pathophysiological conditions, such as SCI, leads to excessive production of 
ROS, consequent oxidative stress and secondary cell death. The main damage to cells is 
caused by ROS-induced oxidation of polyunsaturated fatty acids in the plasma membranes 
(lipid peroxidation), oxidation of amino acids in proteins, DNA alteration, Ca2+-ATPase and 
Na+/K+-ATPase inhibition, Ca2+ overload and enhancement of glutamate-mediated 
excitotoxicity (Rohn et al., 1996; Kwon et al., 2004; Park et al., 2004; Xiong et al., 2007; 
Hamann et al., 2008; Hall, 2011; Jia et al., 2012).  
The byproducts of lipid peroxidation are aldehydes, such as malondialdehyde, 4-
hydroxynonenal and α, β-unsaturated acrolein. Acrolein may play a particularly important 
role in SCI cell damage since it is the most reactive and toxic of all known unsaturated 
aldehydes (Esterbauer et al., 1991; Luo and Shi, 2004; Park et al., 2014). Acrolein has a 
significantly longer half-life than the transient ROS and rapidly accumulates in the spinal 
cord following injury, inducing severe membrane disruption through mechanisms 
including ROS generation and subsequent lipid peroxidation. Its formation may thus 
represent a bioamplification step. Importantly, acrolein has been shown to diffuse away 
from the injury site to neighboring healthy tissue and therefore further propagate 
secondary injury following initial mechanical trauma. In addition to membrane damage, 
acrolein can impair cellular glucose transport and glutamate uptake in surviving neurons 
and glia leading to cell death due to excitotoxicity. Moreover, acrolein readily forms 
conjugates with glutathione, resulting in glutathione depletion and compromise of the 
endogenous antioxidant system (Lovell et al., 2000; Luo and Shi, 2004; Luo et al., 2005; 
Hamann et al., 2008; Hamann and Shi, 2009). More recently, it has been shown that acrolein 
is also involved in myelin damage, suggesting its detrimental role in SCI-induced 
demyelination (Shi et al., 2011). Importantly, when injected into uninjured rat spinal cord 
acrolein induces motor deficits and tissue damage (Park et al., 2014). 
In addition to ROS, peroxynitrite, generated by the interaction of nitric oxide and 
superoxide, and peroxynitrite-derived radicals, such as hydroxyl radical, nitrogen dioxide 
radical and carbonate radical, have been shown to play not less important, but maybe even 
more crucial role in oxidative damage after SCI (Liu et al., 2000, 2005; Bao and Liu, 2002, 
2003; Xiong et al., 2007; Hall, 2011). 
2.5.2 Extreme role of Nrf2-ARE pathway in endogenous protection from oxidative stress 
During evolution cells have developed multiple defence mechanisms to protect 
themselves from oxidative stress. They range from free radical scavengers and antioxidant 
enzymes to sophisticated repair mechanisms (Kryston et al., 2011). These mechanisms also 
involve the activation of redox-sensitive endogenous inducible defence systems. The 
transcription factor Nrf2 is the major regulator of such systems in the body (Sandberg et al., 
2014) and belongs to the basic leucine zipper transcription factor family, which also 
contains NF-E2, Nrf1, Nrf3, Bach1, and Bach2 (Motohashi et al., 2002). Since Nrf2 
modulates expression of hundreds cytoprotective genes in response to changes in the redox 
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state of the cell it is often referred to as the ‘’master regulator’’ of the antioxidant, 
detoxification, and cell defence response (Hybertson et al., 2011; Gan and Johnson, 2014; 
Gao et al., 2014). Nrf2 was initially identified about 20 years ago (Moi et al., 1994) and today 
it is known to regulate not only a series of phase II detoxification and antioxidant genes, but 
also cell survival, anti-inflammatory, energy metabolism, and other groups of genes that 
contain a cis-acting DNA sequence, termed the antioxidant response element (ARE), in their 
promoter region (Hybertson et al., 2011; Gao et al., 2014). It therefore plays an extreme role 
in endogenous cellular protection from oxidative damage.   
Under basal conditions Nrf2 is bound in the cytoplasm to its negative regulator Keap1 
which functions as a substrate adaptor protein for Cullin3/Rbx1 E3 ubiquitin ligase complex 
and continuously directs Nrf2 to ubiquitination and degradation by the 26S proteasome 
(Cullinan et al., 2004; Kobayashi et al., 2004; Zhang et al., 2004). Under normal physiological 
conditions the half-life of Nrf2 is only about 10-20 minutes (Stewart et al., 2003; Kobayashi 
and Yamamoto, 2006; Baird and Dinkova-Kostova, 2011). Additionally, studies from Keap1 
deficient mice show that without Keap1, Nrf2 constitutively accumulates in the nucleus 
(Wakabayashi et al., 2003). Overall, the binding of Keap1 to Nrf2 is considered to be 
inhibitory to Nrf2 function because it effectively enhances degradation of Nrf2 and 
provides the low basal expression of cytoprotective genes under physiological conditions 
(Itoh et al., 1999, 2010; Wakabayashi et al., 2003; Zhang et al., 2005; Baird and Dinkova-
Kostova, 2011; Zhang et al., 2013; Baird et al., 2014).  
Keap1 is also the key signaling protein which functions as a molecular sensor for 
oxidants and electrophiles, which recognize and chemically modify specific cysteine 
residues of Keap1 (Dinkova-Kostova et al., 2002; Wakabayashi et al., 2004; Yamamoto et al., 
2008; McMahon et al., 2010; Takaya et al., 2012). Upon exposure to oxidative stress the 
ability of Keap1 to deliver Nrf2 to proteasomal degradation becomes impaired resulting in 
stabilization of Nrf2 along with an extension in half-life to 100-200 minutes (Stewart et al., 
2003; Kobayashi and Yamamoto, 2006; Baird and Dinkova-Kostova, 2011). The stabilized 
Nrf2 protein translocates to the nucleus, binds to the ARE as a heterodimer with one or 
several small masculoaponeurotic fibrosarcoma (Maf) proteins and regulates transcription 
of its downstream target genes that include antioxidant and phase II enzymes as well as 
other genes promoting cell survival (Figure 2) (Itoh et al., 1997, 1999, 2010; Kobayashi and 
Yamamoto, 2006; Kensler et al., 2007; Baird and Dinkova-Kostova, 2011; Zhang et al., 2013; 
Baird et al., 2014; Levonen et al., 2014). In this fashion, oxidants or electrophiles induce Nrf2 
and upregulate cytoprotective genes in order to compensate their harmful effects (Baird 
and Dinkova-Kostova, 2011; Zhang et al., 2013).  
Keap1-independent mechanisms of Nrf2-ARE regulation have also been reported. 
Phosphorylation is another important mechanism regulating expression of Nrf2 
downstream genes. Several protein kinases, such as protein kinase C (PKC), protein kinase 
RNA-like endoplasmic reticulum kinase (PERK), mitogen-activated protein kinases (MAPK) 
and Fyn can phoshorylate Nrf2. In addition, phosphatidylinositol 3-kinase (PI3K) may 
regulate Nrf2 via an indirect mechanism. Because active glycogen synthase kinase 3 (GSK-
3β) phosphorylates Nrf2 Neh6 domain binding β-transducin repeat-containing protein 
leading to Cullin1-dependent ubiquitination and degradation of Nrf2, inhibiting the 
activity of GSK-3β by PI3K results in an increase in Nrf2 (Jain and Jaiswal, 2006; Baird and 
Dinkova-Kostova, 2011; Rada et al., 2011, 2012; Bryan et al., 2013; Chowdhry et al., 2013; 
Zhang et al., 2013; Levonen et al., 2014). Importantly, peroxynitrite has been shown to 
activate Nrf2 via the PI3K-Akt pathway (Kang et al., 2002; Li et al., 2006). However, despite 
the fact that Keap1-independent mechanisms of Nrf2-ARE regulation are well established it 
is believed that Keap1 plays the greatest role in Nrf2 regulation (Baird and Dinkova-
Kostova, 2011). 
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Figure 2. Regulation of Nrf2-ARE pathway. Under basal conditions Nrf2 binds to Keap1 
homodimer allowing its ubiquitination and degradation. Inducers react with Keap1 cysteine 
residues which results in Nrf2 stabilization, translocation to the nucleus and activation of ARE-
dependent transcription (modified from Baird and Dinkova-Kostova, 2011).  
Following translocation to the nucleus, degradation of Nrf2 has been reported to occur 
either directly in the nucleus or in the cytosol, after export of Nrf2 out of the nucleus (Jain 
and Jaiswal 2006; Sun et al., 2007; Niture and Jaiswal, 2009; Kaspar et al., 2012). The latter 
mechanism involves tyrosine kinase Fyn, which phosphorylates Nrf2 and leads to its 
nuclear export, ubiquitination and degradation. The Fyn activity, in turn, is regulated by 
GSK-3β (Jain and Jaiswal, 2007). Regardless of the mechanism, when the inducers are 
removed, degradation of Nrf2 brings down levels of Nrf2 to those resembling basal 
conditions and prevents permanent induction of Nrf2 target genes, which is deleterious to 
the cell. 
A number of biochemical, microarray and chromatin immunoprecipitation-sequencing 
(ChIP-Seq) analyses have demonstrated that Nrf2 regulates the gene expression of a battery 
of cytoprotective proteins that are characterized by extraordinary diversity (Thimmulappa 
et al., 2002; Malhotra et al., 2010; Chorley et al., 2012; Hirotsu et al., 2012, Hayes and 
Dinkova-Kostova, 2014). Approximately one-third of the Nrf2 target genes are involved in 
maintaining redox cellular homeostasis (Hayes et al., 2010; Gao et al., 2014). Among this 
group of Nrf2 downstream genes are heme oxygenase 1 (HO-1), NAD(P)H:(quinine 
acceptor) oxidoreductase 1 (NQO1), glutamate–cysteine ligase or γ-glutamylcysteine 
synthetase (GCL), glutathione-S-transferases (GSTs), catalase, Cu/Zn-superoxide dismutase 
(SOD), sulfotransferases, uridine diphosphoglucuronosyltransferases, thioredoxin and 
many other genes which protect the cell against electrophilic and oxidative stress (Hayes et 
al., 2010; Hayes and Dinkova-Kostova, 2014).  
Inducible HO-1 catalyzes the first and rate-limiting step of heme degradation to carbon 
monoxide, biliverdin and iron (Maines, 1988; Ponka, 1999). Biliverdin is further 
metabolized by biliverdin reductase to bilirubine. HO-1 therefore confers a two-fold 
protection: it degrades toxic heme and generates the antioxidants biliverdin and bilirubin 
(Stocker et al., 1987; Stocker, 1990; Syapin, 2008; Ryter and Choi 2010). NQO1 is a 
flavoprotein catalyzing the two-electron reduction and detoxification of quinones and 
quinoneimines, preventing their participation in redox-cycling and subsequent generation 
of ROS (Prochaska et al. 1987; Bianchet et al., 2004; Dinkova-Kostova and Talalay 2010). In 
addition, NQO1 has also been shown to directly scavenge superoxide (Siegel et al., 2004). 
Glutathione (GSH) is a tripeptide comprised of glutamate, cysteine and glycine and is a 
major antioxidant in the brain. GSH exerts its functions via several mechanisms including 
scavenging of free radicals, especially the hydroxyl radical (Dringen, 2000; Aoyama et al., 
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2008). In addition, it serves as an essential cofactor for a number of enzymes, as a cysteine 
storage form, the major redox buffer maintaining intracellular redox homeostasis and a 
neuromodulator (reviewed in Aoyama et al., 2008). GCL catalyses the first the rate-limiting 
step in the biosynthesis of GSH, mediating the reaction between glutamate and cysteine to 
form γ-glutamylcysteine, which, in turn, reacts with glycine in a reaction catalyzed by GSH 
synthetase to produce GSH (Dringen, 2000). The primary function of GSTs is to catalyze the 
conjugation of electrophilic substrates to GSH (Sheehan et al., 2001; Oakley, 2011; Wu and 
Dong, 2012).  
HO-1 has been shown to be upregulated after SCI (Mautes et al., 2000a; Lin et al., 2007). 
In addition to modulation of oxidative stress, in the acutely injured spinal cord HO-1 
stabilizes the BSB, limits neutrophil infiltration and white matter damage, therefore playing 
an important protective role (Yamauchi et al., 2004; Lin et al., 2007). Similarly to HO-1, 
NQO1 and GST are also induced after SCI (Jin et al., 2014a), suggesting the involvement of 
Nrf2 downstream genes in the protection from oxidative damage in the secondary SCI 
phase.  
Approximately two-thirds of the genes regulated by Nrf2 are not involved in 
detoxification or antioxidant functions, but many of them are considered to be protective 
(Hayes et al., 2010). Thus, Nrf2 is also implicated in regulation of other protective 
mechanisms, such as inhibition of apoptosis (Kotlo et al., 2003; Vargas et al., 2006; Niture 
and Jaiswal, 2012, 2013; Pan et al., 2013) and attenuation of inflammation (Innamorato et al., 
2008; Li et al., 2008; Koh et al., 2009; Piantadosi et al., 2011; Sandberg et al., 2014). Recently, 
Nrf2 and its downstream HO-1 were also shown to be involved in the regulation of 
neurotrophic factor expression (Hung et al., 2010; Sakata et al., 2012). 
Although a deficiency in the Nrf2 gene does not impair normal development, viability 
and fertility of mice, the Nrf2-deficient mice are known to develop white matter 
leukoencephalopathy characterized by widespread astrogliosis and myelinopathy (Hubbs 
et al., 2007). In addition to spontaneous pathological changes in Nrf2-deficient mouse 
brains, suppression of the Nrf2-ARE system by genetic deletion results in decreased 
constitutive and inducible expression of detoxification enzymes and antioxidants and 
therefore, increased susceptibility of the body systems, including CNS, to oxidative stress 
and inflammation (Kobayashi and Yamamoto, 2006; Zhang et al., 2013; Sandberg et al., 
2014). The crucial role of Nrf2 disruption has been demonstrated in various models of 
neurological diseases, such as Parkinson’s disease (Burton et al., 2006; Jakel et al., 2007; 
Chen et al., 2009; Innamorato et al., 2010), ischemic and hemorrhagic stroke (Shih et al., 
2005; Shah et al., 2007; Wang et al., 2007; Zhao et al., 2007; Srivastava et al., 2013), 
experimental autoimmune encephalomyelitis (EAE) (Johnson et al., 2010) and TBI (Jin et al., 
2008, 2009; Hong et al., 2010). Recently, it has been shown that impairment of the Nrf2 gene 
also exacerbates the neurologic deficit and inflammation after compression mouse SCI 
(Mao et al., 2010, 2011, 2012). However, whether Nrf2 disruption has the same consequence 
after contusion SCI yet remains to be explored. 
Activation of Nrf2 and its target genes has been reported in acute brain injuries models 
such as ischemic stroke (Tanaka et al., 2011), intracerebral hemorrhage (Chen and Regan, 
2007; Shang et al., 2013) and TBI (Yan et al., 2008, 2009), suggesting that the upregulation of 
the Nrf2-ARE pathway is an endogenous compensatory attempt to enhance endogenous 
defence in response to these conditions (Zhang et al., 2013). Several studies also observed 
the activation of the Nrf2-ARE pathway within the first 72 h after either compression or 
contusion rat SCI (Wang X et al., 2012b; Jin et al., 2014a) and within the first 24 h after 
compression mouse SCI (Mao et al., 2012). However, the time-course expression of Nrf2 
and its main downstream genes have not been studied in the injured spinal cord, especially 
after contusion injury. Because Nrf2 is known to also regulate inflammation, apoptosis and 
neurotrophic factor expression, investigating these aspects of SCI-induced Nrf2 response is 
also important for deep understanding of the role of the Nrf2-ARE system in traumatic 
spinal cord injuries.   
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2.6 INFLAMMATORY CELLS AND MEDIATORS IN SCI 
Numerous cell types such as astrocytes, microglia, T-cells, neutrophils and monocytes 
take part in the highly complex inflammatory response after SCI (Rowland et al., 2008). 
This inflammatory process may be represented as a dual-edged sword, with both 
neuroprotective and neurotoxic properties. Immune cells residing or invading into spinal 
cord participate in cellular debris clearance and promote regeneration by secreting growth 
factors and protective cytokines. However, at the same time, inflammatory cells promote 
also the secondary damage via release of a cocktail of pro-inflammatory mediators. The 
most intriguing fact is that the same inflammatory elements have both beneficial and 
detrimental effects depending on time and target of their action. Despite the controversial 
role of the inflammatory response in SCI it is apparent that an uncontrolled immune 
response can damage healthy tissue and aggravate the injury. It therefore requires tight 
regulation (Kwon et al., 2004; Rossignol et al., 2007; Donnelly and Popovich, 2008; Rolls et 
al., 2009; Oyinbo, 2011; David et al., 2012) 
Primary injured endothelial cells, as well as the activated resident glia and neurons 
release a number of proinflammatory mediators capable of recruiting neutrophils and                    
monocytes/macrophages to the site of injury. Disruption of the BSB additionally facilitates 
the influx of immune cells from the blood and therefore triggers the secondary 
inflammatory response (Popovich, 2000; Hausmann, 2003; Profyris et al., 2004; Yang et al., 
2005; Hagg and Oudega, 2006; Pineau and Lacroix, 2007; Donnelly and Popovich, 2008; 
Beck et al., 2010).  
2.6.1 Neutrophils 
Polymorphonuclear neutrophils are the first inflammatory cells arriving at the site of 
injury (Carlson et al., 1998; Taoka and Okajima, 2000; Hausmann, 2003; Fleming et al., 2006). 
These cells are particularly abundant in and around the areas with hemorrhage and 
necrosis (Taoka and Okajima, 2000; Hausmann, 2003; Fleming et al., 2006). Thus, already at 
4-5 hours following human SCI neutrophils are localized in blood vessels adherent to 
endothelial cells and in perivascular spaces, but not yet found in the spinal cord 
parenchyma. At one day after human spinal cord trauma, neutrophils are widely spread 
throughout the damaged tissue and their number reaches a peak at this time (Yang et al., 
2004; Fleming et al., 2006). Later than one day after injury, the number of neutrophils 
dramatically declines and only occasional cells persist in the lesion by the third day 
(Norenberg et al., 2004; Yang et al., 2004), although there are evidence to suggest that 
neutrophil infiltration lasts for up to 10 days after human SCI (Fleming et al., 2006).  
In rodent models of SCI a generally similar pattern of neutrophil infiltration is observed. 
Neutrophils appear at the lesion site 4-6 hours after injury, peak in number at 12-24 hours 
and disappear within 5-7 days (Carlson et al., 1998; Hausmann, 2003; Bao et al., 2004; Yang 
et al., 2005; Donnelly and Popovich, 2008; Stirling and Yong, 2008; Stirling et al., 2009). 
Interestingly, in mice at 12 hours after SCI neutrophils were the predominant cell type 
within the cellular infiltrates (Stirling and Yong, 2008). In some cases in mice, a secondary 
peak of neutrophil infiltration is detected at 2 weeks after SCI and these cells persist in 
spinal cord for up to 6 weeks post injury (Kigerl et al., 2006). Beck et al., 2010 observed the 
chronic persistence of neutrophils for even up to 90 days in the contused rat spinal cord. 
Importantly, the number of neutrophils migrated into the spinal cord mostly depends on 
the time after injury and does not depend on the injury type, regardless if it is laceration, 
contusion or compression (Fleming et al., 2006).  
Neutrophils are able to clear tissue debris and restore homeostasis due to their 
phagocytic properties. However, they are also involved in the modulation of the secondary 
injury by generation of ROS and RNS and release of neutrophil proteases (Carlson et al., 
1998; Taoka and Okajima, 2000; Hausmann, 2003; Stirling and Yong, 2008). One such 
protease, neutrophil elastase, has been shown to increase vascular permeability and 
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damage endothelial cells leading to secondary haemorrhage (Taoka and Okajima, 2000; 
Hausmann, 2003). MMP-9, released by neutrophils, is known to participate in BSB 
impairment and vascular dysfunction and also to cleave myelin basic protein and therefore 
to contribute to demyelination of healthy axons (Noble et al., 2002). Myeloperoxidase 
abundantly expressed in neutrophils exacerbates secondary injury and impairs the 
functional recovery after SCI by generating extremely toxic hypochloric acid and enhancing 
neutrophil infiltration (Kubota et al., 2012). Since neutrophils are able to release proteases 
and other cytotoxic factors, such as myeloperoxidase, the general view is that they have a 
detrimental effect after SCI (David et al., 2012). In support of this, a number of studies have 
shown the beneficial effect of reduction of neutrophil infiltration on SCI recovery (Taoka et 
al., 1997; Naruo et al., 2003; Bao et al., 2004, 2008, 2012; Gris et al., 2004; Fleming et al., 2008, 
2009; Nguyen et al., 2012). However, since these treatments do not selectively reduce 
neutrophils but also macrophages, it is difficult to address the observed beneficial effect 
solely to neutrophils (David et al., 2012). Interestingly, in contrast to the general view, one 
recent study showed that selective depletion of neutrophils by >90% without obvious 
alteration of monocyte or lymphocyte numbers resulted in a worsened neurological 
outcome after SCI (Stirling et al., 2009). Even though the obvious discrepancy seen in the 
results may be explained by insufficient specificity and different mechanisms of the 
antibodies used for depletion as well as different types of injuries involved (Bao et al., 2012), 
these findings raise cautionary thoughts against potential therapeutic strategies that inhibit 
infiltration of neutrophils into lesioned spinal cord. Of note is the fact that the positive 
effect of neutrophil depletion manifested only when the treatment was initiated 2 hours 
after injury, whereas delaying treatment by 4 hours yielded no functional recovery 
(Fleming et al., 2009).  
2.6.2 Microglia and macrophages 
Macrophages observed in spinal cord lesions are derived from haematogenous 
monocytes and resident microglia (Popovich et al., 1997, 1999; Fleming et al., 2006; David 
and Kroner, 2011). Microglial cells, the resident immune cells of the CNS, are diffusely 
distributed throughout the brain and spinal cord. They comprise approximately 13% of the 
entire glial cell population in the CNS (Watanabe et al., 1999). Haematogenous or 
circulating monocytes are mobilized into the blood stream from the bone marrow (van 
Furth and Cohn, 1968) or spleen (Swirski et al., 2009). Interestingly, recently it was 
demonstrated that monocytes infiltrating spinal cord lesions predominantly originate from 
the splenic reservoir (Blomster et al., 2013).  
Already in the primary injury phase, as early as 30 minutes after initial damage, 
activation of resident microglia has been reported in human SCI (Yang et al., 2004). This 
rapid microglial response occurs due to release from the damaged tissue of extracellular 
ATP, which upregulates the microglial allograft inflammatory factor-1 and thereby causes 
microglial activation (Schwab et al., 2001; Davalos et al., 2005). At 1-3 days after trauma, the 
number of activated microglial cells is greatly increased and are observed in patches 
around the margin of lesions. Within this period the activated non-phagocytic microglia 
start to change their phenotype and transform into the reactive phagocytic type, also 
referred to as microglial-derived brain macrophages (Popovich et al., 1997; Fleming et al., 
2006). In contrast to abundant activated resident microglia, at this time only a small number 
of circulating monocytes are found adherent to the endothelium of blood vessels and in the 
perivascular space, suggesting the beginning of monocyte infiltration (Fleming et al., 2006). 
At 5-10 days after injury, a great number of phagocytic ‘’foamy’’ macrophages are detected 
in the necrotic areas, whereas early activated microglia are widely present outside areas of 
necrosis in the white matter regions adjacent to the lesion (Yang et al., 2004; Fleming et al., 
2006). As soon as the macrophages establish a ‘’foamy’’ morphology the microglial or 
monocytic origin of these cells cannot be any more distinguished by their morphology or 
antigenic markers. From this time onwards they are referred to as microglia/macrophages 
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(Fleming et al., 2006; David and Kroner, 2011; David et al., 2012; Shechter and Schwartz, 
2013; Kroner et al., 2014). At this time the microglia/macrophages are the predominant type 
of immune cell in the injured human spinal cord (Fleming et al., 2006) and most of them 
within the lesion are thought to be derived from circulating monocytes (Norenberg et al., 
2004). These cells persist in spinal cord tissue for weeks to months after injury (Norenberg 
et al., 2004; Fleming et al., 2006). Importantly, similarly to neutrophils, no differences in the 
pattern of microglial/macrophage activation are observed between the laceration, contusion 
and compression types of injuries (Fleming et al., 2006).  
A similar rapid activation of resident microglia within the first few hours after SCI is 
observed also in rodents (Popovich et al., 1997; Carlson et al., 1998; Yang et al., 2005). 
Starting at 2-3 days after injury, circulating monocytes infiltrate the spinal cord and 
transform into macrophages in tissue. Within the first week after injury the activation of 
resident microglia increases and is followed by subsequent transformation of activated 
microglial cells into phagocytic macrophages. These microglia-derived macrophages 
resemble macrophages derived from circulating monocytes in their morphology and 
antigenic phenotype in histological sections. The numbers of activated 
microglia/macrophages reaches its peak at 5-7 days and they remain in the tissue for 
several weeks or months (Blight, 1992, Popovich et al., 1997; Sroga et al., 2003; Profyris et al., 
2004; Stirling and Yong, 2008; Beck et al., 2010; David et al., 2012). The second peak of 
microglia/macrophage numbers is observed after rat SCI from 60 to 180 dpi, suggesting 
prolonged biphasic response of microglia/macrophage after spinal cord trauma (Beck et al., 
2010). Although the reasons leading to the secondary microglia/macrophage peak and its 
role in SCI pathophysiology are not known, the second phase of macrophage/microglial 
response may contribute to prevention of further loss of function after SCI (Beck et al., 2010). 
Early activated resident microglia are able to release pro-inflammatory cytokines and 
chemokines and together with neurons and astrocytes promote the recruitment of 
neutrophils and circulating monocytes from the blood stream into the injured tissue (Yang 
et al., 2004, 2005; David and Kroner, 2011). Moreover, activated microglial cells along with 
neutrophils are the major source of ROS/RNS in the injured spinal cord (Fleming et al., 
2006). The close proximity of these cells to axons suggest that they are able to contribute to 
lipid peroxidation of the myelin sheath and therefore to demyelination (Fleming et al., 
2006).  
The role of activated macrophages after SCI (either derived from resident microglia or 
circulating monocytes) has been widely debated and is still far from clear (David et al., 
2012). The primary and natural function of macrophages in SCI is to phagocytize cellular 
debris and degenerating myelin and therefore repair injured tissue (Blight, 1992; Popovich 
et al., 1999; Norenberg et al., 2004). Since the large amounts of lipids in necrotic tissues are a 
potential source of ROS and oxidative stress the phagocytic function of macrophages is 
crucial for SCI recovery (Norenberg et al., 2004). Macrophages also release a number of 
growth factors such as fibroblast growth factor (FGF), nerve growth factor (NGF), glial cell-
line derived neurotrophic factor (GDNF), brain derived neurotrophic factor (BDNF) and 
neutrotrpin-3, which promote regeneration and tissue repair (Dougherty et al., 2000, 
Hashimoto et al., 2005; Donnelly and Popovich, 2008). However, in the process of tissue 
repairing the activated macrophages are able to release pro-inflammatory cytokines, 
proteases, glutamate and to produce ROS/RNS, thus contributing to secondary tissue 
damage and demyelination (Popovich et al., 1997, 1999; Carlson et al., 1998; Donnelly and 
Popovich, 2008; David and Kroner, 2011). Depleting macrophages derived from circulating 
monocytes improved functional recovery and tissue protection after SCI (Popovich et al., 
1999; Horn et al., 2008; Ianotti et al., 2011), whereas macrophages activated in vitro and then 
transplanted into injured spinal cord in contrast were neuroprotective and improved 
functional recovery (Rapalino et al., 1998; Bomstein et al., 2003; Schwartz and Yoles, 2006; 
Shechter et al., 2009). The latter led to clinical studies of macrophage transplantation for SCI. 
A phase I study using autologous macrophages activated with autologous skin as treatment 
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for acute complete SCI provided some evidence that this treatment is well tolerated and has  
therapeutic potential in humans (Knoller et al., 2005), whereas a phase II study failed to 
show significant benefit (Lammertse et al., 2012). Thus it is clear that after SCI macrophages 
may promote both secondary injury and repair (Rapalino et al., 1998; Popovich et al., 1999; 
Schwartz and Yoles, 2006; Horn et al., 2008; Donnelly and Popovich, 2008; Busch et al., 2009; 
Gensel et al., 2009; Shechter et al., 2009). 
The discrepancies regarding the effects of activated macrophages after SCI may be 
explained by previous findings from non-neural systems that macrophages exhibit great 
plasticity and can switch their phenotype in response to changes in the microenvironment. 
Macrophages can be polarized to phenotypically and functionally heterogeneous M1 
(classically activated) or M2 (alternatively activated) types with either pro- or anti-
inflammatory properties, respectively. The classically polarized pro-inflammatory M1 
macrophages are activated through exposure to type 1 helper T-cell (Th1) cytokines such as 
interferon-gamma (IFN-γ) and TNF or by products such as lipopolysaccharide (LPS). These 
cells proficiently produce cytotoxic and pro-inflammatory substances and function as 
killers of intracellular pathogens and tumor cells. In contrast, the alternatively activated M2 
macrophages are induced by type 2 helper T-cell (Th2) cytokines such as IL-4, IL-5, IL-13, 
and IL-10. M2 cells reduce inflammation, scavenge debris, promote angiogenesis and are 
involved in tissue remodeling and repair (Gordon, 2003; Mantovani et al., 2004; Schwartz 
and Yoles, 2006; Kigerl et al., 2009; Martinez et al., 2009; Cassetta et al., 2011; David and 
Kroner, 2011; Shechter and Schwartz, 2013). Interestingly, it has been proposed that in 
contrast to the infiltrating monocytes which can transform to anti-inflammatory 
macrophages, resident microglia are generally pro-inflammatory and do not acquire anti-
inflammatory properties at least during the dynamic phase of the SCI repair (Shechter et al., 
2009; Shechter and Schwartz, 2013). 
Classically activated M1 macrophages possess neurotoxic properties as they produce 
pro-inflammatory cytokines (IL-12, IL-23, IL-1β and TNF), release ROS/RNS and proteolytic 
enzymes, thus leading to death of neurons and glia (Kigerl et al., 2009). Since the expression 
of chondroitin sulfate proteoglycan (CSPG), a potent inhibitor of axon growth and 
regeneration, is 16-fold higher in M1 than M2 type macrophages (Martinez et al., 2006), M1 
cells are also implemented in inhibition of axonal regeneration. In addition, macrophages 
stimulated with IFN-γ and LPS facilitate retraction of dystrophic axons at the site of injury 
(Horn et al., 2008). Therefore, M1 cells are believed to be responsible for promoting 
secondary injury and impairing recovery from SCI (Kigerl et al., 2009; David and Kroner, 
2011) and to play a role in axonal ‘’die-back’’ and regeneration failure within the CNS 
(Horn et al., 2008; Busch et al., 2009).  
In contrast, alternatively activated M2 macrophages possess anti-inflammatory 
properties as they express high levels of IL-10 and transforming growth factor beta (TGF-β), 
show impaired nuclear factor κB (NF-κB) activation, exhibit high expression of arginase 1 
and low expression of pro-inflammatory cytokines (Gordon, 2003; Mantovani et al., 2004; 
Sica et al., 2008; Martinez et al., 2009; Sica and Mantovani, 2012). The abundant expression 
of BDNF and reduced release of TNF are thought to be mechanisms of neuroprotective 
action of alternatively activated macrophages preincubated with autologous skin and 
transplanted in contused spinal cord (Bomstein et al., 2003). Recently, it was shown that M2 
macrophages, but not M1 macrophages, are a source of neurotrophic factors (BDNF, NGF) 
in the compressed spinal cord (Hirai et al., 2013). M2 macrophages express a high level of 
mannose receptor CD206 (Gordon, 2003), which is required for non-inflammatory 
sequestration of dying cells (Nauta et al., 2003). Therefore, M2 macrophages could enhance 
clearing of necrotic debris without causing neurotoxicity (Kigerl et al, 2009). Additionally, 
M2 cells promote axonal growth because macrophage-derived proteases are capable of 
degrading axon growth inhibitory molecules without causing overt toxicity. Therefore, M2 
macrophages/microglia are also essential for efficient remyelination as their depletion 
impairs oligodendrocyte differentiation (Miron et al., 2013). These studies all provide 
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evidence that in the injured spinal cord M2 macrophages are essential in the amelioration of 
inflammation and facilitation of reparation (Kigerl et al, 2009).  
Importantly, in contrast to lymphocytes, which have a rather fixed phenotype after 
exposure to polarizing cytokines, macrophages can reversibly shift their functional 
phenotype in response to changes in the cytokine environment. For example, M2 
macrophages can be porarized to M1 phenotype by exposure to LPS or IFN-γ (Stout et al., 
2005; Mylonas et al., 2009). In the injured spinal cord tissue both M1 and M2 macrophages 
are present (Kigerl et al, 2009). However, the microenvironment of the injured spinal cord, 
especially high levels of pro-inflammatory cytokines, such as TNF, that promote the 
activation of macrophages through the classic pathway and low or undetectable levels of 
IL-4, IL-13 and IL-10, favors polarization of macrophages to the M1 type. These pro-
inflammatory macrophages outnumber M2 cells and persist in the spinal cord for weeks 
after injury, whereas M2 macrophages disappear within one week due to suppression or 
downregulation of the M2 phenotype by lesion-derived factors (Kigerl et al, 2009; David 
and Kroner, 2011; Guerrero et al., 2012; Hirai et al., 2013; Kroner et al., 2014). The low 
number of M2 macrophages and their transient appearance after SCI may be some of the 
reasons for the prolonged pro-inflammatory response leading to secondary tissue damage 
and impaired axon regeneration (David and Kroner, 2011; Shechter and Schwartz, 2013). 
Therefore, modulating the microenvironment of the injured spinal cord to reduce excessive 
and prolonged M1 polarization and enhance M2 polarization may be a desirable goal in SCI 
repair (David and Kroner, 2011; Guerrero et al., 2012).  
2.6.3 Lymphocytes  
Adaptive immune cells, such as T- and B-lymphocytes, are activated by SCI and play a 
significant role in secondary injury and repair (Ankeny and Popovich, 2009). 
Interestingly, SCI in humans and rodents causes different patterns of lymphocyte 
infiltration. Only solitary, scattered cytotoxic CD8+ T-lymphocytes are observed in human 
spinal cord within the first 10 days after injury. Weeks and months after injury the CD8+ T-
cells are encountered more often in the damaged area usually randomly distributed among 
macrophages. CD4+ T-helper lymphocytes are fewer and follow the same pattern of 
distribution as CD8+ T-cells, whereas B-cells are not detected in the injured human spinal 
cord (Fleming et al., 2006; Chang, 2007). In mice, T-cells are present in very small numbers 
within the first 96 hours after trauma (Stirling and Yong, 2008). They peak at 14 days after 
injury with a second peak at 6 weeks (Sroga et al., 2003; Kigerl et al., 2006). In contrast to 
mice, rats show a first peak of T-cell infiltration already within the first week (Sroga et al., 
2003) or at 9 days (Beck et al., 2010) after SCI and a second peak between 3 and 4 weeks 
postinjury (Sroga et al., 2003). The number of T-cells remains elevated in the rat spinal cord 
for up to 90 days (Beck et al., 2010). Of note is the fact that in contrast to humans, CD4+ T-
cells outnumber CD8+ T-cells in the rodent spinal cord at all times postinjury (Popovich  et 
al., 1997; Kigerl et al., 2006). 
In contrast to humans, B-cells are found in the injured mouse spinal cord. Similarly to T-
cells they accumulate in the spinal cord tissue mainly 2 weeks after injury and form large B-
cell clusters that are surrounded by T-cells and resemble lymphoid follicles in the 
spleen/lymph node (Ankeny et al., 2006; Ankeny and Popovich, 2010). 
The role of infiltrating T-lymphocytes after SCI still remains ambiguous since both 
beneficial and detrimental effects have been reported (Schwartz and Kipnis, 2001; Hauben, 
2000, 2001; Gonzalez et al., 2003, 2007; Jones et al., 2004; 2005; Ankeny and Popovich, 2009; 
Wang HJ et al., 2012; Laliberte and Fehlings, 2013). The primary injury initiates the release 
of neuroantigens into the blood and lymphatic vessels with drainage into spleen and lymph 
nodes where neuroantigens are processed and presented by antigen presenting cells to 
lymphocytes, triggering primary lymphocyte activation. Later lymphocytes activated in the 
periphery infiltrate to the injury site irrespective of their antigen specificity and persist 
there indefinitely (Ankeny and Popovich, 2009). Within the injured spinal cord T-
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lymphocytes recognize host antigens, such as myelin basic protein. In response to these 
antigens T-cells proliferate and mediate a number of deleterious processes. Thus, activated 
T-lymphocytes destroy target cells, produce cytokines, augment microglia and macrophage 
recruitment and/or activation and promote tissue damage (Gonzalez et al., 2003, Jones et al., 
2005). It has been shown that nude (athymic) rats have improved locomotor recovery 
following SCI (Potas et al., 2006). Additionally, blocking of the chemokine CXCL10, a 
potent T lymphocyte recruiter, reduces neuroinflammation and improves functional 
recovery (Gonzalez et al., 2003, 2007). Moreover, chronic T-cell activation can induce 
pathological fibrosis and scarring (Wynn, 2004). However, several studies demonstrate a 
neuroprotective role of T-cells in SCI, suggesting that autoimmune boosting by the 
administration of autoreactive T-cells (passive immunization) or a CNS antigen to expand 
autoreactive T cell clones (active immunization) may be beneficial. It is believed that 
autoreactive T-cells can serve as a source of neurotrophic factors and cytokines, which 
activate macrophages to ameliorate neurotoxicity, produce growth factors and remove 
inhibitors of axonal growth after SCI (Hauben, 2000, 2001; Schwartz and Kipnis, 2001; 
Schwartz, 2005). Nevertheless, the protective role of autoimmunity following SCI is still 
very questionable (Laliberte and Fehlings, 2013).  
One possible explanation for the contradictory results may be that different subtypes of 
T-lymphocytes mediate distinct T-cell effects. Thus, Th2-lymphocytes or a systemic Th2 
shift is believed to promote neuroprotection and regeneration of axons after CNS injury 
and therefore promoting Th2 shift is considered to be a promising strategy for CNS repair. 
However, the side effect of the systemic Th2 shift is increased susceptibility to infection 
(Hendrix and Nitsch, 2007). Interestingly, recent studies have shown that adoptive transfer 
of Th-1 conditioned lymphocytes, but not Th2 or Th17-conditioned cells activate anti-
inflammatory M2 macrophages, facilitate myelination and improve functional recovery and 
tactile sensation after mouse SCI (Ishii et al., 2012, 2013). 
Increased numbers of studies support a negative effect of humoral immunity after SCI 
(Ankeny and Popovich, 2010). Activated B-cells synthesize pathogenic autoantibodies that 
may augment neuroinflammation and cause neurotoxicity (Ankeny et al., 2006). Moreover, 
injured mice lacking B cells demonstrate improved neurological function compared with 
mice with normal B-function, suggesting a pathogenic role for B cells (Ankeny et al., 2009). 
Therefore, it is generally considered that B-lymphocytes and SCI-induced antibodies 
exacerbate tissue damage and impair neurological recovery after SCI (Ankeny et al., 2006, 
2009; Ankeny and Popovich, 2010). 
Finally, studies with RAG2-/- and NOD-SCID mice which lack both functional T- and B-
lymphocytes show that activated T- and B- cells, as the effectors of the adaptive immune 
response, are harmful to the regenerating spinal cord and show evidence that immune 
suppression is beneficial for SCI recovery (Luchetti et al., 2010; Wu B et al., 2012). 
2.6.4 Inflammatory mediators 
Numerous pro- and anti-inflammatory mediators tune the cellular response after SCI. 
Among them TNF, IL-1β and IL-6 are considered to be key pro-inflammatory cytotoxic 
cytokines (Hausmann et al., 2003). TNF and IL-1β are produced in the injured spinal cord 
almost immediately (within 5-15 minutes) after initial impact. The upregulation of TNF and 
IL-1β is followed by elevation of IL-6 (Pineau and Lacroix, 2007). In human injured spinal 
cord upregulation of TNF, IL-1β and IL-6 was found as early as 30 minutes after injury 
(Yang et al., 2004). In mouse spinal cord the peak of TNF expression is observed at 1 hour, 
whereas IL-1β and IL-6 expression levels are highest at 12 hours after injury. After reaching 
maximal levels the expression of these cytokines decreases gradually and is then followed 
by a second prominent peak of TNF and IL-1β at 14 days (Yang et al., 2004, Pineau and 
Lacroix, 2007). Endogenous glia, neurons and endothelial cells are mainly responsible for 
the initial release of TNF, IL-1β and IL-6 resulting in increase of vascular permeability and 
facilitation of neutrophil and macrophage migration into the injured spinal cord. Therefore, 
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it is established that resident CNS cells, but not immune cells recruited from periphery, are 
responsible for the initiation of the inflammatory response following SCI (Yan et al., 2001; 
Hausmann et al., 2003; Yang et al., 2004, 2005; Pineau and Lacroix, 2007). The second peak 
of TNF and IL-1β production is mainly associated with microglia/macrophages and 
coincides with the entry of lymphocytes and glial scar formation (Pineau and Lacroix, 2007). 
In addition to their significant role in recruitment and activation of peripheral leukocytes, 
TNF, IL-1β and IL-6 mediate a number of other processes following CNS injury. Thus, 
release of TNF and IL-1β precedes the activation of astrocytes and shares a similar 
distribution with astrocytic reaction. Therefore, rapid and widespread expression of TNF 
and IL-1β play a role in regulation of astrogliosis (Herx and Yong, 2001; Pineau and Lacroix, 
2007). In support of this, it is known that astrogliosis is attenuated in the brain of adult IL-
1β deficient mice (Herx and Yong, 2001). Another consequence of rapid production of TNF 
and IL-1β is the activation of resident microglia, which has been described both in vitro and 
in vivo (Pineau and Lacroix, 2007). Studies showing that microgliosis, astrogliosis and 
leukocyte infiltration are reduced in IL-6 deficient mice confirm that IL-6 also participates 
in activation of astrocytes and microglia as well as in regulation of leukocyte infiltration 
(Klein et al., 1997; Penkowa et al., 1999). The second peak of TNF and IL-1β expression 
observed 2 weeks after SCI may be important for lymphocyte recruitment as lymphocytes 
enter into mouse spinal cord about 14 days following spinal cord trauma (Sroga et al., 2003; 
Kigerl et al., 2006; Pineau and Lacroix, 2007).  
TNF, IL-1β and IL-6 are thought to play mainly detrimental roles in SCI pathology. Thus, 
TNF is known to be specifically cytotoxic to oligodendrocytes, causing their apoptotic death 
and demyelination in the injured spinal cord (Hisahara et al., 1997; Yan et al., 2001; Yune et 
al., 2003; Genovese et al., 2008, 2009; Inukai et al., 2009). Additionally, TNF has been shown 
to contribute to excitotoxic cell death after SCI (Ferguson et al., 2008). Importantly, TNF is a 
cytokine mainly responsible for sustained M1 polarization of microglia/macrophages in the 
injured spinal cord (Kroner et al., 2014). Although it has been reported that mice deficient 
for TNF receptors exhibit locomotor impairment after SCI due to increased apoptosis (Kim 
et al., 2001), substantial numbers of studies have demonstrated that pharmacological or 
genetic inhibition of TNF or IL-1β, in contrast, reduce apoptosis and cell infiltration, 
decrease tissue damage and improves functional recovery after SCI (Bethea et al., 1999; 
Nesic et al., 2001; Genovese et al., 2006, 2008; Chen et al., 2011). Similarly, overexpression of 
IL-6 in the injured spinal cord enhances inflammation and impaires functional recovery 
(Lacroix et al., 2002), whereas temporal blockade of IL-6 signaling results in improved 
outcome after SCI (Okada et al., 2004; Mukaino et al., 2010; Guerrero et al., 2012). However, 
there is evidence from IL-6 deficient mice that certain levels of this cytokine are still 
required for regeneration within the CNS (Cafferty et al., 2004). 
IL-10 is a potent anti-inflammatory cytokine known to suppress the activation of 
neutrophils, macrophages, eosinophils and T-lymphocytes and therefore limit the 
production of pro-inflammatory mediators. It is thought to play a protective role following 
SCI (Abraham et al., 2004; Genovese et al., 2009; David et al., 2012; Thompson et al., 2013). 
IL-10 deficient mice following SCI show an increased degree of inflammatory response, 
apoptosis and impaired locomotor recovery (Abraham et al., 2004; Genovese et al., 2009), 
whereas most of these effects are reversed with IL-10 treatment (Abraham et al., 2004). 
Administration of IL-10 to contused Sprague-Dawley rats is also beneficial for the 
functional recovery from SCI (Bethea et al., 1999), whereas in the Fisher rat strain IL-10, 
although it reduces spinal gray matter loss, surprisingly fails to facilitate locomotor 
recovery (Takami et al., 2002b). In addition to the anti-inflammatory effects of IL-10 it has 
been demonstrated that IL-10 activates signaling pathways involved in neuronal survival 
and growth and therefore exerts direct neuroprotective effects on neurons (Zhou et al., 
2009b). Accordingly, local upregulation of IL-10 at the injury site with vector-mediated IL-
10 gene transfer results in significant neuronal survival and improves functional outcome 
after a hemisection injury (Zhou et al., 2009a). Importantly, IL-10 is known to induce 
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polarization of macrophages to the anti-inflammatory M2 phenotype (Shechter et al., 2011; 
Deng et al., 2012; Sica and Mantovani, 2012), which may be one reason for the functional 
improvement observed after IL-10 treatment (Thompson et al., 2013). 
In addition to TNF, IL-1β, IL-6 and IL-10, an enormous number of other inflammatory 
mediators such as granulocyte-macrophage colony-stimulating factor (GM-CSF), leukemia 
inhibitory factor (LIF), TGF-β, IFN-γ, chemokines (MIP-1, IP10, MCP-1) and proteinases, 
especially the MMPs, regulate inflammatory processes in the injured spinal cord and have 
been studied at different extent in various SCI models (Hausmann et al., 2003; Profyris et al., 
2004; David et al., 2012). Many of these mediators have both beneficial and deleterious 
effects, depending on when and at which extent they are released, and on which cellular 
population they act upon.  
Finally, several studies have shown that activation of the complement system, composed 
of over 30 cellular and plasma/serum proteins, negatively contribute to secondary injury 
following SCI (Anderson et al., 2004; Qiao et al., 2006; Galvan et al., 2008; David et al., 2012). 
Within one day of SCI classical (C1q and C4), alternative (Factor B) and terminal (C5b-9) 
complement pathways are strongly activated. Disruption of the BSB allows entry of the 
complement proteins into the spinal cord parenchyma in addition to induction of local 
synthesis of the complement proteins in oligodendrocytes and neurons. As a result, 
complement proteins are deposited on oligodendrocytes, neurons, and axons in injured 
spinal cords. The association of complement activation with axons suggests that the 
complement cascade plays an important role in demyelination or axonal degeneration 
(Anderson et al., 2004). The detrimental role of the complement system in SCI is confirmed 
by studies where mice deficient for the complement proteins show improved functional 
recovery and increased tissue sparing (Qiao et al., 2006, 2010; Galvan et al., 2008; Guo et al., 
2010; Li et al., 2014). 
Additionally, pharmacological inhibition of C3, C5a or Factor B components of the 
complement system result in improvements in neurological recovery (Qiao et al., 2006, 2010; 
Li et al., 2014). Since complement activation mediates the recruitment of inflammatory cells 
the protective effect of complement deficiency/inhibition may be associated with 
attenuation of neutrophil and monocyte infiltration, inhibition of microglia/macrophage 
activation and reduction of astrogliosis (Qiao et al., 2006; Li et al., 2014). In addition, 
complement inhibition leads to reduction of the membrane attack complex (MAC) 
formation. The MAC, the terminal product of the complement cascade, may contribute 
directly to neuronal and glial injury and demyelination but can also induce the production 
of pro-inflammatory mediators, thus augmenting the inflammatory response after SCI 
(Qiao et al., 2006). 
2.6.5 Interleukin-33, a novel mediator of inflammation in CNS 
IL-33, initially discovered as a nuclear factor from high endothelial venules (Baekkevold 
et al., 2003), later was identified as a member of the IL-1 cytokine family that is most closely 
related in structure to IL-18 and IL-1β (Schmitz et al., 2005). However, in contrast to highly 
inflammatory IL-1β and IL-18 promoting Th1 response, IL-33 has been shown to induce the 
production of Th2 cytokines (Schmitz et al., 2005). Additionally, in contrast to other IL-1 
family members, IL-33 is not mainly produced by sentinel immune cells, but instead 
constitutively produced predominantly by tissue-related cell types such as endothelial cells, 
smooth muscle, fibroblasts, cardiomyocytes, keratinocytes, adipocytes and mucosal 
epithelial cells (Schmitz et al., 2005; Moussion et al., 2008; Smith, 2010).  
IL-33 functions both as a classical cytokine by binding to its specific receptor on the 
plasma membrane and as an intracellular nuclear factor involved in transcriptional 
regulation of gene expression (Ali et al., 2007, 2011; Carriere et al., 2007; Chackerian et al., 
2007; Moussion et al., 2008; Cayrol and Girard, 2009; Haraldsen et al., 2009; Lüthi et al., 2009) 
(Figure 3). 
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Figure 3. The dual role of IL-33 in inflammation. 1: In response to a pro-inflammatory stimulus 
IL-33 is upregulated in the nucleus. Upregulated IL-33 represses NF-κB and thereby prevents 
expression of NF-κB target genes. 2: Cell damage and necrosis result in release of intracellular 
IL-33 from the cells. 3: Released IL-33 binds to a variety of target cells expressing the IL-33 
receptor (IL-1RacP/ST2) and induces their activation, differentiation and proliferation. 4: 
Soluble St2 form acts as a decoy receptor to bind and inhibit IL-33 activity. MQ - macrophages, 
G - granulocytes, B - B cells, T2 – T2 cells, NK - natural killer cells, MC - mast cells (modified 
from Sattler et al., 2013).   
 
Intracellular IL-33 is localized in the nucleus associated with heterochromatin and 
negatively regulates gene transcription in a non–IL-33 receptor mediated fashion (Carriere 
et al., 2007; Roussel et al., 2008). Importantly, intracellular IL-33 interacts with p65 subunit 
of NF-κB repressing the activity of this transcription factor. NF-κB is a well-known trigger 
of pro-inflammatory cytokine expression and therefore IL-33-NF-κB interaction results in 
inhibition of NF-κB target genes, such as TNF (Ali et al., 2011). However, under 
pathological conditions, strong signals leading to activation of many p65 subunits can 
overcome the IL-33 mediated repression and result in induction of full NF-κB activity (Ali 
et al., 2011).  
The IL-33 protein does not contain a classical secretory signal sequence that directs it for 
secretion via the ER–Golgi pathway (Schmitz et al., 2005). It is currently believed to be 
released mainly passively when cells undergo damage and necrotic cell death (Moussion et 
al., 2008; Lüthi et al., 2009; Smith, 2010). However, there are also reports indicating that 
release of IL-33 in the absence of cellular necrosis might also be possible (Kouzaki et al., 
2011; Kakkar et al., 2012). Regardless of the mechanism, nuclear IL-33 when released from 
the cell in response to infection or tissue damage begins to function as an alarmin to alert 
and activate the immune system (Moussion et al., 2008; Cayrol and Girard, 2009; Lüthi et al., 
2009; Haraldsen et al., 2009; Kakkar et al., 2012).  
Extracellular IL-33 exerts cytokine activities and binds to its receptor consisting of a 
heterodimer between ST2 and IL-1 receptor accessory protein (IL-1RAcP) (Ali et al., 2007; 
Chackerian et al., 2007; Palmer et al., 2008; Liu et al., 2013). ST2 and IL-1RAcP recruit the 
adaptor molecules MyD88 and IL-1 receptor-associated kinases to induce activation of the 
transcription factor NF-κB as well as MAPKs in target cells (Schmitz et al., 2005). This 
results in expression of various downstream genes, leading to the release of various 
cytokines and chemokines or causing cell differentiation, polarization, and activation, 
depending on the target cell (Sattler et al., 2013; Villarreal and Weiner, 2014). In addition to 
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the transmembrane form of ST2, the soluble ST2 isoform (sST2) is produced and acts as a 
decoy receptor to bind and effectively inhibit IL-33 activity (Hayakawa et al., 2007), 
therefore playing an important role in regulation of IL-33 signaling (Smith, 2010). 
Th2 lymphocytes, but not Th1 lymphocytes, have been shown to express ST2 (Xu et al., 
1998), and were the first immune cells identified to respond to IL-33 stimulation (Schmitz et 
al., 2005). Further studies demonstrated that in addition to Th2 cells, the IL-33 receptor is 
expressed on a broad range of innate and adaptive immune cells, including neutrophils, 
basophils, eosinophils, NK and NKT cells, mast cells and macrophages and, therefore, IL-33 
stimulates many immune cell types to exert their diverse effector functions (reviewed in 
Liew et al., 2010; Smith, 2010; Sattler et al., 2013; Villarreal and Weiner, 2014). Thus, IL-33 
accelerates the production of pro-inflammatory leukotrienes and cytokines in mast cells 
(Allakhverdi et al., 2007; Moulin et al., 2007; Enoksson et al., 2011), promotes the production 
of Th2 cytokines in T-lymphocytes (Schmitz et al., 2005; Chackerian et al., 2007) and 
dendritic cells (Rank et al., 2009), and shifts the macrophage polarization from M1 to M2 
type (Kurowska-Stolarska et al., 2009; Miller et al., 2010). IL-33 is also believed to act as 
selective Th2 chemoattractant (Komai-Koma et al., 2007), suggesting an important role for 
IL-33 in Th2 cell mobilization.  
Initially IL-33 was thought to be mainly involved in initiating and expanding Th2-driven 
responses (Schmitz et al., 2005), however, recently it has been found that depending on the 
immune cells targeted by IL-33, it is able not only to promote Th2 expansion, but also to 
contribute to the development of the Th1 immune response (Smithgall et al., 2008; 
Bourgeois et al., 2009; Smith, 2010; Villarreal et al., 2014). In addition, IL-33 has been shown 
to amplify the CD8+ T cell response (Yang et al., 2011; Bonilla et al., 2012; Villarreal et al., 
2014). Therefore, it is now believed that in different conditions, depending on the type of 
target cells and the microenvironment, IL-33 can exert different functions either associated 
in promoting Th2-immune or Th1-immune responses (Villarreal and Weiner, 2014). 
IL-33 is a cytokine possessing pleiotropic activities which can regulate complex innate 
and adaptive immune responses in immunity and disease. Increased levels of IL-33 may 
have a dual function, as its intracellular form can negatively modulate NF-κB-mediated 
activity and dampen pro-inflammatory signaling, whereas its extracellular form stimulates 
adaptive and innate immune cells in order to clear the initial trigger and repair damaged 
tissues.  
IL-33 is known to be highly expressed in the naïve mouse brain and spinal cord (Schmitz 
et al., 2005). However, it is only recently that the production and function of IL-33 in the 
CNS have attracted great attention (Han et al., 2011).  
The cellular localization of IL-33 and its receptor in the CNS remains controversial. In 
glial cultures IL-33 has been shown to be inducible in astrocytes and upon induction by 
inflammatory stimuli it is localized to the nucleus (Hudson et al., 2008). In addition to 
astrocytes, IL-33 expression is also observed in brain endothelial cells, but in contrast to 
astrocytes, in endothelial cells it is not upregulated by inflammatory stimuli (Yasuoka et al., 
2011). IL-33 expression has not been observed in microglia (Hudson et al., 2008; Yasuoka et 
al., 2011). In vivo, IL-33 has been shown to be upregulated primarily in astrocytes in spinal 
cords of mice with EAE (Yasuoka et al., 2011) and bone cancer-induced pain (Zhao et al., 
2013), as well as in human brains from patients with multiple sclerosis (Christophi et al., 
2012), indicating that IL-33-expressing astrocytes may act as a potentially critical regulator 
of immune responses in the CNS. However, in a recent study utilizing the mouse model of 
EAE the levels of IL-33 was shown to be increased in both neurons and astrocytes (Jiang HR 
et al., 2012). The expression and cellular localization of IL-33 in other neurological diseases 
and specifically CNS injuries have not been examined.  
While neurons express only the IL-1RAcP subunit, astrocytes and microglia have been 
shown to express both ST2 and IL-1RAcP in vitro, suggesting that microglia and astrocytes 
may be a main target cell for IL-33 in CNS (Yasuoka et al., 2011). This was further 
confirmed by studies where IL-33 treatment was shown to induce a Th2 immune response 
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in IL-33-treated glia (Hudson et al., 2008), increase proliferation of microglia, induce 
production of TNF, IL-1β and IL-10 by microglial cells and enhance microglial phagocytosis 
(Yasuoka et al., 2011). Moreover, recently it has been shown that IL-33 is able to induce the 
release of pro-inflammatory mediators from mouse astrocytes and mediate neuronal 
damage and death in mixed glia-neuronal cultures (Kempuraj et al., 2013). Another study 
has demonstrated that ST2 is expressed in astrocytes, but not in neurons or microglia 
(Andre et al., 2005). Interestingly, in spinal cord tissue of mice with EAE the ST2 protein is 
detected in neurons, but not in astrocytes (Jiang HR et al., 2012).  
The existing data as to whether IL-33 is beneficial or detrimental to CNS diseases is also 
controversial. Blockade of IL-33 inhibits the onset and severity of EAE, whereas when 
administered before the onset of clinical symptoms recombinant IL-33 augments the disease 
course of EAE (Li et al., 2012). In contrast, IL-33 treatment attenuates EAE when it is 
administered after EAE induction (Jiang HR et al., 2012). An increase in Th2-associated 
cytokine production together with polarization of macrophages towards M2 is proposed as 
the main mechanism of IL-33-mediated protection in EAE (Jiang HR et al., 2012). Given that 
Th2-expansion and M2-polarization are believed to be beneficial for SCI recovery (Schwartz, 
2005; Kigerl et al., 2009; David and Kroner, 2011; Guerrero et al., 2012) IL-33 might be a 
promising candidate for SCI treatment. 
2.7 ASTROGLIAL ACTIVATION AND GLIAL SCAR FORMATION AFTER SCI 
Reactive astrogliosis is a prominent hallmark of CNS trauma, including SCI. It involves 
changes in astrocyte morphology and molecular expression. In severe cases, astroglial 
activation results in a formation of glial scar. In response to injury reactive astrogliosis is 
triggered by many different mediators including cytokines and growth factors such as IL-6, 
LIF, TNF, IFN-γ, IL-1, IL-10, TGF-β, FGF2, neurotransmitters such as glutamate and 
noradrenaline, LPS and Toll-like receptor ligands, ROS/RNS, endothelin-1, ATP, fibrinogen 
and many others (Faulkner et al., 2004; Silver and Miller, 2004; Fitch and Silver, 2008; 
Rowland et al., 2008; Sofroniew, 2009; Hamby and Sofroniew, 2010; Sofroniew and Vinters, 
2010; Cregg et al., 2014). Reactive astroglia are heterogeneous in the injured spinal cord. 
Thus, a recent study demonstrated that following SCI mature scar borders are mainly 
consisting of newly proliferated, elongated astrocytes with overlapping processes, whereas 
at a distance from scar borders the reactive astrocytes are non-proliferative, hypertrophic 
stellate cells with non- or overlapping, far less extensive processes (Wanner et al., 2013).  
It is well known that reactive astrogliosis and formation of astroglial scar consisting of 
glial (mainly astrocytic) and fibrotic components, create a physical barrier and inhibitory 
environment at the lesion site, leading to unsuccessful axonal regeneration (Silver and 
Miller, 2004; Fitch and Silver, 2008; Kawano et al., 2012; Cregg et al., 2014). Therefore, for a 
long time it was thought that reactive astrogliosis and scarring are the main obstacles on the 
way to functional recovery after SCI. Indeed, a number of studies have demonstrated that 
the molecular composition of the scar and the production of molecules inhibiting axonal 
growth, including tenascin, semaphorin 3A, ephrins and CSPGs family are the key factors 
contributing to failure of regeneration following SCI (McKeon et al., 1991, 1995; Fawcett 
and Asher, 1999; Rhodes and Fawcett, 2004; Silver and Miller, 2004; Fitch and Silver, 2008; 
Rolls et al., 2009; Kawano et al., 2012; Cregg et al., 2014). Elimination of these inhibitors or 
neutralization of their effect has been reported to enhance axonal regeneration in the 
injured spinal cord (Bradbury et al., 2002; Caggiano et al., 2005, Kaneko et al., 2006; Tan et 
al., 2006). These findings suggest that activation of astrocytes is detrimental for clinical 
outcome. However, the total inhibition of reactive astrogliosis is not a feasible therapeutic 
strategy for SCI (Sofroniew, 2009; Hamby and Sofroniew, 2010; Sofroniew and Vinters, 
2010).  
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Numerous studies have demonstrated that the astroglial scar is much more than just a 
physical barrier impeding axonal regeneration and have provided compelling evidence that 
reactive astrocytes are able to protect adjacent tissue by different mechanisms including 
uptake of excitotoxic glutamate, free radical scavenging, facilitation of BSB repair, reduction 
of vasogenic edema and limiting the spread of inflammatory cells into healthy tissue 
(Faulkner et al., 2004; Rolls et al., 2009, Sofroniew, 2009; Hamby and Sofroniew, 2010; 
Sofroniew and Vinters, 2010; Kawano et al., 2012). In addition, astrocytes provide trophic 
support in the injured site by producing nutrients and growth factors (Rolls et al., 2009). 
Therefore, astrocytes have multiple responses to CNS trauma. Scar formation is one of them 
and represents the extreme form of reactive astrogliosis in response to overt tissue damage 
and inflammation (Sofroniew, 2009). The importance of reactive astrogliosis and glial scar 
for SCI repair is supported by experiments where ablation of reactive astrocytes and 
disruption of scar formation result in increased inflammatory cell infiltration, failure of BSB 
repair, increased demyelination and tissue damage leading to impaired functional recovery 
(Faulkner et al., 2004). Furthermore, conditional knockout of STAT3 (intracellular signal 
transducer for various cytokines including IL-6) from astrocytes markedly reduces 
astrogliosis and scar formation and result in aggravated neuropathology and reduced 
locomotor recovery (Okada et al., 2006; Herrmann et al., 2008). More recently, Wanner et al., 
2013 demonstrated that following SCI scar forming, the astrocytes are able ‘’to corral 
inflammatory and fibrotic cells into discrete areas separated from adjacent tissue that 
contains viable neurons’’ (Wanner et al., 2013). The inhibition of scar formation by selective 
deletion of STAT3 from astrocytes leads to increased inflammation and aggravated 
neuronal death in adjacent healthy tissue (Wanner et al., 2013). Importantly, genetic 
ablation of astrogliosis in addition to other harmful effects fails to promote desired axonal 
regeneration (Okada et al., 2006; Herrmann et al., 2008), which is possibly in part due to 
extended inflammation (Kawano et al., 2012). Taken together, these studies show that 
reactive astrogliosis, including scar formation, is an adaptive process, which exerts multiple 
beneficial functions in preventing the spread of inflammation and protecting intact 
neuronal elements from secondary damage (Faulkner et al., 2004; Rolls et al., 2009; 
Sofroniew, 2009; Hamby and Sofroniew, 2010; Cregg et al., 2014). Therefore, total 
suppression of glial scar formation cannot be a useful strategy for SCI treatment (Hamby 
and Sofroniew, 2010; Kawano et al., 2012). 
However, under certain circumstances reactive astrocytes may play also a harmful role 
through several mechanisms including overproduction of ROS/RNS or/and pro-
inflammatory cytokines (Sofroniew, 2009; Sofroniew and Vinters, 2010). Moreover, selective 
inhibition of certain signaling mechanisms in astrocytes, for example NF-κB, is associated 
with an improved outcome (Brambilla et al., 2005). Since different specific signaling 
mechanisms can induce reactive astrocytes to have different and sometimes opposite effects 
(pro-inflammatory or anti-inflammatory, increase or reduce oxidative stress), reactive 
astrocytes may exhibit both beneficial and detrimental effects depending on astrocytic 
location, severity or phase of response (Rolls et al., 2009; Sofroniew, 2009; Sofroniew and 
Vinters, 2010). Therefore, instead of total inhibition of reactive astrogliosis, novel 
therapeutic strategies should target specific signaling mechanisms in astrocytes with the 
aim to improve axon regrowth past the astroglial scar without altering its reparative and 
neuroprotective function (Hamby and Sofroniew, 2010; Wanner et al., 2013). Recently, it 
was demonstrated that transplantation of hESC-derived progenitors promotes astrogliosis 
through activation of signaling mechanisms that support axonal survival. The transplanted 
cells in synergism with reactive astrocytes created a permissive environment for axonal 
regeneration, inhibiting expression of detrimental genes such as CSPG and tenascins and 
increasing the expression of beneficial ones therefore resulting in improved functional 
recovery after spinal cord transection (Lukovic et al., 2014). 
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2.8 CELL DEATH AND DEMYELINATION AFTER SCI 
Both necrotic and apoptotic mechanisms contribute to cell death after SCI. The initial 
mechanical damage results in haemorrhagic necrosis in gray matter involving the swelling 
of neuronal and glial cells, disruption of organelles and release of the intracellular contents 
through the ruptured membrane. The secondary injury cascade leads to further spread of 
the necrotic wave (Beattie et al., 2002; Hausmann et al., 2003; Kwon et al., 2004; Profyris et 
al., 2004).  
Apoptosis, a form of programmed cell death, initially occurs in the lesion core 6 hours 
after injury (Crowe at al., 1997). At this moment, it accompanies necrosis in damaging 
multiple types of cells. By the end of the first week the level of apoptosis decreases and in 
several days the second wave of apoptotic death starts predominantly in white matter. 
Although apotosis also involves neuronal cells, mainly it affects oligodendrocytes and lasts 
for weeks, leading to persistent demyelination (Crowe at al., 1997; Profyris et al., 2004; 
Mekhail et al., 2012). Many of the secondary injury mechanisms contribute to apoptosis of 
oligodendrocytes. The most important ones are ischemia, oxidative stress, Ca2+ overload, 
excitotoxicity and release of extracellular ATP (Casha et al., 2001; Mekhail et al., 2012; 
Plemel et al., 2014). Another factor contributing to death of oligodendrocytes is the 
increased level of pro-inflammatory cytokines and particularly TNF, which is especially 
cytotoxic to oligodendrocytes (Hisahara et al., 1997; Yan et al., 2001; Yune et al., 2003; 
Genovese et al., 2008, 2009; Inukai et al., 2009; Mekhail et al., 2012; Plemel et al., 2014). After 
SCI, oligodendrocytes also overexpress the death receptors FAS and p75, which are via 
their respective ligands responsible for initiating of the apoptotic process (Casha et al., 2001; 
Beattie et al., 2002; Demjen et al., 2004; Keane et al., 2006). In addition to apoptosis, another 
form of programmed cell death, namely autophagy (Tsujimoto and Shimizu, 2005), was 
recently implemented in the death of oligodendrocytes (Kanno et al., 2009b, 2011). 
As oligodendrocytes are responsible for myelinating neuronal axons their death results 
in widespread demyelination (Kwon et al., 2004; Mekhail et al., 2012; Plemel et al., 2014). 
Since one oligodendrocyte myelinates multiple axons, loss of a single cell might induce the 
demyelination of many axons surviving after initial trauma (Profyris et al., 2004). The loss 
of myelin sheaths results in impairment of axonal transmission and over time may result in 
degeneration of denuded axons (Irvine and Blakemore, 2008). It is thought that prominent 
early loss of oligodendrocytes which occurs by both necrosis and apoptosis within the first 
24 hours after trauma underlies the loss of function observed after injury, while delayed 
apoptotic oligodendrocyte death results in impaired functional recovery (Plemel et al., 
2014).  
Although spontaneous remyelination is known to occur in the injured spinal cord, it is 
very often an incomplete and abnormal process (Totoiu and Keirstead, 2005; Mekhail et al., 
2012; Powers et al., 2012). Therefore demyelination might be an attractive target for 
therapeutic intervention after SCI. 
2.9 CURRENT CLINICAL STRATEGIES IN SCI MANAGEMENT 
Although our understanding of pathological mechanisms involved in SCI has broadened 
significantly over the last decades, effective treatments for SCI are limited and there is no 
complete restorative therapy (Olson, 2013; Oudega, 2013; Varma et al., 2013).  
Currently the management of acute SCI includes surgical and pharmacological 
intervention followed by physical therapy and rehabilitation (Raslan and Nemecek, 2012).  
2.9.1 Surgical treatment 
Surgical treatment involves the application of surgical decompression to remove the 
bones that compress the spinal cord as well as spinal stabilization (Wilson and Fehlings, 
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2011; Raslan and Nemecek, 2012). The timing of surgical intervention in SCI management 
for a long time was one of the most controversial topics (La Rosa et al., 2004; Fehlings and 
Perrin, 2006; Wilson and Fehlings, 2011; Raslan and Nemecek, 2012). However, the results 
of the recent Surgical Timing in Acute Spinal Cord Injury Study (STASCIS) show that 
decompression within 24 hours following SCI is safe and leads to improved neurologic 
outcome (Fehlings et al., 2012). 
2.9.2 Pharmacological treatment 
The main aim of pharmacological intervention after SCI is to reduce the secondary injury 
cascade and protect the cells that initially survived after mechanical injury and thus 
promote functional recovery (Kwon et al., 2004; Raslan and Nemecek, 2012). Although it is 
not approved by regulatory authorities (Hurlbert et al., 2013), synthetic glycocorticoid 
methylprednisolone (MP) remains the only drug used worldwide for the treatment of acute 
SCI in clinical practice (Varma et al., 2013; Chikuda et al., 2014). MP administration after 
acute SCI has been the subject of debate for more than 20 years. The beneficial effect of 
high-dose MP was initially reported in a series of National Acute Spinal Cord Injury Studies 
(NASCIS) in the 1990s. It has been demonstrated that MP administered systemically in very 
high doses can reduce human neurological deficits after SCI when the first dose is given 
within the first 8 hours after injury (Bracken et al., 1990; 1998). Inhibition of lipid 
peroxidation and inflammatory response are considered to be the main mechanisms of MP 
action after SCI (Bracken et al., 1990; Hall, 1992; 1993). However, the use of high-dose MP in 
treating acute SCI is controversial due to significant dose related adverse effects (gastric 
bleeding, hyperglycemia requiring insulin administration, sepsis, pneumonia, urinary tract 
infections, acute corticosteroid myopathy, wound infection) and relatively modest 
neurological improvement (Bracken et al., 1990; Gerndt et al., 1997; Qian et al., 2005; 
Suberviola et al., 2008; Ito et al., 2009; Hurlbert et al., 2013; Chikuda et al., 2014). As a result, 
many centers have ceased to use this drug. Moreover, as there is clear medical evidence 
suggesting that high-dose MP administration is associated with a variety of complications, 
there are recommendations that MP should not be routinely used in the treatment of 
patients with acute SCI (Hurlbert et al., 2013). Of note is the fact that it has been proposed 
that most of the adverse effects are due to toxicity associated with the high systemic dosage 
of MP, whereas the modest beneficial effects are due to insufficient dosing to the lesion site 
(Kim et al., 2009).  
2.9.3 Rehabilitation 
An additional component in SCI management is physical therapy and rehabilitation, 
which can make a significant impact on the overall recovery (Fouad and Tetzlaff, 2012; 
Raslan and Nemecek, 2012). After several studies showing that paralyzed cats with 
complete spinal cord transection could be trained to maintain weight supported stepping 
on a treadmill (Lovely et al., 1986, 1990; Barbeau and Rossignol, 1987; de Leon et al., 1998) 
the potential of the plasticity within the adult spinal cord became clear (Roy et al., 2012). 
The observations suggesting that plasticity after injury in the spinal cord is significantly 
influenced by physical activity led to novel rehabilitation strategies for SCI (Silva et al., 
2014), including developing of robotic systems for automating locomotor training in 
patients (Wu M et al., 2012). However, although rehabilitative physiotherapy and training 
are nowadays routinely used in many centers around the world after SCI, the optimal use of 
rehabilitative training, the underlying mechanisms and possible side effects are still to be 
determined (Marsh et al., 2010; Onifer at al., 2011; Fouad and Tetzlaff, 2012). 
 
Overall, the long-term outcome after SCI is a combination of the initial extent of the 
injury, natural recovery from it, surgical and pharmacological interventions, rehabilitation, 
and social/community reintegration (Raslan and Nemecek, 2012). However, even despite 
early medical care and specialized rehabilitation, SCI is associated with a dramatic decrease 
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in quality of life for affected individuals, resulting in lower life expectancy than that of the 
general population (Ahoniemi et al., 2011; Varma et al., 2013). Therefore, there is need to 
explore new therapeutic strategies for restoring neurological function after SCI and also to 
expand the knowledge on the cellular and molecular mechanisms of this devastating 
condition.   
2.10 ANIMAL MODELS IN SCI RESEARCH 
The use of animal models is crucial for studying SCI mechanisms and development of 
new SCI treatments (Silva et al., 2014). Rat and mouse are the most widely used species in 
SCI research (Silva et al., 2014). Despite the fact that SCI pathophysiology in mice is 
probably even further different from human SCI pathophysiology than in rats (Rosenzweig 
and McDonald, 2004), use of mouse SCI models has increased exponentially. This is mainly 
due to the availability of genetically modified mice, which allow elucidating the function of 
specific genes in molecular mechanisms of secondary injury and repair (Kundi et al., 2013; 
Zhang et al., 2014). The use of non-human primates, although is very important to prove 
safety and efficacy in the late stages of treatment development, is limited due to high costs 
and ethical reasons (Silva et al., 2014). 
Three general classes of SCI experimental animal models are frequently used: transection, 
contusion and compression (Rosenzweig and McDonald, 2004).  
The transection-based or laceration model requires the opening of the dura and cutting 
of spinal cord with a sharp instrument, usually microsurgical knife or spring scissors 
(Rosenzweig and McDonald, 2004, Zhang et al., 2014). This SCI model is useful primarily 
for assessment of axon regeneration after SCI. Because transection or full disruption of 
spinal cord is relatively rarely observed in human patients (Rowland et al., 2008) many 
researchers use compression and contusion injury models (Rosenzweig and McDonald, 
2004; Silva et al., 2014).  
The compression injury model is induced by compressing the spinal cord with a 
modified aneurysm clip (Rivlin and Tator, 1978), forceps, or a compression balloon 
(Borgens and Shi, 2000; Vanicky et al., 2001). The clip compression model allows precise 
control over the applied pressure and the time of compression, however, this model does 
not truly mimic human injury (Kundi et al., 2013). Insertion of balloons also produces 
adjustable compression lesions, however, this method is not optimal in rodents because of 
their small subarachnoid space (Vanicky et al., 2001).  
The contusion models are currently believed to be the most clinically relevant injury 
models of SCI (Kwon et al., 2010; Zhang et al., 2014). This type of SCI model is induced by 
hitting the exposed spinal cord with a blunt contusion force without disruption of the dura. 
Several types of computer-controlled contusion devices are available that produce 
consistent and reproducible contusion injuries in rats and mice (Wrathall et al., 1985; 
Gruner, 1992; Jakeman et al., 2000; Young, 2002; Scheff et al., 2003; Ghasemlou et al., 2005). 
Currently the most widely used are Ohio State University's electromagnetic spinal cord 
injury device (ESCID), New York University's MASCIS Impactor (NYU Impactor) and 
Infinite Horizone Impactor (IH Impactor) (Ghasemlou et al., 2005). While ESCID uses 
electromagnetic force to create contusion of the spinal cord (Jakeman et al., 2000), NYU 
Impactor utilizes the dropping a rod of different weights from different heights (Gruner, 
1992; Young, 2002). The NYU Impactor has been extensively utilized on rats but does not 
produce reproducible lesions in mice (Zhang et al., 2014). In contrast to the NYU Impactor, 
the IH Impactor allows the experimenter to determine the severity of injury by adjusting 
the impact force that is applied to the exposed spinal cord (Scheff et al., 2003). After 
laminectomy, the impactor tip rapidly displaces the exposed spinal cord tissue and when 
the desired force is obtained, it is withdrawn (Scheff et al., 2003). Importantly, recently, in 
addition to the widely used thoracic SCI models, contusion cervical SCI models were 
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developed in rats and mice using the IH Impactor (Aguilar and Steward, 2010; Lee et al., 
2012; Streijger et al., 2013). This is of utmost importance since the majority of human spinal 
cord injuries occur in the cervical spinal cord (Norenberg et al., 2004; Lee et al., 2012; 
Streijger et al., 2013). 
The main advantages and disadvantages of SCI models are summarized in Table 1. 
 
Table 1.Summary of SCI models 
 
Instrument Mechanism Advantages Disadvantages Animal 
Knife, 
scissors Transection 
Easy to perfom, large 
animals, optimal for 
regeneration studies 
Uncommon clinical SCI 
type, not suitable to study 
pathophysiology of 
secondary injury 
Mice, rats, cats, 
dogs, primates 
Clip Compression 
Widely used,  
reproducible,                
easy to perform, 
inexpensive, controlled 
force and duration  
Injury parameters not 
recorded Mice, rats 
Forceps Compression Easy to perform, inexpensive 
Injury parameters not 
recorded Mice, rats 
Baloon Compression Inexpensive,          large animals 
Not optimal in rodents, 
inconsistent injury, injury 
parameters not recorded 
Dogs, rabbits, 
primates 
ESCID Contusion 
Reproducible,             
consistent force and 
displacement, most 
clinically relevant 
Not commercially available, 
requires vertebral 
stabilization, requires 
displacement calibration 
Mice, rats 
NYU Impactor Contusion 
Widely used, 
Reproducible,           
most clinically relevant  
Requires vertebral 
stabilization,                    
not optimal in mice 
Mice, rats 
IH Impactor Contusion 
Widely used, 
Reproducible, 
consistent force, most 
clinically relevant 
Expensive,                        
requires vertebral 
stabilization  
Mice, rats 
2.11 PRECLINICAL STRATEGIES FOR SCI TREATMENT 
Although effective treatments for SCI remain limited, in recent years there have been 
many promising studies from the clinical translational perspective that are aimed at 
preventing secondary damage, promoting regeneration and replacing of destroyed spinal 
cord cells (Varma et al., 2013; Silva et al., 2014).  
2.11.1 Targeting secondary injury following SCI 
Given the crucial role of the secondary injury cascade in SCI pathogenesis a variety of 
therapies have been exploited to reduce excitotoxic damage to neurons, decrease oxidative 
stress and alter neuroinflammation (Hawryluk et al., 2008; Rowland et al., 2008; Kwon et al., 
2011; Varma et al., 2013; Silva et al., 2014).   
 
Targeting excitotoxicity following SCI 
Since overstimulation of NMDA receptors due to high glutamate levels after SCI leads to 
the uncontrolled influx of extracellular calcium and sodium into the cell and results in 
neuronal and glial damage (Fehlings and Agrawal, 1995; Agrawal and Fehlings, 1996, 1997; 
Kwon et al., 2004; Rowland et al., 2008), the therapeutic potential of either sodium channel 
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blockers, such as riluzole, or NMDA receptor antagonists, such as magnesium sulfate, have 
been studied in SCI in order to protect the spinal cord tissue from excitotoxic injury.  
Riluzole is a benzothiazole anticonvulsant, which has been approved for patients with 
amyotrophic lateral sclerosis (ALS) (Miller et al., 2007). The neuroprotective effects of 
riluzole result from blockade of voltage-activated sodium and calcium ion channels, 
inhibiting presynaptic glutamate release and activating potassium ion channels (Doble, 
1996; Duprat et al., 2000; Wang et al., 2004). In animal models of SCI, Riluzole has been 
found to promote tissue sparing, decrease oxidative stress, reduce neuronal loss and 
promote functional recovery (Stutzmann et al., 1996; Mu et al., 2000; Schwartz and Fehlings, 
2001; Ates et al., 2007; Nógrádi et al., 2007). Additionally, Riluzole may promote outgrowth 
of sensory neurons (Shortland et al., 2006). Based on these encouraging preclinical results 
two multicenter clinical trials for acute human SCI have been initiated (NCT00876889 and 
NCT01597518). The recently completed NCT00876889 Phase I study demonstrated that 
Riluzole treatment was well tolerated and the pilot data suggested that Riluzole may have a 
beneficial effect on motor outcome in cervical SCI that was manifest at 90 days postinjury 
(Grossman et al., 2014). Further studies of the pharmacokinetics, safety, and effects of 
Riluzole on neurological outcome in acute traumatic SCI will be carried out in a phase II 
trial (Grossman et al., 2014).  
The potential mechanisms of magnesium sulfate action include the attenuation of 
excitotoxicity by blockage of NMDA receptors and of voltage-gated calcium channels 
resulting in reduction of intracellular calcium levels, the inhibition of free radical 
generation and glutamate release, as well as the reduction of apoptosis (Nowak et al., 1984; 
Lee et al., 2004; Kwon et al., 2009). In SCI animal models, magnesium sulfate administration 
has been shown to improve tissue sparing, reduce apoptosis and lipid peroxidation, restore 
BSB integrity, and improve functional recovery (Kaptanoglu et al., 2003; Ozdemir et al., 
2005; Wiseman et al., 2009). More recently, it was demonstrated that magnesium 
formulated within a hydrophilic polymer, polyethylene glycol, resulted in improved tissue 
sparing at the lesion site and greater locomotor recovery after thoracic and cervical rodent 
SCI even when administered intravenously at a low doses (Ditor et al., 2007; Kwon et al., 
2009; Lee JH et al., 2010a). Importantly, the formulation of magnesium within polyethylene 
glycol will be used in the upcoming Phase II multicenter clinical trial (Silva et al., 2014). 
Interestingly, memantine, a clinically used NMDA receptor antagonist, was not protective 
after experimental SCI probably due to insufficient affinity of memantine for spinal cord 
NMDA receptors (von Euler et al., 1997). 
AMPA/kainic acid receptor antagonists have also been tested in preclinical SCI studies. It 
has been shown that 2,3-dihydro-6-nitro-7-sulfamoyl-benzo(f)quinoxaline (NBQX) 
promotes grey matter sparing and improves functional recovery after thoracic SCI 
(Wrathall et al., 1996, 1997), but not cervical SCI (Gensel et al., 2012). An AMPA-specific 
antagonist, Topiramate, which is clinically used for treatment of migraines and epileptic 
seizures, was recently reported to preserve oligodendrocytes and neurons after severe 
cervical SCI. However, in this study Topiramate did not promote functional recovery and 
its neuroprotective effect did not expand to moderate SCI (Gensel et al., 2012). Further 
studies are required to estimate the therapeutic potential of Topiramate for SCI treatment.  
 
Targeting oxidative stress following SCI 
As oxidative stress is strongly implicated in SCI pathogenesis, alleviating free radical 
damage is considered to be an effective strategy in SCI treatment (Hall, 2011; Jia et al., 2012). 
The assumption that antioxidants may minimize the degree of secondary damage has 
resulted in extensive research on the neuroprotective properties of different antioxidant 
compounds in SCI preclinical models (Jia et al., 2012). Probably one of the first antioxidants 
shown to be beneficial for SCI recovery was vitamin E. Supplementation with high-dose 
oral vitamin E attenuates posttraumatic ischemia in spinal cord white matter and 
significantly improves hind limb motor function compared to controls when it is 
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administered before injury (Hall and Wolf, 1986; Anderson et al., 1988; Iwasa et al., 1989). 
However, despite these beneficial effects, the use of vitamin E for treatment of acute SCI is 
limited due to the long time required to achieve a significant increase in CNS tissue levels 
(Machlin and Gabriel, 1982). Inhibition of lipid peroxidation is also one of the main 
mechanisms of MP action (Hall et al., 1992). However, the potential for adverse effects has 
resulted in the continued search for compounds with antioxidant properties that are safer 
and more effective than MP. Furthermore, given the complexity of the oxidant-antioxidant 
system, instead of attempting to restore the balance by the administration of one 
antioxidant or another, a promising alternative might be to enhance endogenous protection 
from oxidative stress by activating the Nrf2-ARE pathway (Hybertson et al., 2011). 
Importantly, while the Nrf2-ARE pathway is induced after SCI, it is obviously unable to 
provide adequate protection and therefore must be amplified and temporally accelerated in 
order to combat oxidative damage induced by SCI (Miller et al., 2014). Hence, induction of 
Nrf2-ARE pathway in order to augment endogenous antioxidant defences may be a useful 
approach to SCI treatment (Jia et al., 2012). Recently, the administration of a natural 
activator of Nrf2, sulforaphane, to injured rats has been shown to enhance Nrf2 expression 
and phase II detoxification enzyme production leading to neuroprotection with enhanced 
tissue sparing and improvement in coordination (Benedict et al., 2012; Wang X et al., 2012b). 
The potential of Nrf2 activators has been further confirmed as dimethyl fumarate, recently 
identified as a novel Nrf2 activator, has been shown to be beneficial in two Phase III clinical 
trials and has been approved as a first-line oral treatment of multiple sclerosis by FDA and 
European Medicines Agency (EMA) (Ruggieri et al., 2014). To date, there is no information 
available about clinical trials involving compounds activating Nrf2 in SCI.  
Since α,β-unsaturated aldehyde acrolein, a reactive byproduct of lipid peroxidation, is 
likely responsible for continuously propagating degeneration in SCI (Lovell et al., 2000; Luo 
and Shi, 2004; Luo et al., 2005; Hamann et al., 2008; Hamann and Shi, 2009) suppressing 
acrolein might be a promising strategy for SCI treatment (Hamann and Shi, 2009; Park et al., 
2014). Indeed, in a recent study hydralazine, a proven acrolein scavenger, was shown to 
ameliorate tissue damage, motor deficits, and neuropathic pain in the rat contusion SCI 
model (Park et al., 2014). 
 
Targeting inflammation following SCI 
Traditionally immune reactions following SCI have been considered to be 
unambiguously deleterious to axonal regeneration and functional recovery (Taoka et al., 
1997; Popovich et al., 1999; Young, 2002; Profyris et al., 2004) and therefore the efforts of 
many researchers have been directed to limiting inflammation after SCI.  
The nonsteroidal anti-inflammatory drugs (NSAIDs), such as indomethacin and 
ibuprofen, which are known as potent inhibitors of endogenous prostaglandin synthesis, 
were used in early attempts to attenuate the inflammatory components of the secondary 
injury cascade after SCI (Priestley et al., 2012; Silva et al., 2014). Although indomethacin 
treatment in certain studies resulted in decreased edema and tissue damage as well as 
reduced microgliosis and astrogliosis (Winkler et al., 1993; Schwab et al., 2004; Pantovic et 
al., 2005), behavioral outcomes were rather contradictory (Simpson et al., 1991; Guth et al., 
1994) and even adverse effects have been reported, suggesting that indomethacin treatment 
may be harmful in SCI (Guven et al., 1999). Interestingly, high doses of ibuprofen have been 
found to promote functional recovery when administrated 3 or 7 days post injury (Fu et al., 
2007; Wang et al., 2009). These benefits might be in part attributed to the ability of 
ibuprofen to reduce RhoA activation (Zhou et al., 2003). Since small GTPase RhoA is a key 
molecule in the axonal re-growth inhibitory cascade (Kopp et al., 2012), ibuprofen in 
addition to attenuation of inflammation is believed to promote axonal sprouting (Fu et al., 
2007; Wang et al., 2009; Xing et al., 2011), prevent loss of oligodendrocytes, and enhance 
myelination (Xing et al., 2011). However, re-assessment of Fu et al., 2007 data only partially 
replicated the observed behavioral benefits and failed to detect any effect of ibuprofen 
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treatment on axonal growth (Sharp et al., 2013). Moreover, in another recent study, chronic 
ibuprofen administration after rat contusion SCI, despite early positive effect on reducing 
microgliosis, failed to provide functional or histological evidence of neuroprotection. This 
suggests that early inhibition of inflammation may be detrimental for recovery from SCI 
(Redonda-Castro and Navarro, 2014). Nevertheless, in the beginning of 2014 a clinical trial 
in order to assess safety of ibuprofen to treat acute traumatic SCI has been initiated 
(NCT02096913). 
Statins, which are commonly used for the treatment of high cholesterol levels and 
prevention of cardiovascular/cerebrovascular diseases, are additionally known to possess 
antioxidant and anti-inflammatory properties (Stuve et al., 2003; Farooqui et al., 2007) and 
were also examined for SCI treatment. Atorvastatin has been found to reduce apoptosis, 
astrogliosis and macrophage infiltration resulting in increased tissue sparing and improved 
functional recovery (Pannu et al., 2005, 2007; Dery et al., 2009). However, similarly to 
ibuprofen, a recent attempt to replicate these results failed to demonstrate any beneficial 
outcome (Mann et al., 2010) and therefore further preclinical investigation of statins in SCI 
is warranted.  
Erythropoietin (EPO) is a cytokine stimulating proliferation and differentiation of 
erythroid precursor cells (Jelkmann, 1992). After SCI, EPO provided neuroprotection by 
reducing inflammation and oxidative stress, limiting neuronal apoptosis, and increasing 
tissue sparing, which resulted in improved locomotor recovery (Gorio et al., 2002; Boran et 
al., 2005; Yazihan et al., 2008; Huang et al., 2009; Ning et al., 2011; Wang S et al., 2012). 
Derivatives of EPO lacking hematopoietic effects, such as asialoerythropoietin and 
carbamylated erythropoietin, have also been shown to be neuroprotective in preclinical SCI 
models (Erbayraktar et al., 2003; Leist et al., 2004). Interestingly, recently EPO was shown to 
promote the induction of Nrf2 signaling pathway after SCI, suggesting a novel mechanism 
of EPO-mediated neuroprotection (Jin et al., 2014a). However, despite these promising 
results two studies were not able to confirm the efficacy of EPO in experimental SCI (Mann 
et al., 2008; Pinzon et al., 2008a). Furthermore, EPO has been also tested in patients with SCI. 
However, this clinical trial was suspended without public explanations (NCT00561067) and 
another clinical trial administrating EPO to patients with malignant spinal cord 
compression was also prematurely terminated due to insufficient accrual (NCT00220675). 
The broad-spectrum antibiotic minocycline is known to reduce neural inflammation and 
prevent cell death in several animal models of neurodegenerative diseases and CNS trauma 
(Tikka et al., 2001; Stirling et al., 2005). Beneficial effects of minocycline for SCI treatment 
have been reported in a number of studies and include inhibition of lipid peroxidation, 
reduction of astrogliosis and microgliosis, enhancement of axonal sprouting, reduction of 
lesion size and improvement of functional recovery (Lee et al., 2003; Wells et al., 2003; 
Stirling et al., 2004; Teng et al., 2004; Festoff et al., 2006; Sonmez et al., 2013). However, 
similarly to the above-mentioned compounds, several studies have failed to demonstrate 
beneficial effects of minocycline in SCI models (Lee JH et al., 2010b; Pinzon et al., 2008b; 
Saganova et al., 2008). Despite this contradictory data, a human clinical trial was initiated in 
Canada (NCT05594494). Minocycline treatment was proven to be feasible and safe since no 
severe adverse effects were reported. Importantly, it showed a tendency towards 
improvement in several studied parameters (Casha et al., 2012). Although this study did 
not confirm the efficacy of minocycline for SCI treatment, the results were accepted as 
encouraging. In 2013, a Phase III Study of Minocycline in Acute Spinal Cord Injury was 
initiated in Calgary, Alberta and is currently recruiting participants (NCT01828203). 
In addition, numerous studies utilizing agents that target neuroinflammation in general 
or its cellular effectors have reported improved functional recovery following SCI. 
However, even at the clinical trial phase, these strategies failed to prove the expected 
beneficial effect (reviewed in David et al., 2012; Priestley et al., 2012; Plemel et al., 2014; 
Silva et al., 2014). Given that there is now strong evidence that not all immune cell subsets 
are detrimental and some are even beneficial, probably the desirable therapeutic strategy 
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might be to modulate the inflammatory response in such a way that to harness its beneficial 
effects and minimize its harmful effects, rather than to fully abolish it (Rossignol et al., 2007; 
David et al., 2012; Plemel et al., 2014; Silva et al., 2014).  
One of these attractive immunomodulatory strategies, which has emerged recently, is the 
manipulation on residing microglial cells or macrophages infiltrating the injured spinal 
cord in order to induce their polarization to the M2 state (David and Kroner, 2011; Guerrero 
et al., 2012; Jiang MH et al., 2012, 2013). Indeed, the introduction of substance P (Jiang MH 
et al., 2012, 2013) or temporal blockade of IL-6 (Guerrero et al., 2012) inhibits neutrophil 
recruitment, reduces TNF and IFN-γ levels, augments IL-4 and IL-13 expression and 
therefore promotes M2 macrophage polarization resulting in enhanced phagocytosis and 
axonal regeneration with subsequent improvement of locomotor recovery (Guerrero et al., 
2012). Recently, Guo et al., 2013 showed that administration of G-CSF within 72 h after SCI 
can promote an anti-inflammatory response via inhibiting M1 activation and favoring M2 
polarization. Interestingly, minocycline has recently been demonstrated to dampen 
selectively the M1 inflammatory response without altering M2 subsets (Kobayahi et al., 
2013). In light of this, IL-33, which is known to inhibit the M1 and augment the M2 
response, might be a promising candidate for immunomodulatory therapy following SCI. 
2.11.2 Regenerative approaches for SCI treatment 
As it was mentioned earlier in the chapter 2.4, the glial scar forms a physical barrier and 
by expressing inhibitory molecules including CSPGs and tenascin creates a 
microenvironment that is inhibitory to axonal regeneration within the injured spinal cord 
(McKeon et al., 1991; Silver and Miller, 2004; Fitch and Silver, 2008; Kawano et al., 2012; 
Cregg et al., 2014).  However, not only glial scar and CSPGs are responsible for the lack of 
regeneration after SCI. For instance, myelin contains several molecules that inhibit axonal 
growth after trauma (Schwab and Caroni, 1988; Schnell and Schwab, 1990; Chen et al., 2000; 
Grandpre and Strittmatter, 2001; Fournier et al., 2001). One of the most potent of these is the 
250-kDa glycoprotein Nogo-A. Interacting with its receptor Nogo-A activates RhoA, 
leading to growth cone collapse and axonal outgrowth inhibition (Chen et al., 2000; 
Grandpre and Strittmatter, 2001; Fournier et al., 2001; Schwab, 2004; Teusch and Kiefer, 
2006). In addition, many ligands including myelin-associated glycoprotein and 
oligodendrocyte myelin glycoprotein bind and activate Nogo receptors and, therefore, 
prevent regeneration after SCI (Barton et al., 2005; Lauren et al., 2007). 
In order to overcome the inhibitory effect of myelin components on regeneration 
strategies directed to blockade of Nogo-A or its receptors have been proposed. Already 
prior to Nogo-A discovery, it had been shown that a blocking antibody (IN-1) raised 
against myelin-associated neurite growth inhibitory proteins induced axonal sprouting and 
long-distance corticospinal regeneration leading to improved behavioral outcome after rat 
SCI (Schnell and Schwab, 1990; Bregman et al., 1995). After Nogo-A was identified (Chen et 
al., 2000) the beneficial effect of anti-Nogo-A antibodies on regeneration after SCI have been 
demonstrated in rats (Liebscher et al., 2005; Atalay et al., 2007) and non-human primates 
(Fouad et al., 2004; Freund et al., 2006, 2007, 2009). Similarly, blocking Nogo receptors with 
the competitive antagonist NEP 1–40 enhances corticospinal tract growth and functional 
recovery after SCI (GrandPre at al., 2002; Li and Strittmatter, 2003). However, a more recent 
study failed to replicate the positive effect of NEP 1-40 (Steward et al., 2008). Nevertheless, 
the pre-clinical data supporting the beneficial effect of Nogo-A inhibition for SCI recovery 
resulted in a Phase I safety trial in patients with acute SCI (NCT00406016). Even though the 
trial was completed in 2011, no results have yet been reported. 
Interestingly, genetic deletion of Nogo or the Nogo receptor do not necessarly improve 
regeneration (Zheng et al., 2003; Teng and Tang, 2005; Zheng et al., 2005; Steward et al., 
2007; Young, 2014). Although it has been reported that Nogo knockout mice are able to 
regenerate (Kim et al., 2003), other studies were not able to confirm these results (Zheng et 
al., 2003, 2005; Steward et al., 2007) or reported only a modest increase of regenerative 
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capacity (Simonen et al., 2003; Lee JK et al., 2010). It is also worth mentioning that 
regeneration was also observed in the injured spinal cord even without eliminating Nogo 
or glial scar (Liu et al., 2010; Zukor et al., 2013; Lewandowski and Steward, 2014; Young, 
2014). Therefore, it is still questionable whether Nogo, CSPGs and glial scar are sufficient to 
abolish spinal cord regeneration. Instead of limiting the inhibition, a useful approach may 
be to increase intrinsic regenerative mechanisms (Young, 2014). 
2.11.3 Gene therapy approaches for SCI treatment 
The idea to deliver therapeutic genes using viruses as vectors in order to treat human 
diseases first emerged more than 40 years ago (Friedmann and Roblin, 1972). Since then 
many viral systems, such as adenoviruses (AV), adeno-associated viruses (AAV), 
herpesviruses (HV) and retroviruses (RV) including lentiviruses (LV) have been developed 
as vectors for therapeutic gene delivery (Lim et al., 2010; Lentz et al., 2012). Each of them 
possess their own properties which determine specific advantages and disadvantages of 
every vector type. To estimate the potential of different viral vectors it is important to 
consider several aspects including specific tropism for target tissue, efficiency of 
transduction of the target cells, duration and level of transgene expression and side effects 
such as the host immune response (Lim et al., 2010; Lentz et al., 2012; Maguire et al., 2014).  
Viral vectors are powerful tools for transgene delivery to specific regions of the brain. 
Due to the limitations imposed by the blood-brain barrier (BBB), the most common delivery 
route of viral vectors is direct injection into the brain parenchyma, which allows bypassing 
the BBB (Maguire et al., 2014). However, recently several AAV serotypes were shown to be 
able to cross the BBB and provide expression during systemic delivery (Zincarelli et al., 
2008; Foust et al., 2009; Zhang et al., 2011; Bourdenx et al., 2014). LV vectors are believed to 
have low immunogenicity and an ability to transduce neuronal cells with high efficiency. 
Importantly, they possess higher packaging capacity than AAV vectors (Wong et al., 2006; 
Lentz et al., 2012; Palfi et al., 2014). The ability of lentiviruses to integrate into the host 
genomes allows stable transduction of the host cells (Wong et al., 2006; Lundberg et al., 
2008; Lim et al., 2010). However, random integration may lead to insertional mutagenesis 
and is the primary safety concern for LV use in gene therapy (Dave et al., 2004; Bokhoven et 
al., 2009; Lim et al., 2010; Lentz et al., 2012). Substantial advancement in the field of gene 
delivery with lentiviruses was the development of non-integrating lentiviral vectors that 
are deficient in integrase activity (Apolonia et al., 2007; Sarkis et al., 2008). Random 
integration of AAV vectors associated with tumorigenesis in mice has also been reported 
(Deyle and Russell, 2009). However, in the case of AAV vectors the risk of insertional 
mutagenesis is very low (Lentz et al., 2012). 
Gene therapy for several neurodegenerative diseases including AD and PD has already 
moved from preclinical studies to Phase I and Phase II clinical trials (Tuszynski et al., 2005; 
Kaplitt et al., 2007; Christine et al., 2009; Mandel et al., 2010; Marks et al., 2010; Muramatsu 
et al., 2010; LeWitt et al., 2011; Palfi et al., 2014) and offers a promising approach also for 
SCI treatment.  
In SCI settings, gene delivery can provide long-term expression of therapeutic proteins 
in the injured spinal cord. For example, EPO delivery to the spinal cord by direct injection 
of HV vector in a model of cervical hemicord contusion resulted in robust and sustained 
EPO expression. Vector-mediated expression of EPO reduced the injury size and enhanced 
tissue sparing resulting in improved functional recovery (Wang S et al., 2012). Gene transfer 
of GDNF with adenovirus vector has been reported to preserve neuronal fibers and 
promote hind limb recovery following spinal cord contusion injury (Tai et al., 2003). 
Recently, chondroitinase ABC (ChABC) was delivered via LV vector in order to assess the 
efficacy of large-scale CSPG digestion after SCI. CSPGs are known to inhibit repair 
following SCI (Silver and Miller, 2004; Carulli et al., 2005; Bradbury and McMahon, 2006) 
and their large-scale digestion was found to result in significant neuroprotection and long-
term functional improvement following spinal contusion injury. Interestingly, LV-ChABC 
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gene transfer induced polarization of macrophages to alternatively activated M2 phenotype 
in this study (Bartus et al., 2014).  
In addition to single gene transfer, the delivery of different transcription factors to the 
injured spinal cord with gene therapy enables simultaneous induction or repression of 
various genes sharing a common regulatory pathway. For example, intraspinal delivery of 
AV-HIF-1α, a subunit of hypoxia-inducible factor 1, which is a transcription factor playing 
essential roles in the mammalian development and physiology, resulted in simultaneous 
induction of vascular endothelial growth factor (VEGF), antiapoptotic B-cell lymphoma 2 
(Bcl-2) and repression of proapoptotic bcl-2-like protein 4 (BAX). Amelioration of neuronal 
apoptosis and promoting of angiogenesis with HIF-1α gene delivery led to enhanced 
functional recovery (Chen et al., 2013). In another study, the intraspinal delivery of 
transcription factor Sox11, which is proposed to be involved in the development and 
regeneration of the brain (Jankowski et al., 2006), enhanced neuronal regeneration, 
increased expression of BDNF and promoted locomotor function after SCI (Guo et al., 2014).  
In oxidative stress conditions the simultaneous induction of antioxidant genes may be a 
better approach than administration of a single antioxidant, or gene transfer with 
individual antioxidant genes (Levonen et al., 2007, 2008). Since Nrf2 is orchestrating 
antioxidant and cytoprotective responses to oxidative and electrophilic stress (Hybertson et 
al., 2011; Gan and Johnson, 2013; Gao et al., 2014), overexpression of this transcription 
factor with gene delivery in the tissues affected by oxidative stress might be a promising 
therapeutic strategy. Recently, human Nrf2 was delivered into the mouse hippocampus, an 
area of the brain affected in AD. This resulted in sustained Nrf2 expression in the 
hippocampus and improved spatial learning and memory of transgenic AD mice 
(Kanninen et al., 2009). Whether Nrf2 gene transfer would be beneficial in SCI remains to be 
elucidated. 
2.11.4 Cellular approaches for SCI treatment 
Cell transplantation is a promising treatment strategy for promotion of repair in the 
injured spinal cord. A number of preclinical studies demonstrate that cell transplantation 
can provide neuroprotection by reducing inflammation and gliosis in the injured spinal 
cord and therefore ameliorate secondary injury enhancing preservation of host neuronal 
and glial cells. Cell therapy also restores lost tissue through replacement of damaged 
neuronal and glial cells and restoration of neuronal circuitry. Beneficial effects of cell 
therapy in SCI also include remyelination of spared axons, increased expression of 
beneficial neurotrophins/cytokines by transplanted or host cells, and stimulation of 
endogenous angiogenesis and neurogenesis. Importantly, transplanted cells create an 
environment favorable for plasticity and axonal regeneration (Mothe and Tator, 2012; 2013). 
Various cell types have been tested for transplantation into the injured spinal cord, 
including olfactory ensheathing cells, Schwann cells, mesenchymal stem cells, 
oligodendrocyte and neural progenitor cells (reviewed in Sahni and Kessler, 2010; Fehlings 
and Vawda, 2011; Tetzlaff et al., 2011; Wright et al., 2011; Mothe and Tator, 2012, 2013; 
Vawda and Fehlings, 2013; Dasari et al., 2014; Roet and Verhaagen, 2014; Silva et al., 2014). 
 
Olflactory ensheathing cells 
Olfactory ensheathing cells (OECs) are a specialized type of glia that exist exclusively 
within the olflactory system in the olfactory nerves and olfactory nerve layer of the 
olfactory bulb. These unique cells throughout the whole life of adult mammals actively 
support regeneration of primary olfactory axons from the olflactory mucosa in periphery 
into the olflactory balb in CNS (Doucette, 1991; Boyd et al., 2005; Mackay-Sim and St John, 
2011; Roet and Verhaagen, 2014) and therefore represent cells potentially capable of 
creating a microenvironment favorable for axonal regeneration across the injury site. 
For clinical application, the OECs can be isolated through nasal biopsies (Feron et al., 
1998; Bianco et al., 2004) and enough cells for autologous transplantation can be obtained 
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by culturing the cells for 4–6 weeks (Feron et al., 2005). Due to the time required to generate 
and culture the autologous cells their use in the acute stages of SCI is not possible (Feron et 
al., 2005; Rubio et al., 2008).  
In 1990s, Ramón-Cueto and Nieto-Sampedro were the first to report the use of OECs to 
repair the injured rat spinal cord (Ramón-Cueto and Nieto-Sampedro, 1994). Since this 
pioneering study, many research groups have reported improved functional recovery after 
OECs transplantation into a wide range of SCI models, including transections and 
contusions, and several mechanisms underlying functional recovery after OECs 
transplantation have been identified (Li et al., 1997; Ramón-Cueto et al., 2000; Lu et al., 2002; 
Plant et al., 2003; Ramer et al., 2004; López-Vales et al., 2006; Muñoz-Quiles et al., 2009; 
Ziegler et al., 2011; Granger et al., 2012). Probably the main one is the promotion of axonal 
outgrowth and the creation of a permissive pathway for axonal growth (Gladwin and Choi, 
2013). Other mechanisms include increased tissue sparing, reduction of astrogliosis and 
modulation of inflammation, remyelination and angiogenesis. In addition, the OECs 
produce and release neurotrophic factors, such as NGF and BDNF, and recruit Schwann 
cells to the injury site (Gladwin and Choi, 2013; Roet and Verhaagen, 2014; Silva et al., 2014).  
Despite numerous successful reports of regeneration with OEC transplantation, negative 
studies also exist (Takami et al., 2002a; Riddell et al., 2004; Barakat et al., 2005; Steward et al., 
2006; Pearse et al., 2007). The reasons for this are not very clear but may include variability 
of the cell sources, cell culture conditions or surgical techniques (Riddell et al., 2004; 
Tetzlaff et al., 2011; Gladwin and Choi, 2013).  
Nevertheless, the potential of the OECs has led to their use in clinical trials. A phase I/IIa 
clinical study was initiated in Australia to examine the effects of autologous transplantation 
of human OECs for treatment of chronic SCI. This study included 6 patients with complete 
thoracic paraplegia. After three years no adverse effects were detected, however, no 
significant functional improvement was either reported (Feron et al., 2005; Mackay-Sim et 
al., 2008). More encouraging are the results of the Phase I clinical trial recently completed in 
Poland (Tabakow et al., 2013). At one year after OECs transplantation into three patients 
suffering from chronic thoracic paraplegia, neurological improvement was observed in 
transplant recipients, but not in non-operated controls. Importantly, no adverse effects 
related to transplantation of OECs at one year after surgery have been reported. Safety and 
possible efficacy of OECs transplantation were also shown in six patients with complete 
chronic spinal cord injuries which received fetal OECs transplants in China (Rao et al., 
2013). These results show that implantation of OECs in humans appears safe and well-
tolerated, however, to confirm the beneficial effect of the therapy future clinical trials 
should include larger numbers of patients (Roet and Verhaagen, 2014). 
 
Schwann cells 
Schwann cells (SCs) are the myelin-forming cells of the peripheral nervous system. 
Following SCI endogenous SCs are known to migrate from the periphery into the injury 
site and remyelinate the spared axons (Beattie et al., 1997; Oudega and Xu, 2006; Fehlings 
and Vawda, 2011). In addition, they provide injured axons with a permissive 
microenvironment for regeneration producing extracellular matrix molecules, such as 
laminin, fibronectin and collagen, which are known to support axon growth, and releasing 
of a variety of growth factors, such as NGF, BDNF, NT3, CNTF, GDNF and FGF. SCs also 
express on their surface cell adhesion molecules that support axon growth (reviewed in 
Oudega and Xu, 2006; Silva et al., 2014). 
Transplantation of SCs for SCI repair is promising as it is possible to obtain them from an 
autologous source and these cells are not tumorigenic (Fehlings and Vawda, 2011). 
Although several studies have demonstrated the ability of transplanted SCs to promote 
axonal regeneration and remyelination in the injured spinal cord, which resulted in 
functional improvement (Takami et al., 2002a; Barakat et al., 2005; Firouzi et al., 2006; 
Schaal et al., 2007), it is generally thought that SCs alone are not sufficient to promote 
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regeneration of corticospinal tract axons. Because of this, SCs are often used in combination 
with other treatments, such as neuroprotective agents or other cell substrates (Fehlings and 
Vawda, 2011; Tetzlaff et al., 2011). For autologous SCs transplantation, the sacrificing of 
peripheral nerve is required. To overcome this limitation, SCs have been derived from skin 
or bone marrow. When transplanted into contused or transected spinal cord these 
treatments lead to functional improvement in preclinical models (Kamada et al., 2005; 
Biernaskie et al., 2007; Novikova et al., 2011). However, the time required for generation of 
amount of cells sufficient for transplantation is another limitation of this autologous 
approach for the acute SCI treatment (Tetzlaff et al., 2011). 
Despite the lack of preclinical data a clinical trial utilizing SCs has been completed in 
Iran. In this study autologous SCs were transplanted into 33 patients with chronic thoracic 
and cervical SCI. After 2 years of follow-up no adverse effects were reported and 
neurological improvements have been observed in some of patients in terms of motor, 
sensory, and sphincter abilities (Saberi et al., 2008, 2011). Recently, a phase I clinical trial has 
been initiated in the USA which aims to assess the safety of autologous human SCs in 
subacute SCI patients (NCT01739023). 
 
Mesenchymal stem cells 
Mesenchymal stem cells (MSCs) are multipotent, tissue-specific stem cells that can be 
obtained from multiple easily accessible sources such as bone marrow, umbilical cord blood, 
Wharton's jelly, the placenta, dental pulp and adipose tissue (reviewed in Vawda and 
Fehlings, 2013; Dasari et al., 2014). The possibility to avoid the immunological and ethical 
problems together with low tumorigenesis of the transplanted cells make MSCs attractive 
for different regenerative applications including SCI. Importantly, transplanted MSCs 
display significant anti-inflammatory, antiapoptotic and immunosuppressive features, 
which might be useful for SCI repair (Uccelli et al., 2011; Vawda and Fehlings, 2013; Dasari 
et al., 2014; Silva et al., 2014).  
The bone marrow derived MSCs (bmMSCs) are probably the most widely used stem 
cells in SCI experiments (Tetzlaff et al., 2011; Vawda and Fehlings, 2013; Silva et al., 2014). 
Although their neurogenic differentiation potential is controversial (Brazelton et al., 2000; 
Mezey et al., 2000; Woodbury et al., 2000; Castro et al., 2002; Lu et al., 2004), bmMSCs were 
successfully used in a number of preclinical studies utilizing rodent, porcine, canine and 
nonhuman primate SCI models (Cízková et al., 2006; Deng et al., 2006; Zurita and Vaquero, 
2006; Lu et al., 2007; Zurita et al., 2008; Shin et al., 2013; Penha et al., 2014). The beneficial 
effect of bmMSCs transplantations mostly has been reported after intraspinal delivery, but 
has also been observed after intrathecal (Ohta et al., 2004; Urdzíková et al., 2014) or even 
intravenous transplantation (Urdzíková et al., 2006; Shin et al., 2013). However, some 
studies have reported no functional benefits from bmMSCs transplantation (Yano et al., 
2006; Yoshihara et al., 2006; Sheth et al., 2008) or have detected highly variable outcomes 
(Neuhuber et al., 2005; Himes et al., 2006).  
The exact mechanisms by which bmMSCs are able to provide neuroprotection and 
improve functional recovery are still debated. However, they apparently include secretion 
of trophic factors, modulation of inflammation, recruitment of endogenous stem and 
Schwann cells leading to reduced cell death, and increased tissue sparing (Tetzlaff et al., 
2011). Interestingly, in a recent study bmMSCs transplanted in an acute SCI rat model 
modified the inflammatory environment in the lesion by macrophages polarization from 
M1 to M2 phenotype and therefore provided an environment favorable for axonal growth 
and functional recovery (Nakajima et al., 2012). 
The relatively convincing preclinical data as well as the easy access to bmMSCs for 
autotranplantations explain their use in several clinical trials. However, these studies have 
enrolled small numbers of patients and mostly have used autologous BM-derived cells 
instead of purified stromal cells. Despite the fact that transplanted cells were safe and even 
provided modest improvement (Sykova et al., 2006; Yoon et al., 2007; Karamouzian et al., 
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2012; Dai et al., 2013; Jiang PC et al., 2013) long-term and large scale multicenter clinical 
studies are required to determine the precise effect of MSCs therapy. Several clinical trials 
are currently active or recruiting patients in order to analyze the safety and efficacy of 
autologous MSCs transplantation in patients with SCI (NCT01694927, NCT01446640, 
NCT01676441 and NCT02152657). 
MSCs from umbilical cord gelatinous matrix, known as Wharton's jelly reduce 
microgliosis and astrogliosis, and promote axonal regeneration associated with functional 
recovery when transplanted into a rat model of spinal cord transection (Yang et al., 2008). A 
similar beneficial outcome was reported after transplantation of MSCs derived from 
umbilical cord blood (Park et al., 2012; Cui et al., 2014), adipose tissue (Zhang et al., 2009; 
Zhou et al., 2013; Menezes et al., 2014) and dental pulp (de Almeida et al., 2011; Sakai et al., 
2012). However, more preclinical data are required in order to move these types of cells to 
clinical trials (Silva et al., 2014). 
 
Neural stem/progenitor cells 
Neural stem/progenitor cells (NS/PCs) are multipotent cells that self-renew, readily 
expand in vitro and are able to differentiate into neurons, oligodendrocytes, and astrocytes. 
They can be obtained from adult and fetal brains/spinal cords, pluripotent ESCs or iPSCs 
(Figure 4). Transplantation of NS/PCs in SCI settings aims at the replacement of lost cells, as 
well as provision of trophic support to the survived tissues (Gage, 2000; Fehlings and 
Vawda, 2011; Mothe and Tator, 2013; Nakamura and Okano, 2013; Puttonen et al., 2013; 
Silva et al., 2014). The great advantage of NS/PCs for transplantation is that unlike other 
types of stem cells they are inherently specified along the neural lineage (Mothe and Tator, 
2013). 
Adult NS/PCs are typically harvested from the subventricular zone of the brain or 
ependymal region of rodent spinal cord, and then expanded as neurospheres or as an 
adherent monolayer prior to transplantation (Fehlings and Vawda, 2011; Mothe et al., 2011; 
Mothe and Tator, 2013; Faulkner et al., 2014). When transplanted into rat or mouse spinal 
cord, adult-derived rodent NS/PCs have been shown to promote functional recovery in 
several studies (Hofstetter et al., 2005; Karimi-Abdolrezaee et al., 2006; Parr et al., 2008; 
Bottai et al., 2008; Moreno-Manzano et al., 2009; Cusimano et al., 2012; Wilcox et al., 2014). 
Grafted NS/PCs mainly developed an oligodendroglial phenotype, while the expression of 
neuronal markers was generally rare (Vroemen et al., 2003; Karimi-Abdolrezaee et al., 2006; 
Parr et al., 2007, 2008; Wilcox et al., 2014). Recently, human NS/PCs isolated from the adult 
spinal cord of organ transplant donors have been shown to differentiate to both glia and 
neurons following transplantation into rats with SCI, although no behavioral data has been 
reported (Mothe et al., 2011). The key advantages of adult-derived NS/PCs are the lack of 
tumorigenicity and ethical controversy. However, the very limited neuronal differentiation 
using the current protocols is a potential problem. In addition, autologous derivation of 
these cells is almost unfeasible in clinical settings (Fehlings and Vawda, 2011; Faulkner et al., 
2014). 
Several studies have shown that NS/PCs generated from mouse ESCs and rat fetal stem 
cells (FSCs) give rise to neurons, astrocytes and oligodendrocytes, form functional synapses 
with host neurons, and promote functional recovery when transplanted into an injured 
rodent spinal cord (McDonald et al., 1999; Ogawa et al., 2002; Okada et al., 2005). Human 
fetal forebrain-derived NS/PCs transplanted into immunodeficient mice with subacute 
(Cummings et al., 2005,2006; Hooshmand et al., 2009) or chronic SCI (Salazar et al., 2010) 
similarly integrated into the injured spinal cord, provided remyelination and improved 
functional recovery. Importantly, when subacutely transplanted into a non-human primate 
SCI model, these cells exhibit trilineage neural differentiation and also improve functional 
recovery (Iwanami et al., 2005).  
 
37 
 
 
 
 
Figure 4. Sources of NS/PCs for transplantation after SCI and their proposed effects in the 
injured spinal cord. 1 – cell replacement, 2 – remyelination, 3 - promoting axonal sprouting, 4 – 
secretion of neurotrophic factors, 5 – synapse formation, 6 – angiogenesis (modified from 
Mothe and Tator, 2012). 
In addition to ESCs-NS/PCs, oligodendrocyte progenitor cells derived from ESCs (ESC-
OPCs) remyelinate spared axons and promote functional recovery after transplantation into 
injured rat spinal cord (Nistor et al., 2005; Sharp et al., 2010). These promising results have 
led into a phase I clinical trial, which was initiated by Geron in 2009 and was the first 
approved clinical trial that utilized ESC-derived cells. However, the trial was discontinued 
in 2011 for financial reasons. Currently, one phase I/II clinical trial evaluating the safety and 
therapeutic potential of human fetal central nervous system stem cells (HuCNS-SC) in 
patients with thoracic SCI is ongoing (NCT01321333) and two more are recruiting patients 
(NCT01772810, NCT01725880). Moreover, in 2014 another clinical trial was initiated, which 
will evaluate the safety and efficacy of HuCNS-SC transplantation into patients with 
cervical SCI (NCT02163876). 
Despite the fact that preclinical studies overall show the beneficial potential and safety of 
ESCs/FSCs-derived progenitors for transplantations in SCI settings one of the potential 
concerns with transplantation of the cells from these sources is the possibility of 
tumorigenesis due to incomplete differentiation of pluripotent cells. In addition, the clinical 
applications of ESC/FSCs-derived NS/PCs are limited by ethical and immunological 
(allogeneic nature) reasons (Mothe and Tator, 2013). These limitations might be solved by 
using induced pluripotent cells (iPSCs) which are generated by reprogramming a 
specialized adult cells to an ESCs-like state (Tsuji et al., 2010; Fehlings and Vawda, 2011; 
Kobayashi et al., 2012; Kramer et al., 2013; Nakamura and Okano, 2013; Matsui et al., 2014). 
Reprogramming mouse fibroblasts by retroviral introduction of the transcription factors 
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Oct4, Sox2, c-Myc, and Klf4 was initially performed by Takahashi and Yamanaka in 2006 
(Takahashi and Yamanaka, 2006). In 2007, the first human iPSCs were generated using 
either the original transcription factors (Takashi et al., 2007) or a combination of Oct4, Sox2, 
Nanog, and Lin28 (Yu et al., 2007). Since then enormous progress has been made in iPSCs 
research including the new, improved methods of iPSCs generation (Okano et al., 2013). 
iPSCs share many properties with ESCs. They express stem cell markers, are capable of 
forming teratomas containing cell types from all three germ layers and have the potential to 
differentiate into every cell type of the human body (Patel and Yang, 2010; Kramer et al., 
2013; Nakamura and Okano, 2013; Okano et al., 2013). However, in contrast to ESCs, patient 
specific iPSCs do not have any ethical limitations. Importantly, being obtained from an 
autologous source, the iPSCs theoretically do not require immunosuppression, in contrast 
to allogeneic ESCs. Since SCI patients are prone to opportunistic infections (Nash et al., 
2000) immunosuppressive therapy would compromise their resistance to infections and 
interfere with healing processes (Nutt et al., 2013). Therefore, the possibility to avoid 
immunosuppressive treatments after transplantation is doubtlessly an advantage of iPSC 
over ESCs. Although iPSCs also have some potential for tumorigenesis, the development of 
non-integrating reprogramming methods substantially reduces this risk (Gonzalez et al., 
2011).  
Although preclinical studies evaluating iPSC-derived NS/PCs in SCI settings are scarce, 
the existing preliminary results look very promising. Mouse (Tsuji et al., 2010) and human 
(Nori et al., 2011; Fujimoto et al., 2012) iPSC-derived NS/PCs delivered subacutely into 
mouse contused spinal cord differentiate into trineural lineage, expresse neurotrophic 
factors, stimulate angiogenesis and axonal regrowth, improve remyelination, form 
synapses with host neurons and improve functional recovery. Recently, the beneficial 
outcome of iPSC-derived NSCs transplantations was also demonstrated in the model of 
spinal cord transection (Lu et al., 2014). Human iPSC–derived NS/PCs were further 
evaluated in a non-human primate model of cervical injury. Subacutely intraspinally 
transplanted cells enhance axonal sparing/regrowth and angiogenesis, prevent 
demyelination and promote functional recovery after SCI (Kobayashi et al., 2012). However, 
studies showing negative outcome of iPSC therapy also exist. Undifferentiated human 
iPSCs transplanted subacutely into nude rats failed to provide any benefits by 5 weeks after 
SCI compared to human fibroblast controls (Kramer et al., 2013), whereas in another study 
caudalized human iPSC-derived NS/PCs did not improve functional recovery in an early 
chronic SCI model (Nutt et al., 2013). 
Of note is the fact that most studies evaluating the efficacy of iPSC-derived cells for SCI 
transplantations have utilized immunodeficient rodents to avoid the host immune response. 
However, due to the long time required for generation of appropriately characterized and 
safe autologous iPSC lines, the first clinical trial with iPSCs at least in acute or subacute SCI 
would still require allogeneic cells and therefore immunosuppressive therapy (Fehlings and 
Vawda, 2011; Faulkner et al., 2014). Therefore, more preclinical studies, especially those 
including an immunosuppressive regimen, are required before iPSC-based clinical trials 
can be initiated. 
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3 Aims of the study 
Direct mechanical trauma to the spinal cord causes primary damage, which is followed 
by a wave of complex progressive biochemical and cellular processes that make up the 
secondary injury. Several pathophysiological mechanisms including ionic balance 
disturbances, excitoxicity, oxidative stress and inflammation participate in the secondary 
injury cascade and greatly exacerbate neurological deficits and complicate recovery. In 
spite of almost 4000 years of history, treatment of SCI remains largely palliative. Deep 
understanding of mechanisms involved in the secondary injury cascade as well as the 
search for novel strategies efficiently targeting the secondary injury mechanisms are some 
of the main goals in SCI preclinical research.   
The transcription factor Nrf2 is a unique ‘’master regulator’’ of the antioxidant, 
detoxification, and cell defence response and extremely important for protection from 
oxidative stress. IL-33 is a novel cytokine possessing high potential to beneficially modify 
the CNS microenvironment in inflammatory settings. The impact of Nrf2 in protection from 
secondary injury requires further assessment, whereas IL-33 is a new player in the SCI field. 
Induced pluripotent cells are already at the threshold of translation into humans, however, 
available preclinical studies in SCI are scarce and results are controversial.  
This study was carried out to exploit three novel preclinical strategies to SCI treatment: 
augmenting intrinsic protection against oxidative stress with Nrf2 gene transfer, IL-33-
mediated modulation of inflammation, and adult stem cell therapy. Furthermore, it aims to 
increase our knowledge of Nrf2 and IL-33, both involved in key mechanisms of secondary 
injury, namely oxidative stress and inflammation.  
 
The specific aims were the following: 
 
1. Assess the function of the Nrf2-ARE pathway in the injured spinal cord and exploit 
the possibility to improve recovery following SCI by Nrf2 gene transfer into mouse 
contused spinal cord.  
 
2. Study the cellular localization and expression of intracellular IL-33 in the injured 
spinal cord, evaluate the efficacy of recombinant IL-33 treatment for SCI recovery, 
and to clarify the mechanisms of recombinant IL-33 action in a mouse contusion SCI 
model. 
 
3. Estimate the therapeutic potential of neural progenitors derived from human iPSCs 
for contusion SCI recovery when continuous pharmacological immunosuppression is 
used. 
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4 Materials and methods 
4.1 ANIMALS (I - III) 
All experimental procedures were approved by the Animal Experiment Committee in 
State Provincial Office of Southern Finland and carried out according to the national 
regulation of the usage and welfare of laboratory animals.  
All mice used throughout these studies were at the age of 2-4 months and weighing 18-
23 g at the time of surgery.  
For studies I – III, female C57BL/6J mice from the National Laboratory Animal Center 
(NLAC), University of Eastern Finland, Kuopio, Finland were used. For study I, female 
mice lacking the Nrf2 gene (Nrf2-/-) (Itoh et al., 1997) and their age- and weight-matched 
wild-type (WT) littermates in C57BL/6J background were also bred in the NLAC. Nrf2-/- 
mice and their WT littermates were randomly assigned to experimental groups subjected to 
SCI or only laminectomy as described below. The genotypes of the mice were determined 
by polymerase chain reaction (PCR). 
The mice were housed in groups of three in cages under 12-hour light/dark cycle in 
temperature control environment with drinking water and standard rodent chow provided 
ad libitum. In order to provide easy access to food and water for the paralyzed mice, 
drinking water and powdered rodent chow were placed on the bottom of the cages for the 
first week after surgery.  
4.2 ANESTHESIA (I - III) 
For SCI induction, the mice were anesthetized with isoflurane (Baxter, Deerfield, IL) in a 
carrier gas mixture of 30% O2, 70% N2O (initial dose of 5% which was reduced to 1–1.5% for 
maintaince of surgical depth anesthesia) delivered through a nose mask during the surgery. 
In study III, for the cell transplantations the same anesthesia protocol was used. 
For magnetic resonance imaging (MRI), anesthesia was induced with 5% isoflurane 
(Baxter) in 30% O2/ 70% N2O and maintained at 1% isoflurane during imaging. 
For transcardiac perfusions, mice were terminally anesthetized (ip.) with an overdose of 
tribromethanol (Avertin, Sigma-Aldrich, St.Louis, MO).    
4.3 INDUCTION OF SPINAL CORD CONTUSION INJURY (I - III) 
4.3.1 Spinal cord contusion injury model  
Midline incision of skin was done at the T8 -T12 level. Laminas and lateral processes of 
T9-T11 were cleared of muscles. The T10 lamina was carefully removed with small scissors 
and dura mater was exposed. Vertebraes adjacent to the laminectomy window were 
immobilized with Adson forceps and clinically relevant moderate contusion SCI was 
performed at the T10 level using the Infinite Horizons Spinal Cord Impactor (Precision 
Scientific Instrumentation, Lexington, KY) with a force of 60 kdyn. The special mouse tip 
with a diameter of 1.25 mm was aligned over the exposed spinal cord with intact dura, so 
as to be centered from right to left in order to produce a consistent bilateral injury. Several 
parameters including the actual impact force and spinal cord tissue displacement were 
recorded for each animal. Immediately after impact, the muscles were sutured and skin was 
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closed with wound clips. At the time of surgery the mouse body temperature was 
maintained at a constant level of 37 ± 1 °C with a controlled heating blanket. 
In study I, the dura mater was exposed in a similar manner as above and moderate 
thoracic contusion injury was performed at the T10 level using the NYU Impactor (W.M. 
Keck Center for Collaborative Neuroscience) by dropping the 5.6 g impact head rod from a 
distance of 6.25 cm on exposed dura. The mice injured with NYU Impactor were used only 
in the experiments assessing time-course expression of the Nrf2-ARE pathway. In all other 
experiments throughout the studies I-III Infinite Horizons Impactor was used.  
Laminectomized mice without impact served as sham controls. 
In study II, the majority of the surgeries were performed by Iurii Kidin, MD at the A.I. 
Virtanen Insitute for Molecular Sciences, University of Eastern Finland, Finland. 
4.3.2 Postoperative care procedures  
Immediately after wound closing, 1ml of 0.9% NaCl was injected subcutaneously (s.c.) 
for compensation of blood lost during surgery. After SCI, the mice are unable to maintain 
their body temperature (Wells et al., 2003) and therefore to keep it at the constant level in 
the early postoperative period the mice were housed in cages placed on heating pads at 
37°C for three days after surgery. For analgesia, buprenorfine (Temgesic®, Schering-Plough, 
Belgium) at 0.1 mg/kg was injected subcutaneously 30 min before surgery followed by the 
same dose every 12 hours for 3 days. Bladders were manually evacuated 2 times daily for 
approximately 2 weeks until mice were able to regain normal bladder function.  
4.4 LENTIVIRUS-MEDIATED GENE TRANSFER (I) 
4.4.1 Viral vectors 
The viral vectors used in this study were produced by the laboratory of Professor Seppo 
Ylä-Herttuala at the A.I. Virtanen Institute for Molecular Sciences, University of Eastern 
Finland, Finland. 
Lentiviral vectors expressing enhanced green fluorescent protein (LV-GFP) and human 
Nrf2 (LV-hNrf2) under the control of human phosphoglycerate kinase promoter (hPGK) 
were cloned as described in Kanninen et al., 2009. The lentiviruses were produced and 
titrated as described in Follenzi and Naldini, 2002. The lentiviral vectors encoding GFP 
were used as a control. Prior to intraspinal delivery, the lentiviral vectors were diluted with 
sterile phosphate buffered saline (PBS, Life Technologies) to achieve a titer of 1.88x106 
TU/μl. 
4.4.2 Intraspinal gene transfer 
To deliver viral vectors into the injured spinal cord tissue, two stereotaxical injections 
were performed for each mouse. Immediately after impact (or laminectomy for sham 
controls) the dura matter was incised 0.5 mm from midline at both the rostral (left to the 
midline) and caudal (right to the midline) ends of the laminectomy window and a 33-gauge 
needle attached to a 5-μl Hamilton syringe was lowered 1.3 mm beneath the dorsal surface 
of the spinal cord. Two or three microliters (in the case of experiment with the increased 
amount of viral vector) of PBS, LV-GFP or LV-hNrf2 were delivered into the spinal cord 
tissue at a rate of 0.5 μl/min using the injecting minipump (Nanomite Injector Syringe 
Pump; Harvard Apparatus, Holliston, MA). 7 min after injection the needle was slowly 
raised and the wound was sutured as described above.  
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4.5 IL-33 TREATMENT (II) 
The mice were randomly divided to receive IL-33 or vehicle. In the IL-33 treatment 
group, the mice received i.p 1 μg of IL-33 immediately after wound closing, followed by the 
same dose at 3 days post injury (dpi) and 0.5 μg at 7 and 10 dpi. Control and sham mice 
were injected similarly with 0.0025% bovine serum albumin (BSA) in PBS as a vehicle. Prior 
to administration, recombinant mouse IL-33 (Mouse IL-33 protein, Biorbyt, San Francisco, 
CA) was diluted in 0.0025% BSA in sterile PBS to achieve 5 μg/ml concentration. The IL-33 
dose was selected based on a previous mouse study for treatment of atherosclerosis in 
ApoE-/- mice (Miller et al., 2008).  
4.6 CELL TRANSPLANTATIONS (III) 
Generation and differentiation of iPSC-derived neural progenitor cells (iPSC-NPCs) 
intended for transplantation studies were performed by the Stem Cell Unit, at the A.I. 
Virtanen Institute for Molecular Sciences, University of Eastern Finland, Finland. 
4.6.1 Generation and differentiation of human iPSCs 
Primary fibroblasts were obtained from a skin biopsy of a healthy human adult female 
volunteer (approved by the committee on Research Ethics of Northern Savo Hospital 
district). Cre-excisable constitutive polycistronic (Oct4, Klf4, Sox2 and c-Myc) lentivirus 
reprogramming kit (STEMCCA, Millipore, Temecula, CA, USA) was used to induce 
pluripotency and cell transduction and characterizations were performed as described in 
Qu et al., 2013.   
The generated iPSCs line (UEFhfiPS 1.4) was maintained on the top of mitotically 
inactivated human foreskin fibroblasts (CRL-2429, ATCC, Manassas, VA). Neural 
differentiation was performed in a suspension of cell spheres (Puttonen et al., 2013).  
The success of the neuralization process was assessed with a selected panel of 
pluripotency and neural markers. To confirm neural differentiation, mRNA expression of 
paired box protein 6 (PAX-6), doublecortin (DCX) and microtube-associated protein-2 
(MAP-2) were assessed by quantitative real-time polymerase chain reaction (RT-PCR). The 
last two were also detected at protein level by immunocytochemistry (ICC). To exclude the 
presence of pluripotency, mRNA expression of Nanog was detected by RT-PCR. Octamer-
binding transcription factor (Oct-4) protein expression was investigated by ICC. RT-PCR 
and ICC methodology were described earlier in detail in Puttonen et al., 2013. Analysis of 
disappearing pluripotency and development of neuronal properties was performed every 2 
weeks during the differentiation period. As the result, expression of PAX-6, DCX and MAP-
2 mRNA increased over time (III, Figure 2D - F) and prior to transplantation most of the 
NPCs were positive for DCX and MAP-2 (III, Figure 2A, B), thus proving that neuronal 
differentiation had been achieved. Meanwhile, the reduction of Nanog expression at the 
mRNA level (III, Figure 2C) and Oct-4 by ICC confirmed the disappearance of pluripotency 
in differentiated NPCs. 
Seven to nine weeks after initiation of the differentiation small and homogenous spheres 
were collected and dissociated. Isolated, single NPCs were seeded on polyornithine - 
human laminin coated wells in neural proliferation medium (Puttonen et al., 2013). Two 
days later, these monolayers were transduced with lentiviruses encoding GFP at 
multiplicity of infection 5 for 18 hours to allow in vivo tracking. Just prior to the 
transplantation (at days 5-8 post-transduction) GFP-positive NPCs were collected and 
suspended into PBS (Life Technologies) at a concentration of 100 000 cells/μl. 
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4.6.2 Cell transplantation procedure 
Human UEFhfiPS 1.4 - derived NPCs (UEFhfiPS1.4-NPCs) expressing GFP were 
intraspinally transplanted either into uninjured laminectomized mice immediately after T10 
lamina removal or into injured mice 7 days after contusion. In the latter case, the injury site 
was re-exposed to provide access to the laminectomy window. Two small dura incisions 
were made 0.5 mm from midline rostrally (left to midline) and caudally (right to midline) to 
the lesion epicenter (III, Fig. 1A) and a total of two injections were stereotaxically 
performed for each mouse using a 5 μl Hamilton syringe and the Nanomite Injector Syringe 
Pump (Harvard Apparatus). A 33-gauge needle was lowered 1.3 mm beneath the dorsal 
surface of the spinal cord and 2 μl of PBS containing 200 000 NS/PCs were injected at a rate 
of 0.5 μl/min. The needle was left in situ for 7 min after injection before being slowly raised, 
and the wound was sutured. 2 μl of PBS were intraspinally injected into control mice with a 
similar technique. 
4.7 IMMUNOSUPPRESSIVE THERAPY (III) 
For immunosuppressive therapy, the transplanted and control mice received daily i.p. 
injections of Tacrolimus (2 mg/kg, PrografR, Astellas Pharma a/s, Glostrup, Denmark) until 
the end of the study.  
The dose of Tacrolimus was selected based on several transplantation studies involving 
rodents or minipigs in which this immunosuppressant was administered i.p or s.c. at a dose 
range of 0.05 - 3 mg/kg/24h (Marsala et al., 2004; Cizkova et al., 2007; Usvald et al., 2010; 
Sevc et al., 2013). Additionally, prior to transplantation into SCI mice, we confirmed the 
efficacy of the selected immunosuppression regimen in other projects involving 
transplantations of human NPCs into the brains of uninjured mice, transgenic APdE9 mice 
or mice subjected to permanent focal brain ischemia. A high number of grafted cells were 
consistently detected in the brains of transplanted mice (III, Fig. 1B) at least 5-12 weeks after 
grafting, thus indicating that daily intraperitoneal injections of Tacrolimus at a dose of 2-3 
mg/kg are sufficient to provide immunosuppression in the CNS under basal and pathologic 
conditions. 
4.8 ANALYSIS OF FUNCTIONAL RECOVERY (I-III) 
4.8.1 Basso Mouse Scale open field test (I-III) 
The motor function recovery of hind limbs was evaluated using Basso Mouse Scale (BMS) 
(Basso et al., 2006) in a large Plexiglas field (diameter 1.5 meters) by two independent raters 
who were blinded to the experimental conditions. Each mouse was observed separately for 
4 min in every session. BMS scores for left and right hind limbs were averaged to obtain a 
single value per mouse. The behavioral analysis was performed 24 h after injury, and then 
weekly for up to 28 dpi in study I and up to 42 dpi in studies II and III. Prior to testing, the 
mice were acclimated to the open field during three consecutive days. The mice with a BMS 
score higher than one at 24 h after injury were considered as outliers and were excluded 
from further studies. 
The BMS is a sensitive and reliable scale specially developed and validated for 
assessment of the degree of hind limb locomotor recovery in mice after contusion SCI. It 
ranges from 0 (no ankle movement) to 9 (complete functional recovery) points and includes 
the evaluation of ankle movement at the early phase of recovery, plantar placement of the 
paw, weight support, dorsal and plantar stepping at the intermediate phase of recovery 
and coordination, paw position and trunk stability at the late stage of recovery (Basso et al., 
2006).  
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4.8.2 CatWalk automated gait analysis (III) 
In study III, the precise movements of the hind limbs were analyzed at 42 dpi with the 
CatWalk automated gait analysis system (Noldus, Wageningen, The Netherlands; software 
7.1). The detailed technical description of the system can be found in Hamers et al., 2001 
and Hamers et al., 2006. 
All data acquisition was performed in a dark and silent room. Prior to the testing day, 
the mice were trained during three consecutive days to run without interruption along the 
runway towards the end zone. Since the CatWalk system requires that mice are able to run 
along the walkway with a constant speed only animals that showed at least occasional 
plantar stepping in the open field (BMS score ≥4) were included in the automatic gait 
evaluation. On the day of testing each mouse was placed in front of the start zone of the 
CatWalk runway and footprints of the animal crossing a glass walkway were recorded by 
the video camera positioned under the walkway. Data was collected from the three 
uninterrupted runs per animal. Several gait parameters such as base of support, intensity of 
the paws, print length, width and area, stand and swing speed and duration, max area and 
contact, stride length and regularity index (RI) were analyzed with the CatWalk software. 
The values for every paw were taken and averages between left and right hind paws were 
used for statistical analysis.  
4.9 MAGNETIC RESONANCE IMAGING (MRI) (I-III) 
In order to visualize the contused mouse spinal cord in vivo, MRI was performed two 
weeks after SCI in studies I and II, whereas in study III imaging was done 3 weeks after 
contusion. A 9.4 Tesla Varian scanner (Varian Inc, Palo Alto, CA) interfaced to a Varian 
DirectDrive console was used for imaging. Mice were placed in a custom-built plastic 
mouse holder providing careful and reproducible positioning of the mouse body allowing 
sagittal imaging of the spinal cord. The holder was equipped with a warm water heating 
system to keep the body temperature at a constant level during imaging. The holder was 
positioned within a volume coil (diameter 35mm) serving as transmitter and receiver. 
Lesion volumes were determined from T2-prepared fast spin echo images (minimum 
repetition time 1.5s, echo spacing 7.02ms, four echoes, TE for preparation 30ms, 16 averages, 
field-of-view 16 x 16 mm2, slice thickness 0.5 mm, data matrix 128 x 128, 8 adjoining sagittal 
slices). Imaging data were analyzed using in-house-built Matlab software (Aedes, 
http://aedes.uef.fi) by an observer who was blinded to the experimental conditions. For 
each animal the lesion was manually outlined on each slice, areas were summed and 
converted to micrometers (μm). 
In study II, the majority of the of image acquisition were performed by Iurii Kidin, MD at 
the A.I. Virtanen Insitute for Molecular Sciences, University of Eastern Finland, Finland. 
4.10 BLOOD AND TISSUE COLLECTION AND PROCESSING (I-III) 
4.10.1 Blood collection and processing (II) 
The blood samples were collected from the heart at the time of sacrifice and mixed with 
3.8% trisodium citrate (1:10, Sigma) as anticoagulant. Plasma was separated by 
centrifugation at 2000g for 15 min, and then the upper layer was further centrifuged at 
12,000g for 3 min and stored at −70 °C for subsequent cytometric bead array (CBA). Pellets 
obtained at 8dpi were immediately used for flow cytometry. 
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4.10.2 Tissue collection and processing (I-III) 
At the day of sacrifice, the mice were transcardially perfused with heparinized (2500 
IU/L) (Leo Pharma A/S, Ballerup, Denmark) saline (Baxter) to remove blood from tissues. 
The spleens were snap-frozen in liquid nitrogen and stored at −70 °C until RNA isolation 
and CBA, or used immediately for flow cytometry. Collected inguinal, axillary and brachial 
lymph nodes were immediately processed for flow cytometry. Spinal cords were dissected 
and either 6-mm (study II) or 10-mm (study I) segments centered on the lesion epicenter (or 
respective area in shams) were stored at −70 °C until RNA isolation or CBA.  
When the aim was to collect spinal cords for immunohistochemistry (IHC), transcardiac 
perfusion with heparinized saline was followed by perfusion with 50 ml of 4 % 
paraformaldehyde (PFA) (Sigma-Aldrich). The dissected spinal cords were post-fixed in the 
same fixative overnight at 4°C. After fixation, spinal cords were cryoprotected in 10% 
sucrose (VWR International, Leuven, Belgium) for 24 h followed by 20% sucrose (study II) 
or 30% sucrose (study III) for the next 24 h, or 30% sucrose for 48 h (study I). After 
cryoprotection, 6-mm (studies II and III) or 10-mm (study I) spinal cords segments centered 
on the lesion epicenter (or respective area in shams) were dissected and embedded in 
Tissue-Tek O.C.T. Compound (Sakura Finetek, Zouterwoude, the Netherlands), frozen on 
either dry ice (studies I, III) or liquid-nitrogen-supercooled isopentane (study II) and stored 
at −70 °C for transversal 20 μm thick cryostat serial sectioning (Leica Microsystems GmH, 
Wetzlar Germany). 
4.11 CYTOKINE PROTEIN DETECTION (I,II) 
Cytokine protein levels in spinal cord (study I), plasma and spleens (study II) were 
detected by cytometric bead array (CBA), which allows simultaneous determination of a 
wide range of cytokines in the same sample. The method is based on flow cytometric 
detection of microbeads with unique fluorescence intensity. Each microbead set is pre-
coated with antibodies specific for different cytokines. These capture antibodies are 
recognized by specific labeled secondary antibodies. The cytokine concentration in the 
sample is proportional to the secondary antibody signal and is quantified from a calibration 
curve.  
Frozen spinal cords and spleens were homogenized in buffer containing 10 mM Tris–
HCl (pH 8.0), 5 mM EDTA, 150 mM NaCl, 10 % glycerol, 0.1 % Nonidet P-40 and protease 
inhibitor cocktail (Complete; Roche Applied Science, Mannheim, Germany).  
The levels of IL-2, IL-4, IL-6, IFN-γ, TNF, IL-17 and IL-10 proteins in plasma, spleen and 
spinal cord homogenates were measured by using the Th1/Th2/Th17 kit (BD Biosciences, 
Franklin Lakes, NJ) according to manufacturer’s instructions. Data were acquired using 
FACSCalibur (BD Biosciences, San Jose, CA) and analyzed by FCAP Array software (Soft 
Flow Inc., St. Louis Park, MN). 
CBA were performed by Taisia Rolova, M.Sc. and Paula Korhonen, M.Sc., at the A.I. 
Virtanen Insitute for Molecular Sciences, University of Eastern Finland, Finland. 
4.12 FLOW CYTOMETRY (II) 
Single cell suspensions were prepared from the spleens and lymph nodes by crushing 
organs through 70-μm and 40-μm cell strainers (BD Biosciences), respectively. The resulting 
cells were washed in Hank’s balanced salt solution (HBSS) (BioWhittaker Lonza, Basel, 
Switzerland) supplemented with 1% fetal bovine serum (FBS) (Life Technologies), 
centrifuged for 5 min at 400g, and resuspended in RPMI-1640 medium supplemented with 
5% FBS (Sigma–Aldrich). Red blood cells were removed from blood and spleen cell 
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suspensions by lysis with BD Pharm Lyse (BD Biosciences). After erythrocyte lysis the 
white blood cells were counted on a Z2 Coulter Counter (3.5–10 μm). 
 For detection of CD4+ and CD8+ T-cells in blood, lymph nodes and spleen, cells were 
incubated with CD4-FITC (GK1.5, RM4-5) and CD8-PerCP eFluor710 (53–6.7) antibodies at 
+4C for 45 min.  
For cytokine enumeration, CD4+ cells were isolated from spleen cell suspension using 
magnetically labeled CD4 (L3T4) MicroBeads (Miltenyi Biotec, Lund, Sweden) according to 
manufacturer’s instructions. Purity was confirmed (92.3 ± 0.93%) by flow cytometry. 
Cytokine stimulation was done as described by Foster et al., 2007. Briefly, 1x106 cells were 
stimulated for 5 h at +37C in 5% CO2 in the presence of Brefeldin A (10 μg/ml, Sigma–
Aldrich), Ionomycin (500 ng/ml, Sigma–Aldrich) and phorbol 12-myristate 13-acetate (PMA) 
(10 ng/ml, Sigma–Aldrich). After cytokine stimulation the cells were incubated with CD4-
FITC (GK1.5). Next, the cells were permeabilized with fix/perm buffer (eBioscience) 
overnight and next the day incubated with TNF-PE (MP6-XT22) and IFNγ-PE (XMG 1.2) 
antibodies for 30 min at +4C.  
In order to detect T regulatory Foxp3+ cells (Tregs) in blood and spleen, cells were 
incubated with CD4-FITC (GK1.5, RM4-5) and CD25-APC (PC61.5) antibodies followed by 
permeabilization and incubation with Foxp3-PE (FJK-16s) antibody for 80 min at +4C.  
For blocking of Fc receptors, anti-CD16/CD32 (24.G2) antibody was used. All used 
antibodies were from eBioscience. 
Samples were resuspended in 1% FBS in HBSS and acquired on BD FACSCalibur 
equipped with a single 488 nm argon laser or BD FACSAriaIII equipped with 488 and 633 
nm lasers with the standard detector configuration. Post-acquisition data analysis was 
performed using FCS Express4 (DeNovo, Los Angeles, CA) or Cellquest Pro™ software 
(BD Biosciences). 
Flow cytometry analysis was performed by Sara Wojciechowski and Iurii Kidin, MD, at 
the A.I. Virtanen Insitute for Molecular Sciences, University of Eastern Finland, Finland. 
4.13 HISTOLOGY AND IMMUNOHISTOCHEMISTRY (I-III) 
4.13.1 Luxol fast blue staining (I,II) 
In order to estimate the total spinal cord area (study I) and degree of white matter 
sparing (studies I, II) Luxol fast blue staining (LFB) staining for myelin was performed as 
described in Yune et al., 2007. Transversal spinal cord sections with an interval of 200 μm 
were incubated in 0.1% LFB (Sigma-Aldrich) in acidified 95% ethanol overnight at +60C. 
Differentiation was carried out with 0.05% lithium carbonate (Sigma-Aldrich). The spinal 
cord sections were imaged with an Olympus AX70 microscope and photographed by a 
digital camera (Color View 12; SoftImaging Systems). The LFB-positive area was quantified 
by using ImagePro Plus software (Media Cybernetics, Rockville, MD) in a blinded fashion. 
In study I, LFB staining was used to determine the epicenter of injury. The spinal cord 
section containing the lowest percentage of spared white matter was considered as the 
lesion epicenter. 
4.13.2 Immunohistochemical stainings (IHC) (I-III). 
Frozen spinal cord sections spacing 200 μm apart were air-dried for 1 hour at room 
temperature (RT) and rehydrated in PBS, pH 7.4. Permeabilization and antigen retrieval 
were used when needed. Sections were washed 3 times in PBS with 0.5% Tween (PBST) pH 
7.4. Blocking of unspecific antibody binding was performed with 10% normal goat serum 
(NGS, Chemicon International, Millipore) and sections were incubated with primary 
antibody prepared in 5% NGS in PBST at RT with slow agitation overnight. On the next 
day, sections were again washed in PBST before incubation with appropriate Alexa-fluor 
488 or 568- conjugated secondary antibody (goat anti-mouse, goat anti-rat, goat anti-rabbit 
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or rabbit-anti-goat, 1:200, all from Life Technologies) in 5% NGS in PBST at RT for 2 hours. 
After washing and air-drying, the sections were mounted with Vectashield mounting 
media with Dapi (Vector Laboratories, INC. Burlingame, CA) or consequently processed 
for double-staining with compatible antibodies. All primary antibodies used throughout 
the study are listed in table 2. 
For stainings detecting neuronal nuclear antigen (NeuN), GFP and human nuclei 
(HuNu), M.O.M.TM Mouse Ig Blocking Reagent (Vector Laboratories) was used to block 
endogenous mouse antibody in the spinal cord sections. Permeabilization with 0.4% Triton 
X-100 (Sigma-Aldrich) for 30 min was applied for IL-33, HuNu, DCX and Ki-67 stainings. 
For Arginase-1 staining, antigen retrieval was performed using 0.3% sodium citrate 
dehydrate aqueous solution (Sigma-Aldrich; pH 6.0) preheated to +92C. For CD3 staining, 
after the incubation with the biotinylated secondary antibody (rabbit-anti-rat, 1:500, Vector 
Laboratories) tyramide-based signal amplification (TSA Biotin System; PerkinElmer, 
Waltham, MA) was used according to the manufacturer’s instruction. 
 
Table 2.List of primary antibodies used for Immunohistochemistry 
 
Antibody Manufacturer Source Dilution Catalog ID Study 
GFAP DAKO Rabbit 1:200 Z0334 I-III 
NeuN Millipore Mouse 1:200 MAB377 I 
CD45 Serotec Rat 1:100 MCA1388 I 
Iba-1 Wako Rabbit 1:250 019-19741 II, III 
CD3 Serotec Rat 1:5000 MCA5006A II 
Arginase-1 Santa Cruz Goat 1:200 SC-18351 II 
IL-33 R&D Systems Goat 1:200 AF3626 II 
DCX Cell Signalling Rabbit 1:200 4604 III 
Ki-67 Abcam Rabbit 1:500 Ab16667 III 
Tuj-1 Abcam Rabbit 1:300 Ab52901 III 
Nanog Abcam Rabbit 1:200 Ab21624 III 
GFP Life Technologies Mouse 1:200 A-11120 III 
HuNu Millipore Mouse 1:250 MAB4383 III 
 
Stained spinal cord sections were visualized using an Olympus AX70 microscope 
equipped with a digital camera (Color View 12 or F-Fiew; SoftImaging Systems) and the 
immunoreactive areas or number of cells profiles were quantified using ImagePro Plus 
(Media Cybernetics) or ImageJ (Wayne Rasband, National Institutes of Health, Betheda, 
MD) software. 
In study II, the degree of tissue sparing was assessed by quantification of the total 
remaining area covered by glial fibrillary acidic protein (GFAP) as previously described 
(López-Vales et al., 2005; Klopstein et al., 2012). The spinal cord section with the lowest 
amount of spared tissue (GFAP sparing) was considered as the lesion epicenter. 
Astrogliosis, microglial activation and Arginase-1 were assessed by calculating the 
immunopositive area which was defined as the area with the intensity of the staining 
exceeded the threshold set for the background staining. The results were expressed as the 
percentage of immunopositive area within the selected area of interest. GFAP 
immunoreactivity (astrogliosis assessment) was evaluated within the whole spinal cord 
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section at the lesion epicenter and 1 mm rostrally and caudally (in study I) or in 7.5x103 μm2 
area in the lateral white matter at the lesion epicenter, as well as 0.6 and 1.2 mm rostrally 
and caudally (in study II). Ionized calcium-binding adapter molecule 1 (Iba-1) 
immunoreactivity (microgliosis assessment) was quantified in 3x104 μm2 area in the lateral 
white matter at the lesion epicenter, as well as 0.4 and 0.8 mm rostrally and caudally. 
Arginase-1 immunoreactivity was quantified within the whole spinal cord section at the 
lesion epicenter, 0.2, 0.6 and 1 mm rostrally and caudally.  
Cells positive for IL-33 were manually counted in the lateral white matter (3x104 μm2 
area at the lesion epicenter, 0.4 and 0.8 mm rostrally and caudally) or in the ventral horns 
(3x104 μm2 area 0.8 mm rostrally and caudally to the lesion epicenter). Results were 
expressed as number of cell profiles within the selected area. Cells expressing CD3 were 
counted in a similar way, but within 1 mm around the lesion epicenter in 5 sections per 
spinal cord 200 μm apart and expressed as average number of cell profiles per section. For 
all stainings where quantification was done within the preselected area in the lateral white 
matter or ventral horns, the images were obtained from the left and right sides of the spinal 
cord section and results are expressed as averages at the selected distance.     
Several stainings were performed to investigate the cellular localization of the protein of 
interest. Thus, in study I the cellular distribution of lentivirus vector encoding GFP was 
assessed by the co-localization of GFP with NeuN, GFAP and CD45. In study II, cellular 
localization of IL-33 and Arginase-1 were examined by double-staining with anti-NeuN, 
anti-GFAP and anti-Iba-1 antibodies. In study III, stainings detecting HuNu and GFP were 
performed to track transplanted GFP-positive human cells in vivo, whereas stainings 
detecting Nanog, DCX, Ki-67, GFAP, Iba-1 and neuron-specific class III beta-tubulin (Tuj-1) 
were used for cell characterization based on co-localization of these markers with GFP. For 
all co-localization studies, Zeiss LSM 700 confocal microscope (Zeiss Inc., Maple Grove, 
USA) with an attached digital camera (Color View 12 or F-Fiew; SoftImaging Systems) 
running Zen 2012 Image analysis Software (Zeiss Inc.) was used. All IHC quantifications 
were done in a blinded fashion. 
4.14 QUANTITATIVE RT-PCR (I,II) 
Total RNA was extracted from the spinal cords (study I, II) and spleens (study II) with 
TRIzol reagent (Life Technologies, Carlsbad, CA) according to the manufacturer's 
instructions. Frozen samples were homogenized in TRIzol reagent with 5 mm stainless steel 
beeds in TissueLyzer II homogenizator (Qiagen, Hilden, Germany). The final purity and 
concentration of total RNA were measured with a Nanodrop 1000 spectrophotometer 
(Thermo Fisher Scientific, Waltham, MA). Five hundred nanograms of total RNA were used 
for cDNA synthesis using random hexamer primers (Promega, Madison, WI) as a template 
and Maxima reverse transcriptase (Thermo Fisher Scientific). The relative expression levels 
of mRNA encoding genes of interest (Table 3) were measured according to manufacturer’s 
protocol by quantitative real-time polymerase chain reaction (qRT-PCR) (StepOnePlus; Life 
Technologies) using TaqMan chemistry and specific assays-on-demand target mixes (Life 
Technologies). The expression levels were obtained by normalizing the target gene to 
ribosomal RNA and are presented as fold change in the expression. 
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Table 3. List of genes of interest analyzed by RT-PCR 
 
Gene* Full name  Tissue Time-point Study 
Nfe2l2 Nuclear factor, erythroid 2-like 2 (Nrf2) Spinal cord (SC)  12h, 24h, 3, 7, 21, 42 dpi I 
Hmox1 Heme oxygenase (decycling) 1 (HO-1) SC 12h, 24h, 3, 7, 21, 42 dpi I 
Nqo1 NAD(P)H dehydrogenase, quinone 1 (NQO1) SC 12h, 24h, 3, 7, 21, 42 dpi I 
Gclc Glutamate-cysteine ligase, catalytic subunit (GCLC) SC 12h, 24h, 3, 7, 21, 42 dpi I 
Gclm Glutamate-cysteine ligase, modifier subunit (GCLM) SC 12h, 24h, 3, 7, 21, 42 dpi I 
Mgst1 Microsomal glutathione S-transferase 1 (MGST1) SC 3, 7 dpi I 
Casp3 Caspase 3 SC 3, 7 dpi I 
Bcl2 B-cell CLL/lymphoma 2 (Bcl-2) SC 3, 7 dpi I 
Bcl2l1 BCL2-like 1 (Bcl-xL) SC 3, 7 dpi I 
Ngf Nerve growth factor (beta polypeptide)  SC 3, 7 dpi I 
Gdnf Glial cell derived neurotrophic factor  SC 3, 7 dpi I 
Bdnf Brain-derived neurotrophic factor SC 3, 7 dpi I 
Tnf Tumor necrosis factor (TNF) SC,           Spleen 
24h, 3, 7 dpi                     
24h 
I,II        
II 
Il1b Interleukin 1, beta (IL-1β) SC 24h, 3, 7 dpi I,II 
Il6 Interleukin 6 (IL-6) SC,            Spleen 
24h, 3, 7 dpi                     
24h 
I,II        
II 
Il10 Interleukin 10 (IL-10) SC,           Spleen 
24h, 3, 7 dpi                     
24h 
I,II        
II 
Il4 Interleukin 4 (IL-4) SC, Spleen 24h                                 II          
Ifng Interferon, gamma (IFN-γ) SC, Spleen 24h                                  II          
Il33 Interleukin 33 (IL-33) SC 24h II 
Cd3d CD3d molecule, delta (CD3-TCR complex) (CD3) SC 8 dpi II 
Cd4 CD4 molecule (CD4)  SC 8 dpi II 
Foxp3 Forkhead box P3 (Foxp3) SC,           Spleen 
8 dpi,                            
24h, 8 dpi 
II         
II 
Nos2 Nitric oxide synthase 2, inducible  (iNOS) 
SC,              
Spleen 
24h, 8 dpi                         
42 dpi 
II          
II 
Arg1 Arginase 1 SC,           Spleen 
24h, 8 dpi                         
42 dpi 
II          
II 
Chi3l3 Chitinase 3-like 3 (Ym-1) SC 24h, 8 dpi II 
* Gene names are given in accordance with the HUGO Gene Nomenclature Committee (HGNC). 
http://www.genenames.org; 
 **For clarity, the full gene names or their abbreviations will be used further in the text. 
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4.15 STATISTICAL ANALYSES (I-III) 
All data are shown as mean ± standard deviation (SD) (study III) or mean ± standard 
error of mean (SEM) (study I, II). Unpaired t-test was employed for comparing means of 
two treatment groups. For multiple comparisons, one-way ANOVA followed by Tukey’s 
post hoc test or two-way ANOVA followed by Bonferroni’s post hoc test were used. 
Behavioral data were analyzed using repeated measures two-way ANOVA followed by 
Bonferroni’s post hoc test or non-parametric Mann-Whitney test (for two group comparison) 
and Kruskal-Wallis test followed by Dunn’s post hoc test (for multiple comparisons). All 
statistical analyses were carried out by GraphPad Prism version 5.03 software (GraphPad 
Software, La Jolla, CA, http://www.graphpad.com). p values of less than 0.05 were 
considered to be significant. 
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5 Results 
5.1  NRF2 WAS INVOLVED IN SCI PATHOGENESIS AND ITS GENE 
DELETION AFFECTED THE DEGREE OF SECONDARY DAMAGE AFTER 
CONTUSION SCI (I) 
Oxidative stress is well known to augment the secondary damage after SCI (Hall and 
Braughler, 1989; Rowland et al., 2008). Upon oxidative stress transcription factor Nrf2 binds 
to the ARE and induces the transcription of a number of cytoprotective genes in order to 
compensate the deleterious effect of oxidants and electrophiles (Itoh et al., 1997, 1999; 
Kobayashi and Yamamoto, 2006; Baird and Dinkova-Kostova, 2011). Knowing the 
important role of the Nrf2-ARE system in cell defence, in study I, we aimed to determine 
whether the Nrf2-ARE pathway is involved in SCI pathophysiology. Next, we aimed to 
estimate the magnitude and duration of the Nrf2-ARE response and assess the effect of 
Nrf2 gene deletion on several components of secondary injury including inflammation and 
apoptosis and importantly, functional recovery from mouse contusion thoracic SCI, which 
is currently thought to be the most clinically relevant thoracic SCI model (Kwon et al., 2010; 
Zhang et al., 2014) 
5.1.1 Contusion SCI induced sustained activation of Nrf2 and HO-1 gene expression 
First, we estimated the way that the Nrf2-ARE system responds to the contusion at the 
thoracic level. Messenger RNA expression of Nrf2 and its main target genes were examined 
in acute, subchronic and early chronic phases of disease. We detected upregulation of Nrf2 
and HO-1 genes (gene names according HUGO Gene Nomenclature Committee are given 
in table 3) with a synchronous peak at 7dpi (I, Figure 1A, B). Nrf2 upregulation was 
preceded by HO-1 elevation. Both genes remained elevated for up to at least 6 weeks 
indicating that after contusion lesions induction of Nrf2-ARE pathway has sustained nature. 
Expression of another Nrf2 inducible gene, NQO1, slowly increased simultaneously with 
Nrf2 upregulation and reached statistically significant levels at 42 dpi (I, Figure 1C), 
whereas no correlation was observed between Nrf2 and GCLM/GCLC expression (I, Figure 
1D, E). 
5.1.2 Nrf2 gene deletion altered the expression of genes involved in apoptosis, 
inflammation and neuroprotection in addition to classic Nrf2-regulated genes.  
Next, we took advantage of Nrf2-/- mice to estimate whether deletion of the Nrf2 gene 
results in altered transcription of Nrf2 downstream genes after contusion injury. In addition, 
genes regulating such components of secondary injury as apoptosis and inflammation were 
included in the assessment and finally expression of growth factors was also examined. 
Cytokines were studied at both mRNA and protein levels. Since we observed maximal 
activation of the Nrf2-ARE from 3 to 7dpi these time-points were selected for gene 
expression analysis in Nrf2-/- mice.  
Contusion injury in Nrf2 deficient mice resulted in impaired expression of important 
detoxifying enzyme NQO1 (I, Figure 4A,B) and anti-apoptotic Bcl-xL (I, Figure 5B). Both 
genes were significantly downregulated when compared to WT littermates at 3, 7 dpi 
(NQO1) and 7 dpi (Bcl-xL), respectively. Moreover, upregulation of NGF, a neurotrophin 
important for the neuronal growth and survival, was significantly reduced at 7dpi in mice 
lacking Nrf2 compared to WT (I, Figure 5C). In contrast, the gene expression of pro-
inflammatory TNF and protein levels of IL6 were significantly higher in Nrf2-/- (I, Figure 
5E,F) at this time-point. Additionally, in Nrf2-deficient mice after contusion injury, we 
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identified a clear trend toward delayed upregulation of MGST1, another detoxifying 
enzyme regulated by Nrf2 (I, Figure 4A,B), and GDNF, a growth factor known to promote 
neuronal survival (I, Figure 5D). A surprising result was that at 7 dpi HO-1 expression was 
significantly higher in Nrf2-deficient mice when compared with WT (I, Figure 4B), 
suggesting substantial impact of transcription factors other than Nrf2 in HO-1 regulation 
upon SCI. 
5.1.3 Nrf2 gene deletion increased spinal cord atrophia, demyelination and astrogliosis 
To investigate if alterations observed in Nrf2 deficient mice at acute and subacute SCI 
phases influence the outcome at later stages of recovery, we assessed the degree of spinal 
cord atrophia and demyelination at 28 dpi with LFB staining. The transverse area of the 
spinal cord and preserved white matter were significantly reduced in Nrf2-knockouts (I, 
Figure 3A-C). In addition to increased demyelination at 28 dpi, Nrf2-/- mice exhibited 
increased astrogliosis at regions caudally to the injury epicenter (I, Figure 3D,E).  
5.1.4 Nrf2 gene deletion exacerbated functional recovery 
To estimate whether the observed aggravation of the secondary injury in Nrf2-deficient 
mice was translated to the impairment in functional recovery after contusion SCI, we 
assessed locomotor function of hind limbs in open field using BMS on a weekly basis. 
Indeed, already at 7dpi WT mice significantly surpassed Nrf2 knockouts in the hind limb 
locomotor performance. The observed difference in functional recovery increased over time 
and at 4 weeks after injury resulted in almost 2-fold functional advancement in WT mice 
over Nrf2 deficient counterparts (score 4.7±0.6 in WT vs. 2.8±0.2 in Nrf2-/- mice) (I, Figure 2). 
The observed difference has important biological significance as on average the WT mice 
were able to perform plantar stepping, whereas mice lacking Nrf2 were able only to 
perform extensive ankle movements or plantar placement.  
Taken together, these findings showed significant and broad involvement of Nrf2 in 
regulating the secondary injury cascade and indicated that impairment of the Nrf2-ARE 
response was detrimental for recovery from contusion SCI. 
5.2  NRF2 OVEREXPRESSION IN THE SPINAL CORD PREVENTED 
FUNCTIONAL IMPAIRMENT CAUSED BY LENTIVIRAL TRANSDUCTION 
BUT FAILED TO PROMOTE FUNCTIONAL RECOVERY FROM SCI    
As the protective role of Nrf2 in contusion SCI had been proved, in study I, we further 
exploited the possibility to enhance the SCI-induced Nrf2-ARE response with human Nrf2 
gene delivered directly into the injured spinal cord.  
5.2.1 The transgene was expressed in neurons and astrocytes for 4 weeks after gene 
transfer 
Prior to human Nrf2 gene delivery in SCI, we assessed the distribution of transgene in 
the spinal cord and identified its main cellular targets. Seven days after intraspinal delivery 
of lentiviruses encoding GFP into uninjured tissue, we observed intensive transgene 
expression in the grey matter neurons and astrocytes, but not in microglia (I, Figure 6). 
Next, we confirmed the duration of transgene expression in the uninjured spinal cord. 
Intraspinal delivery of the human Nrf2 gene resulted in stable expression of its mRNA 4 
weeks after gene transfer (350-fold higher than background signal in control).  
5.2.2 Gene transfer with lentivirus vector impaired hind limb motor function  
To assess whether Nrf2 overexpression improves functional recovery after contusion SCI, 
we assessed locomotor performance of hind limbs weekly for up to 28 days after gene 
transfer by the BMS scoring system.  
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Unexpectedly, intraspinal delivery of the transgene with lentivirus vector significantly 
impaired hind limb function compared to PBS injections. The observed impairment in 
functional recovery became evident 2 weeks after gene delivery and was not transgene 
dependent (I, Figure 7A). At this time-point, we also performed MRI to estimate whether 
the functional disturbances correlate with the lesion progression. However, imaging 
revealed that gene transfer did not affect the lesion size. Functional aggravation after 
lentivirus mediated gene transfer persisted up to the end of observation period in both LV-
hNrf2 and LV-GFP treated groups. 
The detrimental effect of gene therapy observed in contused mice prompted us to 
examine whether introduction of the lentivirus vector encoding GFP or human Nrf2 into 
spinal cord affects the locomotor performance of uninjured laminectomized mice in a 
similar way. Indeed, gene transfer significantly impaired locomotor function of sham mice 
(I, Figure 7B). Laminectomized mice injected with LV-GFP were almost paraplegic 14 days 
after gene delivery and were able to perform only ankle movements by the end of the 
observation period. Uninjured mice injected with LV-hNrf2, although they performed in 
BMS remarkably better than LV-GFP, exhibited significantly impaired locomotor 
performance when compared with untransduced mice.  
5.2.3 Increased amount of intraspinally delivered Nrf2 transgene prevented functional 
impairment of hind limbs    
In a subsequent experiment, we increased the total amount of LV-hNrf2, LV-GFP or PBS 
delivered into the spinal cord by 33%. Interestingly, while increasing the transgene amount 
resulted in significantly improved locomotor performance of the contused mice transduced 
with LV-hNrf2 compared to the LV-GFP treated group (I, Figure 7C), it did not provide any 
advancement in comparison with PBS treated animals.  
In addition, an increased amount of LV-hNrf2 delivered to the spinal cords prevented 
impairment in functional recovery, which we observed in uninjured mice in the previous 
experiment. BMS scores of sham mice injected with LV-hNrf2 were not significantly 
different from the BMS scores of uninjured mice in the PBS treated group. At the same time, 
the mice injected with an increased amount of LV-GFP were significantly impaired in 
locomotor performance when compared to LV-hNrf2 and PBS treated groups (I, Figure 7D). 
5.2.4 Gene transfer with lentivirus vector increased expression of pro-inflammatory 
cytokines and growth factors  
Three days after the gene transfer, we assessed whether Nrf2 boosting modulates the 
expression of several groups of genes, namely Nrf2-regulated genes, apoptosis-related 
genes, cytokines and growth factors.  
The successful rate of the gene transfer was confirmed by the 1300-fold higher expression 
of human Nrf2 transgene in the group transfected with LV-hNrf2 when compared with 
background signal in other studied groups. However, surprisingly, even such a high level 
of human Nrf2 expression did not result in upregulation of mouse Nrf2 or HO-1 genes. 
Similarly to our previous findings, Nrf2 or HO-1 were induced by injury, yet human Nrf2 
gene transfer did not further amplify their expression (I, Figure 8A,B). Only NQO1 
responded to LV-hNrf2 delivery accordingly to our expectance since its expression in LV-
hNrf2 group was significantly higher than in controls (I, Figure 8C). Next we observed that 
delivery of either LV-GFP or LV-hNrf2 into the contused spinal cord significantly 
augmented the induction of pro-inflammatory cytokines such as TNF, IL-1β, and IL-6 and 
growth factor such as NGF and GDNF (I, Figure 9A-C, E, F). From all of them only GDNF 
expression was further significantly increased after human Nrf2 gene transfer (I, Figure 9F). 
Since there was no difference in NGF and pro-inflammatory cytokines gene expression 
between the transduced groups it appears that these genes were induced by the virus 
vector itself, but not the transgene. The gene therapy did not affect expression of apoptosis 
related genes (I, Figure 9D). 
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Collectively, these results revealed the inability of human Nrf2 gene transfer to 
remarkably enhance the mouse Nrf2-ARE pathway. Moreover, lentivirus vectors encoding 
GFP and Nrf2 appeared toxic in current titers. Augmenting the amount of introduced Nrf2 
prevented impairment in functional recovery induced by viral vectors, but did not further 
facilitate recovery from contusion SCI. 
5.3  IL-33-MEDIATED MODULATION OF INFLAMMATION PROMOTED 
RECOVERY FROM CONTUSION SCI (II) 
Inflammation is a key component of the secondary injury cascade (Fleming et al., 2006; 
Rossignol et al., 2007; David et al., 2012). A growing number of evidence indicates that 
certain components of the inflammatory response might be protective in SCI (Rossignol et 
al., 2007; David et al., 2012; Plemel et al., 2014). Therefore, in study II, in order to facilitate 
recovery from contusion SCI, we exploited the possibility to regulate the inflammatory 
response following SCI with IL-33, a cytokine known for its ability to modulate 
inflammation. We examined the effect of treatment on functional recovery and investigated 
central and peripheral mechanisms of IL-33 action in SCI. 
5.3.1 Contusion SCI induced sustained activation of intracellular IL-33 in astrocyte nuclei 
The intracellular form of IL-33 is known to act as a transcription factor and negatively 
regulate the expression of p65 subunit of NF-κB (Ali et al., 2011). To estimate whether 
intracellular IL-33 is involved in secondary injury, we assessed IL-33 mRNA levels in the 
injured spinal cord 24 hours after spinal cord contusion and identified distribution and 
cellular localization of IL-33 protein 6 weeks after the insult. 
In the acute SCI phase we observed more than a 3-fold elevation of IL-33 mRNA levels 
(II, Figure 1A), indicating involvement of IL-33 signaling in the secondary injury. Induction 
of intracellular IL-33 persisted for up to at least 42 dpi as we observed a significantly higher 
amount of IL-33 positive cell profiles within 1.6 mm around the lesion epicenter in injured 
group at this time-point when compared to sham mice (II, Figure 1B–E). IHC and confocal 
imaging revealed that IL-33 protein was localized to the nuclei of astrocytes distributed 
within white and grey matter of the spinal cord (II, Figure 1D-F). We did not observe IL-33 
protein in neurons or microglia (II, Suppl. Figure 2).  
5.3.2 Recombinant IL-33 treatment did not affect intracellular IL-33  
To examine whether supplementary IL-33 affects intracellular IL-33 levels we treated 
contused mice (i.p.) with recombinant IL-33 immediately after wound closing. However, 
supplementary IL-33 did not further amplify IL-33 mRNA and IL-33 protein 24 hours and 6 
weeks, respectively, after injury (II, Figure 1A-E). 
5.3.3 Recombinant IL-33 treatment modulated peripheral immunity  
Extracellular IL-33 is known to stimulate a broad range of innate and adaptive immune 
cells including T-lymphocytes and macrophages (Liew et al., 2010; Smith, 2010; Sattler et al., 
2013). Th2 lymphocytes are one of the primary IL-33 cellular targets and promoting Th2 
response was the first reported mechanism of IL-33 action (Schmitz et al., 2005), whereas IL-
33 driven macrophage polarization from M1 to M2 type only recently was identified 
(Kurowska-Stolarska et al., 2009). Therefore, to assess the peripheral effects of recombinant 
IL-33 treatment on innate and adaptive immunity, we analyzed the effect of IL-33 treatment 
on T-cell population and Th1/Th2/Th17 cytokines in the blood, spleen and lymph nodes 
after contusion SCI. In addition, the effect of IL-33 on suppressive T regulatory cells (Tregs) 
in these important T-cell reservoirs was examined. Furthermore, we investigated whether 
IL-33 administration results in altered expression of M1/M2 markers in spleen. 
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Already 24 hours after contusion and first dose of IL-33, we observed an increased level 
of IL-10 protein in the spleen and decreased levels of IFN-γ and IL-17 in plasma when 
compared to the vehicle group (II, Figure 11D-F). Importantly, flow cytometry analysis at 8 
dpi showed that mice treated with IL-33 had a lower percentage and absolute number of 
CD4+ T lymphocytes expressing TNF than vehicle-treated and sham mice (II, Figure 9A,B). 
We also noticed that at 24 hours after injury IL-33 treatment significantly elevated Foxp3 
mRNA expression, a marker of Tregs, in spleen (II, Figure 10). However, increased Foxp3 
expression did not translate into increased numbers of Treg+ (CD4+/CD25+/Foxp3+) 
lymphocytes either in spleen or in plasma at 8 dpi. Additionally, at 42 dpi in the spleen IL-
33 treatment caused a significant reduction of mRNA expression of the iNOS gene, a 
marker of M1 macrophages (II, Fig. 12F). This was accompanied by more than a 30% 
increase in Arginase-1 expression, a marker of M2 macrophages, compared to the vehicle 
treated controls (II, Figure 12G). Notably, we did not observe a significant difference in any 
of above studied parameters when sham mice were compared with mice treated with 
vehicle. 
Overall these results indicate that recombinant IL-33 modulated adaptive and innate 
immunity at the periphery, promoting the Th2/M2 and inhibiting the Th1/M1 response 
after spinal cord contusion. 
5.3.4 Recombinant IL-33 treatment modulated inflammation in the injured spinal cord 
To determine whether IL-33 modulates the inflammatory response in the injured spinal 
cord, we analyzed gene expression and protein levels of pro- and anti-inflammatory 
cytokines, assessed T-cell infiltration, and studied the microglia/macrophage response in 
the spinal cord tissue. To assess T-cell infiltration, we quantified CD3 positive T-
lymphocytes and measured expression of CD3 and CD4 genes, markers of total T cell 
population and T helper cells, respectively. Microgliosis was assessed by Iba-1 staining and 
microglia/macrophage phenotypes were analyzed by mRNA expression of M1 (iNOS) and 
M2 (Arginase-1, Ym-1) markers and Arginase-1 immunohistochemistry. 
SCI significantly elevated the expression of pro-inflammatory cytokines TNF, IL-6 and 
IL-1β at 24 hours after insult. Already the first dose of recombinant IL-33 significantly 
reduced TNF expression compared to the injured mice treated with vehicle, whereas 
mRNA levels of IL-6 and IL-1β were not affected by IL-33 treatment (II, Figure 11A-C). We 
did not detect the mRNA expression of IL-10, IL-4 and IFN-γ gene in the spinal cord at this 
timepoint.  
At 8 dpi, SCI remarkably upregulated the expression of CD4 mRNA, whereas expression 
of CD3 remained unaltered. Furthermore, at 42 dpi, we observed a significant increase in 
the number CD3 positive cell profiles in the injured spinal cord compared to sham mice. 
Recombinant IL-33 treatment significantly reduced CD3 mRNA expression, decreased CD4 
expression level by approximately 40%, and at 42 dpi caused a trend towards reduction in 
the number of CD3 positive cells compared to the vehicle treated group (II, Figure 8).  
SCI significantly induced the expression of iNOS, Arginase-1 and Ym-1 in the contused 
spinal cord compared to the sham mice at 24 hours after trauma, whereas IL-33 did not 
alter the expression of the studied M1 and M2 markers at this time point (II, Figure 12A–C). 
However, already at 8 dpi, the M2 markers Arginase-1 and Ym-1, but not the M1 marker 
iNOS were significantly elevated after IL-33 treatment compared to vehicle (II, Figure 
12D,E). Importantly, at 42 dpi, IL-33 administration resulted in a remarkable increase in 
Arginase-1 protein expression, which at the lesion epicenter was approximately 35-fold 
higher than in the vehicle treated group, whereas in the sham mice Arginase-1 
immunoreactivity was not detected (II, Figure 13A,B). Confocal imaging revealed that 
Arginase-1 protein expression was predominantly localized to Iba-1 positive 
macrophages/microglia (II, Figure 13C,D). Additionally, at 42 dpi, we observed a significant, 
trauma-induced increase in Iba-1 protein expression. IL-33 treatment had no effect on the 
degree of microgliosis in the injured spinal cord tissue (II, Figure 7). 
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Collectively, these results provide evidence that recombinant IL-33 modified the 
inflammatory response in the injured spinal cord, affecting T-cell infiltration and promoting 
M2 polarization of microglia/macrophages. 
5.3.5 Modulation of inflammation after recombinant IL-33 treatment attenuated spinal 
cord tissue loss, demyelination and astrogliosis, and facilitated functional recovery 
To determine if modulation of the inflammatory response identified after recombinant 
IL-33 treatment resulted in reduced secondary tissue damage and improved functional 
recovery after contusion injury, we assessed the degree of astrogliosis, estimated the 
amount of spared spinal cord tissue and preserved myelin, and monitored locomotor 
performance in the open field.  
As expected at 42 days after trauma, the density of GFAP staining was significantly 
reduced in the mice treated with IL-33 compared with vehicle, indicating reduced degree of 
astrogliosis after IL-33 treatment (II, Figure 6). This effect was observed within 2.4 mm 
around the lesion epicenter. Moreover, IL-33 treatment resulted in increased spinal cord 
tissue sparing compared to the vehicle treated controls (II, Figure 4). Similarly, areas of 
preserved myelin were consistently larger in IL-33-treated mice almost at all of the 
analyzed levels (II, Figure 5), thus indicating reduced demyelination after IL-33 treatment.  
Finally, IL-33 treatment significantly facilitated motor recovery of hind limbs in injured 
mice. The improvement became evident at 21 dpi and at the end of the observation period 
mice treated with IL-33 attained an average BMS score of 3.6 ± 0.26 vs. 2.5 ± 0.14 in the 
vehicle treated group. The biological significance of the identified improvement is that the 
mice in the IL-33 treated group were already able to perform stepping or at least plantar 
placement, whereas vehicle-treated mice on average demonstrated only ankle movements.  
The obtained results provide evidence to support the concept that IL-33 modulates 
inflammation and improves locomotor recovery after contusion SCI in mice. 
5.4 HUMAN iPSC-NPCs FAILED TO IMPROVE FUCTIONAL RECOVERY 
AFTER TRANSPLANTATION INTO SPINAL CORD OF CONTUSED MICE 
IMMUNOSUPPRESSED WITH TACROLIMUS (III)  
Transplantation of iPSC-derived neural progenitor cells is a novel and promising 
strategy for SCI repair. Several preclinical studies have demonstrated the beneficial effect of 
iPSC therapy in contusion and transection SCI models when immunodeficient rodents were 
used as the recipients of human cells (Nori et al., 2011; Fujimoto et al., 2012; Lu et al., 2014; 
Sareen et al., 2014). However, clinical translation of autologous iPSCs transplantations for 
the treatment of acute and subacute SCI is barely feasible due to the time required for 
generation of safe autologous iPSC lines (Fehlings et al., 2011; Faulkner et al., 2014). In 
study III we aimed to evaluate the therapeutic potential of human iPSC-NPCs subacutely 
transplanted into spinal cord of mice with contusion SCI when pharmacological 
immunosuppression was used. UEFhfiPS1.4-NPCs generated and characterized at the 
University of Eastern Finland were used for all transplantations. Daily intraperitoneal 
injections of Tacrolimus at a dose of 2 mg/kg were used in all transplantation studies to 
provide immunosuppression in grafted and control vehicle treated mice.  
5.4.1  Human iPSC-NPCs transplanted into spinal cord of uninjured mice 
immunosuppressed with Tacrolimus were safe, survived at least one week after grafting 
and expressed markers of proliferating immature neuronal cells 
First, we transplanted UEFhfiPS1.4-NPCs that had been prelabeled by lentivirus 
encoding GFP into uninjured spinal cord and assessed the efficiency of grafting 7 days after 
transplantation by GFP fluorescence. The GFP positive cells were detected in ventral horns 
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and adjacent white matter within the whole studied 6 mm segment of the spinal cord (III, 
Figure 3A). We also histologically confirmed that undifferentiated pluripotent cells were 
not present in the grafts by Nanog staining (III, Figure 3D). To assess the differentiation state 
of the transplanted cells we applied DCX, Ki-67, Tuj1, and GFAP labeling. Confocal imaging 
revealed that many of the GFP positive cells were positive for DCX and Ki-67, but not Tuj1 
or GFAP, indicating that at 7 days after grafting most of the transplanted cells were still 
proliferating immature neuronal cells (III, Figure 3B,C). Finally, Iba-1 staining revealed 
accumulation of activated microglia/macrophages around the transplanted cells (III, Figure 
3E), suggesting the presence of an immune response towards the transplanted cells. 
Next, to estimate the safety of our stem cell therapy, we transplanted the donor human 
cells or injected vehicle into the spinal cord of uninjured mice seven days after thoracic 
laminectomy and monitored the locomotor performance weekly for the next 5 weeks. 
Within the first 3 weeks after grafting the identified locomotor disturbances included only 
instances of mild trunk instability (BMS score 8) registered in both studied groups, whereas 
starting from day 28 after transplantation all animals achieved the maximal BMS score of 9, 
indicating full functional recovery (III, Figure 4). In addition, at postmortem dissection, no 
tumor formation was observed in the spinal cord. These findings allowed us to consider 
UEFhfiPS1.4-NPCs to be safe for transplantations into the injured spinal cord.  
Taken together, these results confirmed the safety of UEFhfiPS1.4-NPCs transplanted 
into the uninjured spinal cord of pharmacologically immunosuppressed mice and indicated 
that transplanted cells were able to survive for at least one week after grafting and had the 
potential to differentiate along the neuronal lineage. 
5.4.2 Human iPSC-NPCs transplanted into spinal cord of contused mice 
immunosuppressed with Tacrolimus exhibited scarce survival and did not improve 
functional recovery  
In order to determine whether the transplanted UEFhfiPS1.4-NPCs are able to promote 
functional recovery of injured mice, we produced contusion thoracic injury and 7 days later 
injected vehicle or UEFhfiPS1.4-NPCs into the spinal cord. On the day of the cell 
transplantation the BMS scores of mice injected with vehicle were 2.09 ± 0.94 vs. 2.00±0.87 in 
the group transplanted with UEFhfiPS1.4-NPCs (p>0.05) (III, Figure 6), indicating injury 
similarity in the control and transplanted groups prior to cell transplantation. The 
locomotor performance of the hind limbs was evaluated weekly for the next 5 weeks. 
Although we did not detect a statistically significant difference at any time-point between 
the studied groups, the BMS scores in mice transplanted with UEFhfiPS1.4-NPCs were 
constantly lower than in the vehicle treated group. Five weeks after grafting the vehicle 
treated mice attained a BMS score of 5.09±1.11 vs. 4.18±0.84 in the transplanted group. 
According to the BMS scoring system, vehicle treated mice on average were able to perform 
frequent or consistent plantar stepping without coordination or with some coordination, 
but with paws rotation, whereas mice transplanted with donor human cells on average 
demonstrated only occasional plantar stepping. No signs of tumor formation were 
observed in the spinal cords of mice transplanted with UEFhfiPS1.4-NPCs at the time of 
postmortem dissection.  
To confirm the results obtained with BMS, 5 weeks after cell transplantation we used 
CatWalk automatic gait analysis system to evaluate the precise movements of the hind 
limbs in the uninjured sham group, injured vehicle treated group and NPC transplanted 
group. Out of the assessed gait parameters a) Regularity index (RI), reflecting the degree of 
inter-limb coordination during the gait cycle, b) Hind paws intensity, a measure of weight 
support, c) Maximal contact, the time at which the largest part of a paw contacts the ground, 
d) Swing speed, reflecting the velocity of the moving limb during the swing phase, and e) 
Stride length, the distance between successive placements of the same paw (Hamers et al., 
2001), were all significantly higher in the sham group when compared to injured groups (III, 
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Figures 7 and 8). We did not observe significant differences in any of these gait parameters 
between groups treated with vehicle or transplanted with iPSC-derived NPCs.  
In addition, we performed MRI at 2 weeks after cell transplantation to estimate whether 
the transplanted UEFhfiPS1.4-NPCs affect the lesion size. Stem cell transplantations had no 
effect on lesion volume compared to vehicle-treated controls (III, Figure 5). 
In order to find an explanation for the observed poor therapeutic effect of iPSC therapy 
we assessed GFP fluorescence in spinal cord sections of 6 mice transplanted with 
UEFhfiPS1.4-NPCs at 42 days after the transplantation. As expected, no surviving GFP-
positive cells were found in five out of six examined spinal cords, whereas only a few 
survived cells were detected in one sample (III, Figure 9). The scarce iPSCs survival in the 
injured spinal cords was additionally confirmed by anti-GFP and human specific anti-
HuNu immunostaining.  
The obtained results indicate that human iPSC-derived NPCs transplanted into the 
injured spinal cord of mice immunosuppressed with Tacrolimus exhibited very limited 
survival and failed to promote functional recovery.   
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6 Discussion 
Traumatic SCI, leading to paralysis, sensory loss and autonomic nervous system 
dysfunction, even in the 21st century, remains one of the most devastating conditions across 
the globe. With more than 130,000 new cases each year worldwide and primarily young 
males as victims, SCI represents an important target for modern medicine. The initial 
mechanical trauma results in rapid cell necrosis. This is followed by a secondary injury 
cascade that leads to delayed neuronal and glial cell death and demyelination that 
substantially aggravate impairment in functional recovery. Nowadays more than 25 
different mechanisms participating in the secondary injury cascade are identified, including 
oxidative stress and inflammation. Scientific discoveries that have been made during the 
last decades substantially broaden our understanding of these pathophysiological processes. 
Transcription factor Nrf2 has been identified as the main regulator of the expression of 
hundreds of cytoprotective genes in response to oxidative stress. The aim of the present 
study was first to increase knowledge regarding the role of Nrf2 in SCI. This was achieved 
in study I by assessing the SCI-induced response in Nrf2 deficient mice. 
While the initial damage is incurable, secondary injury mechanisms represent potential 
therapeutic targets. Synthetic glycocorticoid Methylprednisolone (MP) administered in 
very high doses is the only drug used for the treatment of acute SCI in patients. However, 
the significant dose-related side effects and relatively modest benefits of therapy make the 
administration of MP unjustified for acute SCI. Therefore, it is of utmost importance to 
identify novel therapeutic strategies that can limit the secondary damage, preserve spinal 
cord tissue and restore impaired function. In the present in vivo preclinical study we probed 
three relatively recently emerged strategies for SCI treatment, namely a) gene transfer, b) 
pharmacological immunomodulation and c) stem cell transplantation. In study I, we aimed 
to enhance the Nrf2-driven response in order to more efficiently withstand oxidative stress. 
In study II, pharmacological immunomodulation was achieved with IL-33, a cytokine with 
pleiotropic activities, but known for initiating and expanding of the Th2/M2 response, 
which is believed to be beneficial for SCI recovery. Lastly in study III, neural progenitor 
cells derived from human iPSCs were used to assess the efficacy of iPSC therapy in 
pharmacologically immunosuppressed mice.  
The main findings presented in chapter 5 will be discussed below. 
6.1 METHODOLOGICAL CONSIDERATIONS AND LIMITATIONS (I-III) 
The most commonly used SCI models are contusion, compression and transection. As 
most spinal cord injuries in humans occur as the result of blunt, non-penetrating trauma, 
models in which the spinal cord is rapidly contused are currently thought to be the most 
relevant way to model typical injuries in humans (Kwon et al., 2010; Zhang et al., 2014). 
Therefore, in the present study, we used a bilateral contusion SCI model. To produce the 
moderate contusion injury in mice, we used two commercially available devices: NYU 
impactor, where a 5.6 gram weight was dropped from the standardized height of 6.25 cm, 
and Infinite Horizon Impactor, where a hit with a force of 60 kDyn was applied to the 
spinal cord tissue. Both devices allow the creation of reproducible spinal cord contusion 
injuries of different severity in rodents. Since the NYU Impactor was originally designed 
for modeling contusion SCI in rats (Gruner, 1992), in the present study, we used the 
minimum available weight of the rod and the drop was done from the lowest possible 
height. Despite this, we noticed that in some cases the NYU Impactor disrupted the dura in 
mice. Therefore, this type of impactor was only used in the experiment assessing the time-
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course expression of Nrf2 and its target genes in study I, whereas in all subsequent 
experiments we utilized the Infinite Horizons Impactor.  
In the present study, we selected to induce contusions at the T10 thoracic level, which 
allowed us to study recovery of hind limb function using standardized behavioral tests, e.g. 
BMS scoring system. While most human injuries occur at the cervical level (Norenberg et al., 
2004; Lee et al., 2012), cervical spinal cord models significantly increase the need for animal 
care. In addition, by the time most of the experiments were planned and performed no 
validated cervical contusion SCI mouse model had been reported. 
Inherent strain differences in mice can significantly affect the response to SCI (Basso et 
al., 2006; Kigerl et al., 2006; Lee and Lee, 2013). Therefore, to minimize variability in the 
injury response, appropriate control mice were chosen to match the genetic background. 
For Nrf2-deficient mice, we used WT littermates as controls. 
In the present study, the functional recovery of the hind limbs was evaluated by the BMS 
scale, a scoring system specially designed and validated for mouse SCI (Basso et al., 2006). 
The BMS is ordinal and the degree of difference between ranks does not necessarily equal 
to the degree in functional improvement. Therefore, while interpreting BMS results it is 
always important to consider the biological significance of the identified changes (Basso et 
al., 2006; Hodgetts et al., 2013). For instance, the change in the BMS score from 3 to 4 reflects 
a transition from no stepping to stepping, and would have higher biological significance, 
than a similar one-point increase from 1 to 2 (improvement from slight to extensive ankle 
movements). 
In study I, human Nrf2 gene was delivered into mouse spinal cord with a lentivirus 
vector. Nrf2 is evolutionally conserved with high-sequence homology in many species, 
including mouse and human (Cho, 2013). Human Nrf2 delivered into mouse hippocampus 
was capable of inducing mouse Nrf2 downstream genes (Kanninen et al., 2009). Therefore, 
delivery of the human Nrf2 gene in a mouse SCI model in the present study was justified.  
The lentivirus vector titer (study I) was chosen based on the previous study where 
lentiviruses at approximately at the same titer were used in hippocampus of a mouse 
model of Alzheimer’s disease (Kanninen et al., 2009). The dosing scheme of IL-33 in study II 
and Tacrolimus in study III were selected according to the earlier published reports of 
rodents studies (Marsala et al., 2004; Cizkova et al., 2007; Miller et al., 2008; Usvald et al., 
2010; Sevc et al., 2013) and also based on our preliminary data.  
In studies I and II, the administration of LV-hNrf2 and IL-33 were initiated immediately 
after injury. However, to deliver the patient from the scene of an accident to the hospital, 
resuscitate and define diagnosis often requires several hours. In the present study, we did 
not aim to assess the effect of delayed administration of LV-hNrf2 and IL-33. This may be a 
subject of subsequent studies. 
In study III, we transplanted iPSC-NPCs into spinal cord 7 days after trauma. This 
corresponds to the subacute phase of SCI and is considered as the optimal time window for 
NPCs transplantation (Nakamura and Okano, 2013). The acute phase of SCI is not suitable 
for transplantation due to the extensive inflammatory response developing at this time and 
the presence of an extremely hostile microenvironment, whereas in the chronic phase 
regeneration is prevented by glial scar formation.  
In study III, we used PBS as a control for the transplanted cells. Although non-viable 
cells, such as fibroblasts, are generally considered to be a better control, PBS is also often 
used in cell transplantation studies. Notably, most studies where iPSC-NPCs were 
transplanted into SCI models have utilized PBS or medium as control (Tsuji et al., 2010; 
Nori et al., 2011; Fujimoto et al., 2012; Kobayashi et al., 2012).  
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6.2 ESSENTIAL ROLE OF NRF2 IN LIMITING SECONDARY TISSUE 
DAMAGE IN SCI (I) 
Numerous preclinical and clinical studies have shown that oxidative stress is an 
important component of the secondary injury cascade, resulting in the delayed death of 
neuronal and glial elements. In the secondary injury phase, several processes, including 
ischemia, mitochondrial dysfunction, calcium overload and inflammation, lead to the 
imbalance between ROS production and antioxidant defence system resulting in the 
oxidative stress and secondary cell death (Hall and Braughler, 1989; Kwon et al., 2004; 
Rowland et al., 2008; Jia et al., 2012). Nrf2 is a redox-sensitive transcription factor, which is 
known to modulate the expression of hundreds cytoprotective genes containing the ARE in 
their promoter region (Hybertson et al., 2011; Gan and Johnson, 2013; Gao et al., 2014). 
Activation of Nrf2 and Nrf2-regulated genes has been reported in a number of neurological 
diseases, including stroke and TBI (Chen and Regan, 2007; Tanaka et al., 2011; Shang et al., 
2013), suggesting an attempt of endogenous defence systems to protect brain cells from the 
oxidative stress in these conditions. Recently, induction of the Nrf2-ARE pathway has been 
reported in the early phase of acute SCI (Mao et al., 2012, Wang X et al., 2012b, Jin et al., 
2014a). However, whether activation of the Nrf2-ARE system after SCI has a transient or 
sustained nature has not been investigated.  
In study I, we for the first time determined the magnitude and duration of the Nrf2-ARE 
response in the mouse contusion thoracic SCI model. In the injured spinal cord, we 
observed remarkable sustained induction of the Nrf2 gene and its downstream target HO-1. 
After rat contusion SCI, Nrf2 is activated already within the first 6 hours (Wang X et al., 
2012b). However, in mouse contusion SCI model, we observed that Nrf2 induction was 
delayed for 72 hours, suggesting a different pattern of Nrf2 response in mouse and rats. The 
upregulation of Nrf2 expression was preceded by even earlier induction of HO-1, which 
later showed a sharp peak simultaneously with Nrf2 at one week after injury. Although 
HO-1 is one of the main Nrf2-regulated genes, its expression can also be modulated by 
other transcriptional regulators (Schipper et al., 2009; Paine et al., 2010; Foresti et al., 2013). 
For instance, the early induction of HO-1 may be driven by NF-κB which is known to be 
activated shortly after SCI (Bethea et al., 1998; Paine et al., 2010). The important protective 
role of HO-1 in SCI has been previously established (Yamauchi et al., 2004; Lin et al., 2007; 
Kanno et al., 2009a). In our study the activation of both Nrf2 and HO-1 persisted for at least 
42 days after contusion, indicating that the Nrf2-ARE pathway functions not only in acute 
and subacute phases of the SCI, but is also implicated in its chronic phase of recovery.  
NQO1 is a redox-regulated flavoenzyme and one of the most robust responders to Nrf2 
activation (Dinkova-Kostova and Talalay, 2010). Early upregulation of NQO1 has been 
shown after rat contusion/compression and mouse compression SCI (Wang X et al., 2012b; 
Mao et al., 2011, 2012; Jin et al., 2014b). However, in our study induction of NQO1 was 
observed only at 42 days post injury. In addition, we detected transient induction of the 
two GCL subunits GCLM and GCLC within the first 24 hours after injury, which shifted to 
downregulation several days after the injury. The reasons for the observed pattern of 
NQO1 and GCLC/GCLM gene expression are not clear, however, we could assume that the 
difference in model, species or strains used may have affected the results. Nevertheless, the 
observed changes indicate that NQO1 and GCL contribute to SCI at different stages of 
recovery.   
Overall, our results provide evidence for the involvement of Nrf2 and its downstream 
genes in acute, subacute and chronic phases of SCI. While the genes tested in the current 
study do not represent the full scope of Nrf2-driven genes, it is well conceivable that the 
Nrf2-ARE response to contusion SCI is not limited to the studied genes. We also may 
assume that the remote activation of Nrf2 and its target genes in cells outside of the lesion 
area or even in the periphery contribute to the Nrf2-ARE response to SCI.  
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Although the induction of Nrf2-regulated genes is known to provide cell protection, 
chronic upregulation of some Nrf2 downstream genes may in contrast augment injury 
(Stahnke et al., 2007). Therefore, to estimate whether the observed Nrf2-ARE response 
confers protection from SCI, we assessed the effect of Nrf2 gene deletion on the outcome of 
contusion mouse SCI.  
Our results showed dramatically impaired hind limb functional recovery in Nrf2-/- mice, 
which became apparent already seven days after contusion injury and preserved until the 
end of the observation. These findings are in line with the deficit in motor function reported 
after compression model in Nrf2-deficient mice (Mao et al., 2012). Delayed apoptotic death 
of oligodendrocytes results in demyelination of many spared axons and is believed to 
underlay the impaired locomotor recovery after SCI (Basso et al., 2006; Plemel et al., 2014). 
Indeed, in our study the genetic ablation of Nrf2 resulted in increased atrophy and 
demyelination in the injured spinal cord. The observed effect of Nrf2 deficiency on myelin 
sparing is consistent with the previous studies demonstrating that Nrf2-/- mice exhibit 
greater demyelination than WT mice in EAE (Johnson et al., 2010). As reactive astrogliosis 
is triggered by many factors, including the broad spectrum of pro-inflammatory mediators, 
aggravated astroglial reaction observed in the current study in Nrf2-/- mice may indicate the 
increased pro-inflammatory status in spinal cords of mice deficient for Nrf2. In support of 
this, pro-inflammatory cytokines such as TNF and IL-6 were strongly elevated in Nrf2 
deficient mice compared to wildtypes at the time when the impairment in functional 
recovery became evident. On the other hand, activated astroglia are a well-known source of 
pro-inflammatory cytokines (Pineau and Lacroix, 2007) and Nrf2 is highly inducible in 
astrocytes (Bell et al., 2011; Dowell and Johnson, 2013). In the absence of Nrf2 primary 
cultured astrocytes expressed higher levels of pro-inflammatory cytokines than wildtype 
astrocytes in response to injury (Pan et al., 2012). Therefore, we cannot also exclude the 
possibility that the increased inflammatory response observed in Nrf2-deficient mice is 
secondary to activation of astrocytes.  
It is thought that by decreasing oxidative stress Nrf2 inactivates redox-sensitive 
transcription factor NF-κB and thereby negatively regulates pro-inflammatory cytokines (Li 
et al., 2008). Indeed, the deletion of Nrf2 resulted in greatly increased NF-κB activity in the 
acute phase of SCI (Mao et al., 2010). Although in our study we did not provide evidence 
showing that Nrf2 activation directly inhibited NF-κB signaling, it is possible to assume 
that the increased levels of pro-inflammatory cytokines was mediated by insufficient NF-κB 
suppression in Nrf2-deficient mice. Both TNF and IL-6 are critical mediators of the post-
traumatic inflammatory response and are believed to play a mainly deleterious role in SCI 
pathology (Hausmann et al., 2003; Okada et al., 2004; Genovese et al., 2008). Importantly, 
TNF is specifically cytotoxic to oligodendrocytes, mediating their apoptotic death (Hisahara 
et al., 1997; Yune et al., 2003; Genovese et al., 2008, 2009; Inukai et al., 2009). Therefore, 
elevated levels of TNF observed in Nrf2-deficient mice in the current study might be at 
least in part responsible for the increased demyelination. During the secondary injury 
phase oligodendrocytes die mainly through apoptosis (Crowe et al., 1997; Profyris et al., 
2004; Mekhail et al., 2012). Despite the fact that there is little information available on 
whether Nrf2 affects apoptotic cell death after SCI, Nrf2 has been proposed to prevent 
apoptosis by regulating the expression of anti-apoptotic Bcl-2 and Bcl-xL in vitro (Niture 
and Jaiswal, 2012, 2013; Son et al., 2014). Recently curcumin and EPO were shown to reduce 
apoptosis after rat compression SCI and their effect probably was mediated through Nrf2 
activation (Jin et al., 2014a,b). In line with these reports, we observed altered expression of 
Bcl-xL in Nrf2-/- mice at 7 days after insult, indicating that Nrf2 is involved in regulating 
apoptosis in the contused mouse spinal cord. Collectively, these data indicate that Nrf2 is 
important for prevention of demyelination and limiting of astrogliosis, inflammation and 
apoptosis after contusion SCI.  
Surprisingly, the impaired motor recovery in Nrf2-/- mice was not associated with 
reduced expression of such an important Nrf2 downstream gene as HO-1, suggesting the 
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Nrf2 independent regulation of HO-1 in the injured spinal cord and supporting our 
previous observation that after contusion injury upregulation of HO-1 precedes the 
activation of Nrf2. However, Nrf2 deficient mice exhibited significantly diminished 
expression of NQO1 and a clear trend in reduced MGST1 expression, prior to and at the 
time of the onset of the motor impairment, indicating an altered ability of these mice to 
cope with oxidative stress in the absence of Nrf2. 
Finally, Nrf2 deficiency resulted in diminished upregulation of NGF compared to 
wildtype mice. In addition, we observed a clear trend towards less GDNF expression in 
Nrf2 deficient mice, indicating a possible role of Nrf2 in regulation of this growth factor 
expression. Nrf2 has been reported to regulate NGF production in glioblastoma cells and 
astrocytes (Mimura et al., 2011). In line with this, our findings show that Nrf2 might be also 
involved in neurotrophic factor signalling in vivo. Growth factors, such as NGF and GDNF 
modulate neuronal survival, facilitate neurite outgrowth, improve synaptic plasticity and 
neurotransmission, and exogenous administration of growth factors represents a potential 
therapy for SCI (reviewed in Awad et al., 2013). Therefore, lack of NGF and GDNF 
upregulation in Nrf2 deficient mice may negatively affect the recovery from SCI.    
Overall our results indicate that Nrf2 deficient mice exhibit significantly enhanced 
secondary damage leading to impairment in functional recovery after contusion SCI. 
Therefore, proper functioning of Nrf2 is crucial for SCI outcome. While our work was in 
progress, several studies reported that Nrf2 deletion impairs recovery from compression 
SCI in mice (Mao et al., 2010, 2011, 2012). These studies are in full agreement with our 
findings that Nrf2 is essential for limiting secondary tissue damage after contusion SCI. 
Furthermore, altered expression of genes regulating inflammation, apoptosis and neuronal 
survival observed after Nrf2 deletion in our study indicate an even broader role of this 
transcription factor in SCI. 
6.3  NO ADDITIONAL BENEFIT OF LENTIVIRUS-MEDIATED NRF2 
OVEREXPRESSION OVER ITS NORMAL INDUCTION IN THE INJURED 
SPINAL CORD (I) 
While activation of Nrf2 and its downstream genes after SCI confers substantial 
protection from the secondary injury it is obviously not sufficient to fully abolish the 
pathologic process. Augmentation of Nrf2 activity via chemical inducers may be a feasible 
strategy to boost cellular defence mechanisms and thus to mitigate the secondary tissue 
damage. Indeed, chemical compounds such as sulforaphane, curcumin and more recently 
EPO have been reported to provide neuroprotection against SCI in mice and rats through 
activation of the Nrf2 pathway (Mao et al., 2011; Benedict et al., 2012; Wang X et al., 2012b; 
Jin et al., 2014a,b). However, the degree of impact of Nrf2 activation in the beneficial effect 
of these chemicals in SCI is not very clear. For example, the protective effect of 
sulforaphane is mediated at least in part through inhibition of the NF-κB pathway (Cheung 
and Kong, 2010). Mechanisms of EPO neuroprotection in addition to NF-κB inhibition 
engage activation of the Janus kinase 2 (JAK-2) signaling pathway (Carelli et al., 2011). In 
contrast, introduction of a certain transcription factor with a gene therapy approach allows 
specifically boosting its expression and dissecting associated effects. Therefore, to estimate 
whether Nrf2 enhancement confers additional protection against SCI, in study I, we 
examined the possibility to overexpress this transcription factor in the injured spinal cord 
by direct introduction of a lentivirus encoding human Nrf2.  
Through intraspinal gene transfer, we achieved strong overexpression of the transgene 
mainly throughout the grey matter, including both neurons and astrocytes. Human Nrf2 
expression was sustained in the spinal cord tissue at substantially high levels for at least 
one month after gene delivery. However, surprisingly, Nrf2 overexpression not only failed 
to promote functional recovery after contusion SCI, but even worsened locomotor function 
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compared to vehicle control. In addition, we observed that both LV-hNrf2 and LV-GFP 
delivered into spinal cords of uninjured mice severely impaired the motor function of hind 
limbs. Interestingly, introduction of an increased volume of LV-hNrf2 into the spinal cord 
of uninjured or contused mice significantly mitigated the observed toxicity, but still was not 
sufficient to provide additional benefit over vehicle.  
The reasons for the toxic effect observed in the current study are not clear since 
approximately at the same titers lentiviral vectors have been successfully used for 
intraspinal delivery of ChABC (Bartus et al., 2014), and LV-hNrf2 was delivered in the 
hippocampus of a mouse model of Alzheimer’s disease without apparent toxicity 
(Kanninen et al., 2009). Recently, successful transduction of neurons in cortex and 
hippocampus after intranasal treatment with LV-hNrf2 has been reported. No side effects 
or toxicity related to lentiviral transduction were observed compared with untreated 
control animals in this study (Wang et al., 2014). However, in our experiments both LV-
hNrf2 and LV-GFP dramatically increased the expression of pro-inflammatory cytokines, 
such as TNF, IL6 and IL-1β over levels of vehicle treated controls. Although the increased 
inflammatory response did not result in extension of the lesion volume and was not 
associated with the altered expression of proapoptotic and anti-apoptotic genes, we may 
suppose that it underlaid the observed impairment in functional recovery. It is possible to 
assume that both transgenes at high expression rates induced toxicity in the spinal cord. 
Indeed, as an exogenous protein, GFP has been reported to be immunogenic and induce 
cytotoxicity promoting oxidative stress and apoptosis (Liu et al., 1999; Stripecke et al., 1999; 
Goto et al., 2003; Yang et al., 2014), whereas permanent induction of Nrf2 and its 
downstream genes might also be deleterious for the cells (Stahnke et al., 2007; Ni et al., 
2014). However, increasing the amount of LV-hNrf2 delivered into the spinal cord did not 
further augment functional impairment, but instead prevented it. Therefore, it is more 
likely that at least in the case of the LV-hNrf2 gene transfer, the observed inflammatory 
response was triggered by the lentivirus itself, whereas an increased volume of delivered 
LV-hNrf2 protected the spinal cord from the lentivirus mediated toxicity. 
The absence of the beneficial effect of Nrf2 gene transfer at least in part may be explained 
by the failure of the transgene to activate Nrf2-ARE pathway in the mouse spinal cord 
shortly after gene delivery, even in the experiment where the amount of LV-hNrf2 
introduced into the spinal cord was increased by 33%. Indeed, 3 days after gene transfer, 
only NQO1 was further upregulated in the LV-Nrf2 group, whereas Nrf2, HO-1 and 
MGST-1 were not altered by human Nrf2 gene transfer. The increased expression of NQO1 
was obviously not sufficient to provide improvement in the functional recovery over 
vehicle controls, especially during conditions of increased inflammatory response, which 
we observed after the gene transfer. However, together with increased GDNF expression, 
NQO1 may be involved in preventing functional impairment seen after the delivery of LV-
hNrf2 at a relatively low amount.  
The lack of functional improvement after Nrf2 overexpression observed in this study 
does not diminish the importance of Nrf2 for recovery from SCI, nor does it contradict the 
results obtained in experiments with Nrf2 deficient mice. In Nrf2-knockout animals the 
expression of Nrf2 is absent since the first days of embryonic development in all cell types 
of the body, whereas the LV-hNrf2 was introduced into the spinal cord only right after the 
contusion and its expression was limited only to neurons and astrocytes. Our current 
findings also do not contradict the previous studies showing the beneficial effect of 
chemical compounds activating Nrf2 for recovery from SCI (Mao et al., 2011; Benedict et al., 
2012; Wang X et al., 2012b; Jin et al., 2014a,b). We can assume that these chemicals reach 
their targets in all cell types in the spinal cord and in periphery, and in addition, possess 
Nrf2-independent mechanisms of action. Therefore, the insufficient beneficial effect of LV-
Nrf2 treatment on SCI functional recovery observed in the current study may be due to late 
administration or more likely restriction of its expression within certain cell types. Also, we 
cannot rule out the possibility that variations in virus vector preparation could affect the 
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outcome. Considering the possible role of Nrf2 in preventing apoptosis, the prominent role 
of apoptosis in delayed oligodendrocyte death, and the importance of oligodendrocytes for 
functional recovery after SCI it might be crucial to achieve stable Nrf2 overexpression in 
this specific cell type. Further efforts should be also made to estimate the optimal time of 
administration and titer of the virus vector to achieve functional improvement and avoid 
the toxicity associated with the gene transfer approach.  
6.4 MODULATION OF INFLAMMATION WITH IL-33 AS A POTENTIAL 
THERAPEUTIC APPROACH FOR SCI (II) 
It is now becoming increasingly clear that traditionally widely used anti-inflammatory 
strategies, such as high doses of steroids or NSAIDs, have yielded little success to improve 
functional recovery after SCI. Therefore, the traditional view that inflammation is 
absolutely harmful for the recovery from SCI requires re-assessment. It is obvious that 
immune cells are much more heterogeneous than it was previously thought and there are 
much more diverse functions of these immune cell subtypes. In light of this, modulation of 
inflammation in order to harness its components that are important for repair appears 
extremely attractive (Rossignol et al., 2007; David et al., 2012; Plemel et al., 2014). 
Macrophages are a highly heterogeneous group of effector cells of innate immunity known 
to exert both beneficial and detrimental effects in SCI (Kigerl et al., 2009; David et al., 2012; 
Plemel et al., 2014). The ability of macrophages to shift their functional phenotype in 
response to changes in the microenvironment makes them an attractive target for 
immunomodulatory therapy. Unfortunately, the microenvironment of the injured spinal 
cord is favorable to the neurotoxic M1 subtype, whereas the presence of the anti-
inflammatory M2 subtype is transient (Kigerl et al., 2009). IL-33 is a cytokine that stimulates 
T-lymphocytes to produce cytokines required for the M2 shift and therefore create an 
environment favorable for M2 polarization (Schmitz et al., 2005; Chackerian et al., 2007; 
Kurowska-Stolarska et al., 2009). The potential of IL-33 to harness the immune response 
encouraged us, in study II, to explore whether IL-33 treatment could be beneficial in a 
mouse model of contusion SCI.    
6.4.1 Recombinant IL-33 as a modulator of central and peripheral inflammation after SCI 
Administration of recombinant IL-33 after contusion injury resulted in improved 
functional recovery when compared to vehicle treated mice. We observed that improved 
functional recovery in IL-33 treated mice was associated with increased tissue sparing, 
reduced demyelination and decreased astrogliosis in the spinal cord, indicating that IL-33 
provided tissue protection and reduced secondary tissue damage. Although we did not 
observe a reduction in lesion volume with MRI, the contradictory results between IHC and 
imaging could be attributed to the different time-points. MRI was performed one week 
prior to the time when the improvement in functional recovery was identified, whereas 
tissue sparing was assessed at the endpoint when the improvement in functional recovery 
was obvious.   
Although in the present study we did not specifically tag IL-33 we may assume that it 
penetrates into the injured spinal cord due to the damage to the BSB. Indeed, BSB 
permeability typically peaks at 24 hours following SCI and lasts at for least 2-4 weeks after 
trauma (Noble and Wrathall, 1989; Popovich et al., 1996; Mautes et al., 2000b). In support of 
this, a reduction of TNF expression in the spinal cord after IL-33 treatment was detected as 
early as 24 hours after the first dose. The exact mechanisms of TNF inhibition after IL-33 
treatment remain unclear, however knowing that resident spinal cord cells are mainly 
responsible for the release of TNF at this time-point we may suppose that by binding to its 
receptor in these cells IL-33 was able to dampen TNF release. Since astrocytes and microglia 
express the full IL-33 receptor, whereas neurons lack the ST2 subunit (Andre et al., 2005; 
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Yasuoka et al., 2011) we may assume that the observed effect is mainly mediated by the 
interaction of IL-33 with glial cells. At the same time we did not observe altered expression 
of IL-6 and IL-1β after IL-33 treatment in the injured spinal cord. Interestingly, recent in 
vitro data shows that IL-33 induces the release of pro-inflammatory cytokines from glia 
(Yasuoka et al., 2011; Kempuraj et al., 2013). While these discrepancies should be resolved 
in future studies, we suppose that the early reduction of TNF detected in the current 
experiments was crucial for functional recovery improvement observed after IL-33 
treatment. Our findings are in line with studies showing that pharmacological inhibition of 
TNF is protective in SCI. Thus, Etanercept, which is a clinically approved TNF antagonist, 
has been shown to reduce secondary injury, decrease tissue damage, and improve 
functional recovery after SCI (Genovese et al., 2006; Chen et al., 2011).  
As it was previously discussed in chapter 6.2, TNF might be responsible for increased 
demyelination due to specific cytoxicity towards oligodendrocytes. Activation of astrocytes 
is also mediated by TNF signaling. Therefore, reduced demyelination and astrogliosis 
detected after IL-33 treatment might be at least partly attributed to TNF inhibition.  
TNF plays a significant role in the activation of peripheral leukocytes and their 
recruitment to the injured spinal cord (Pineau and Lacroix, 2007) and therefore, reduced 
TNF expression after IL-33 treatment could mitigate T-cell infiltration. Indeed, in our study, 
IL-33 treatment reduced the expression of T-lymphocyte markers already 8 days after 
injury and induced a trend towards reduction in the number of infiltrating T-cells at 6 
weeks post injury, the time when the second peak in the T-cell infiltration into the injured 
mouse spinal cord usually occurs (Sroga et al., 2003; Kigerl et al., 2006). These findings are 
well in line with the previously reported capacity of IL-33 to reduce T-cell infiltration in 
vivo (Turnquist et al., 2011). In the injured spinal cord, the infiltrating T-lymphocytes 
recognize specific antigens, such as myelin basic protein. Proliferating in response to these 
antigens, the T-cells promote axonal injury, demyelination, and functional loss (Gonzalez et 
al., 2003; Jones et al., 2005). However, activated T-cells can also provide neuroprotection 
and increase axonal regeneration (Schwartz and Kipnis, 2001; Hauben 2000, 2001; Schwartz, 
2005). Th2-lymphocytes produce IL-4, IL-5, IL-13 and IL-10 required for polarization of 
macrophages to the beneficial anti-inflammatory M2 phenotype (Gordon, 2003; Mantovani 
et al., 2004; Martinez et al., 2009). IL-33 is known to stimulate T-lymphocytes to produce 
these cytokines (Schmitz et al., 2005; Chackerian et al., 2007) and therefore to promote the 
M2 shift. Since we did not specifically study the T-cell populations in the spinal cord tissue, 
we lack direct evidence to demonstrate an IL-33-induced Th2 response in the injured spinal 
cord. In addition, we did not observe an increased expression of Th2 cytokines in the spinal 
cord tissue after IL-33 treatment. However, it is worth noticing that in our study the 
expression of Th2 cytokines was assessed 24 hours after SCI, whereas T-cell infiltration into 
mouse spinal cord typically occurs 2 weeks after injury (Sroga et al., 2003; Kigerl et al., 
2006). At the same time, the finding that IL-33 treatment decreased levels of Th1/Th17 
cytokines, IFN-γ and IL-17, in plasma, elevated IL-10, and reduced the percentage and 
absolute number of CD4+ T helper cells expressing TNF in the spleen indicate the 
suppression of the Th1 response and induction of the Th2 response in the periphery. Future 
research may answer the question of whether beneficial effects of IL-33 treatment after SCI 
in addition to attenuation of T-cell infiltration involve skewing of T-lymphocytes into the 
Th2 phenotype in the injured spinal cord. 
 In the spinal cord lesions, M1 microglia/macrophages outnumber M2 cells and they are 
believed to be detrimental to recovery after SCI (Kigerl et al., 2009; David and Kroner, 2011). 
Recently, TNF was identified as the main cytokine responsible for prolonged M1-
polarization of microglia/macrophages in the injured spinal cord (Kroner et al., 2014) and, 
therefore, reduced TNF levels might create an environment favorable for chronic 
persistence of beneficial M2 cells. We observed that IL-33 treatment induced a dramatic 
increase in the expression of Arginase-1 and Ym-1, two M2 markers, in the spinal cord 8 
days after injury, i.e. at the time when the numbers of activated microglia/macrophages 
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reaches its peak (Sroga et al., 2003). The increased number of Arginase-1-positive M2 
microglia/macrophages persisted in the injured spinal cord for at least up to 6 weeks after 
injury. Our results are in line with a previous study showing that IL-33 treatment induces a 
shift towards the M2 type macrophage activation in the lymph nodes and spleen of a 
mouse model of EAE (Jiang HR et al., 2012). However, the current study is the first showing 
the ability of IL-33 to induce a remarkable M2 response in the CNS, and specifically in the 
spinal cord. Recently, spleen has been identified as the main source of monocytes 
infiltrating the spinal cord after SCI (Blomster et al., 2013). Therefore, we may speculate that 
in our study recombinant IL-33 treatment targeted infiltrating macrophages, including 
those originating from the spleen. This view was further supported by the findings that IL-
10 levels were elevated in spleen shortly after IL-33 treatment. The important functions of 
IL-10 are to increase arginase activity and inhibit pro-inflammatory cytokine production 
and NO release (Liu et al., 2011). As IL-10 is one of the main cytokines responsible for M2 
polarization (Shechter et al., 2011; Deng et al., 2012), it might have induced a shift of splenic 
monocytes into the M2 type. In addition, CD4+CD25+ Treg cells express a unique 
transcription factor, Foxp3, (Fontenot et al., 2003) and are known to induce M2 macrophage 
differentiation in vitro (Tiemessen et al., 2007) and in vivo (Liu et al., 2011). In the present 
study, we observed increased Foxp3 expression in spleen at the same time when IL-33 was 
elevated, suggesting that shortly after injury IL-33 created an environment favorable for M2 
polarization in the spleen. It is interesting to note that one week after injury we did not 
observe increased numbers of Tregs in spleen or plasma, indicating the transient nature of 
the Tregs response on IL-33 treatment. Finally, we observed a significant reduction of the 
M1 marker iNOS expression and a tendency towards upregulation of Arginase-1 
expression in the spleen 6 weeks after IL-33 treatment. This further supports the skew to the 
M2 phenotype in the spleen after IL-33 treatment. Additional studies utilizing 
splenectomised mice are required to estimate the contribution of splenic macrophages in 
M2 polarization detected in injured spinal cord after IL-33 treatment. Since it is impossible 
to distinguish fully activated resident microglia and infiltrating macrophages by their 
morphology or antigenic markers (Fleming et al., 2006; David and Kroner, 2011), we also 
cannot exclude the possibility that resident microglia may have acquired the M2 phenotype 
in our experiments, and therefore contributed to the observed beneficial effects of IL-33 
treatment. Importantly, the degree of microgliosis was not altered by the treatment, 
indicating that IL-33 induced a shift in microglia/macrophage phenotype without alteration 
of their activation. 
6.4.2 Intracellular IL-33 is involved in SCI-induced inflammatory response 
In addition to its extracellular cytokine function, IL-33 also acts as a nuclear transcription 
factor regulating gene expression in a non-IL-33 dependent manner (Carriere et al., 2007; 
Roussel et al., 2008). The cellular source of IL-33 in CNS is controversial (Yasuoka et al., 
2011; Jiang HR et al., 2012) and whether it is involved in the SCI-induced response has not 
been investigated. Since in the current study endogenous IL-33 was induced in the spinal 
cord shortly after contusion, our results indicate that IL-33 as a transcription factor readily 
responds to the SCI. We also observed that IL-33 protein expression persists at high levels 
for at least 6 weeks after injury and its protein expression is restricted to astrocyte nuclei. 
Therefore, our findings are in line with the observations that astrocytes are the main 
cellular source of IL-33 in the CNS (Hudson et al., 2008; Yasuoka et al., 2011; Christophi et 
al., 2012; Zhao et al., 2013). Since we have not studied the time-course of IL-33 expression, 
we lack information about whether the rate of its activation changes with the progression of 
secondary injury. However, our results show that IL-33 remains activated also in the 
chronic phase of SCI.  
Intracellular IL-33 is known to repress NF-κB activity and transcription of NF-κB 
downstream genes (Ali et al., 2011). Therefore, the induction of intracellular IL-33 after 
trauma may be an attempt to inhibit an excessive inflammatory response after SCI. Future 
68 
 
 
 
studies involving IL-33-knockout mice are required to estimate the precise role of IL-33 in 
the secondary injury response. It is important to notice that recombinant IL-33 did not affect 
the level of intracellular IL-33 expression. This indicates that the effects of recombinant IL-
33 were independent from the function of nuclear IL-33.  
Collectively, our results suggest that intracellular IL-33 contributes to the immune 
response after contusion SCI, whereas recombinant IL-33 treatment modulates both central 
and peripheral inflammation, leading to reduced secondary damage and improved 
functional recovery. Although more intensive research is needed to define the precise 
mechanisms of IL-33 action, our study has provided the first insights into the beneficial role 
of IL-33 in recovery after contusion SCI. We believe that optimization of IL-33 dosing and 
estimation of the optimal treatment regimen may produce even better results in future 
studies. The proposed mechanisms of IL-33 action in SCI are summarized in Figure 5. 
 
Figure 5. Proposed immunomodulatory mechanisms of IL-33 action resulting in neuroprotection 
after contusion SCI.  
6.5 TRANSPLANTED HUMAN iPSC–DERIVED NEURAL PROGENITORS 
NEITHER SURVIVE NOR PROMOTE FUNCTIONAL RECOVERY OF 
CONTUSED MICE IMMUNOSUPPRESSED WITH TACROLIMUS (III) 
Numerous preclinical studies have convincingly demonstrated that stem cell 
transplantation approaches have great potential to yield repair and recovery of lost 
function in different CNS diseases, including SCI. The patient-specific iPSCs, generated by 
the reprogramming of adult somatic cells, avoid ethical concerns common for ESCs and can 
be used for autologous transplantations without the risk of immune rejection (Kramer et al., 
2013; Mothe and Tator, 2013). Differentiated along the neural lineage the iPSCs represent a 
potentially unlimited source of neural cells for cell replacement therapy. However, in the 
case of acute injuries, such as SCI, the translation of NPCs derived from patient-specific 
iPSCs in clinical practice is limited by the time required to properly characterize and 
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carefully validate autologous iPSCs in sufficient quantities. Therefore, carefully pre-
evaluated allogeneic iPSCs lines are likely more suitable for transplantations into patients 
with acute SCI (Fehlings and Vawda, 2011; Kramer et al., 2013; Faulkner et al., 2014). In this 
situation immunosuppressive drugs will be required to blunt the recipient's immune 
response. Recently, human iPSC-derived NS/PCs transplanted into spinal cord have been 
shown to improve the outcome after SCI in several preclinical studies (Nori et al., 2011; 
Fujimoto et al., 2012; Kobayashi et al., 2012; Lu et al., 2014; Sareen et al., 2014). However, in 
most of these reports NS/PCs were transplanted into genetically immunocompromised 
rodents to avoid the host immune response (Nori et al., 2011; Fujimoto et al., 2012; Lu et al., 
2014; Sareen et al., 2014). From these studies it is not clear whether the beneficial effect of 
iPSC therapy would be preserved in the more clinically relevant settings of 
pharmacological immunosuppression. In study III, we addressed this question by using the 
calcineurin inhibitor, Tacrolimus, which is widely used in clinical practice to prevent 
rejection after allograft transplantation (Fukudo et al., 2005; Fukuoka et al., 2010; Choi and 
Reddy, 2014).  
In the present study, we used iPSC-derived NPCs (UEFhfiPS1.4) generated and 
characterized in our laboratory (Qu et al., 2013). Prior to grafting, we assured that cells lose 
pluripotency and express the neural markers PAX-6, MAP-2 and DCX. By transplanting the 
cells into spinal cords of uninjured laminectomized mice, we further confirmed the 
potential of iPSC-derived precursors to differentiate into neuronal lineage in vivo. Thus, one 
week after grafting confocal imaging revealed that many of the transplanted cells actively 
proliferated and were still at the stage of immature neuronal cells at that time.  
Since iPSCs are potentially tumorigenic (Miura et al., 2009; Tsuji et al., 2010; Kramer et al., 
2013), controlling the safety of the grafted iPSC-derived NPCs is of particular importance. 
The presence of even small amounts of undifferentiated cells after in vitro or in vivo 
differentiation may result in tumor formation in the recipient (Miura et al., 2009; Fu et al., 
2012). Seven days after grafting into injured mice we did not observe any cells positive for 
Nanog, a marker detecting undifferentiated pluripotent cells. Usually, the tumor formation 
in the spinal cord results in substantial impairment in locomotor performance already 
within 10 days after stem cell grafting, which is followed by the full hind limb paralysis 
(Wang X et al., 2012a). However, in our study, uninjured transplanted mice did not exhibit 
functional impairment at least up to 5 weeks after transplantation. Furthermore, no signs of 
tumor formation were observed at postmortem dissection, indicating the safety of NPCs 
used in our studies.  
These results encouraged us to further explore whether UEFhfiPS1.4-NPCs are able to 
improve the outcome of contusion SCI. We transplanted NPCs into the spinal cords one 
week after contusion injury, which is considered to be within the optimal time window for 
cell transplantations into injured spinal cord (Nakamura and Okano, 2013). However, 
transplanted cells failed to improve functional recovery and did not reduce the lesion size 
when compared to the vehicle-treated mice. Moreover, BMS scoring showed sustained 
impairment in recovery of motor function in the group transplanted with UEFhfiPS1.4-
NPCs, which appeared already one week after grafting and at the end of the observation 
period resulted in occasional plantar stepping. Vehicle-treated mice performed frequent or 
constant stepping. Although the observed impairment was not statistically significant, 
given the ordinal nature of the BMS scale we may speculate that the transplanted cells 
possibly even worsened the behavioral outcome in our study. 
Since any beneficial effect of transplanted cells on functional recovery is usually 
interrelated with good cell survival, we presumed that the poor effect of NPCs 
transplantation in our study was associated with limited cell survival in the injured spinal 
cord. Indeed, very scarce numbers of cells were found only in one sample at 5 weeks after 
the cell transplantation, whereas the others were devoid of viable transplanted cells. 
Interestingly, it has been reported that an 18-20% survival rate of transplanted mouse and 
human iPSC-derived progenitors into immunodeficient mice is enough to promote 
70 
 
 
 
functional improvement (Tsuji et al., 2010; Fujimoto et al., 2012). Clearly, the amount of 
survived cells in our study was insufficient to provide functional improvement. 
 While our results contradict the majority of studies reporting the beneficial effect of 
iPSC therapy in acute SCI models (Nori et al., 2011; Fujimoto et al., 2012; Kobayashi et al., 
2012; Lu et al., 2014; Sareen et al., 2014), studies reporting no effect from iPSC therapy in 
subacute SCI settings also exist (Kramer et al., 2013). ESCs are known to induce a strong 
immune response involving both T-lymphocytes and NK cells (English and Wood, 2011; 
Kramer et al., 2013), whereas immunogenic properties of iPSCs have also been reported 
(Zhao et al., 2011; Cao et al., 2014). Throughout our study, to prevent the graft rejection, we 
used the same immunosuppressive regimen, which included daily administration of the 
calcineurin inhibitor, Tacrolimus, in a dosage commonly used in allogeneic cell 
transplantation studies (Marsala et al., 2004; Cizkova et al., 2007; Usvald et al., 2010; Sevc et 
al., 2013). Notably, most of the successful reports utilized genetically immunocompromised 
rodents including nonobese diabetic – severe combined immunodeficient mice (NOD-
SCID). These mice have severe impairment in both innate and adaptive immunity, as they 
lack complement hemolytic activity and both mature T- and B-lymphocytes. In addition, 
the function of NK cells, dendritic cells and macrophages is altered in this mouse strain 
(Schultz et al., 1995; Greiner et al., 1998; Anderson et al., 2011). Importantly, while 
calcineurin inhibitors effectively target the T-cell response, these immunosuppressants do 
not affect NK cells or other rejection mechanisms (Anderson et al., 2011). As an immune 
response to transplanted cells may not only result in graft rejection, but also affect the cell 
fate (Sontag et al., 2013) it is not surprising that outcome of cell grafting in genetically and 
pharmacologically immunosuppressed rodents may be different. In the present study, we 
observed accumulation of microglia/macrophages around the grafts in uninjured mice 
already one week after transplantation, indicating the triggering of an immune response 
towards the transplanted allogeneic cells even in the uninjured mice. Together with the 
limited graft survival and absence of functional improvement in injured mice, our results 
suggest that monotherapy with Tacrolimus is not sufficient to provide an effective 
immunosuppression for successful iPSC grafting after contusion SCI. 
The poor effect of pharmacological immunosuppression has been reported in the 
majority of preclinical allogeneic transplantation studies (Luchetti et al., 2010; Anderson et 
al., 2011). For example, Tacrolimus monotherapy fails to provide efficient 
immunosuppression in studies involving the G93A SOD1 animal model of ALS (Yan et al., 
2006; Hefferan et al., 2011). In traumatic injury models, such as SCI, it may be even more 
challenging to achieve effective and long-term immunosuppression, due to the complex 
nature of the immune response involving numerous cell types and mediators, and 
especially BSB breakdown enhancing access of the immune cells to the injured spinal cord 
(Anderson et al., 2011). In line with this, in our experiments when human ESCs or iPSC-
derived NPCs were transplanted into the brains of uninjured mice, transgenic APdE9 mice 
and mice subjected to permanent focal brain ischemia, we observed graft survival for 5-12 
weeks despite the immunosuppressive regimen used in those experiments being similar to 
the current study. This indicates that the beneficial effect of immunosuppressants in 
promoting transplanted cell survival observed in intact animals or other models may be 
cancelled out in SCI by the complex and diverse immune response in the injured spinal 
cord. In support of this, recent studies have shown that immunosuppression is associated 
with increased efficacy in focal cerebral ischemia (Lees et al., 2012), whereas in SCI, in 
contrast, efficacy of immunosuppressants is reduced (Antonic et al., 2013).  
The calcineurin inhibitors Cyclosporine and Tacrolimus are the most widely used 
immunosuppressants in the clinical practice (Choi and Reddy, 2014). Although both drugs 
act in a similar manner, there is substantial evidence that Tacrolimus exerts stronger 
immunosuppression than cyclosporine (Saudek et al., 2005; Grimm et al., 2006; Krämer et 
al., 2008; Fukuoka et al., 2010) and has a lower nephrotoxicity potential (Naesens et al., 
2009). In light of this, it is interesting that recently a beneficial effect was reported after 
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transplantation of human iPSC-NS/PCs into a contused nonhuman primate spinal cord 
when monotherapy with Cyclosporine was used for immunosuppression (Kobayashi et al., 
2012). Quite often in clinical settings calcineurin inhibitors are combined with other drugs 
to increase the efficacy of immunosuppression (Choi and Reddy, 2014). In preclinical 
studies the increased efficiency of combined immunosuppression (Tacrolimus + Sirolimus, 
Tacrolimus + Mycophenolate or Tacrolimus + anti-CD4 antibody) in comparison with 
Tacrolimus monotherapy has also been reported (Yan et al., 2006; Hefferan et al., 2011;  
Sontag et al., 2013). Of note, very recently the combination of Cyclosporine, Azathioprine 
and Methylprednisolone have been reported to provide efficient and long-term 
immunosuppression after transplantation of human iPSC-derived NPCs into spinal cords 
of rats with compression SCI (Romanyuk et al., 2014). While more future studies should 
determine whether combined immunosuppression would be efficient enough in acute SCI, 
our study is the first one where monotherapy with Tacrolimus was used for allogeneic stem 
cell transplantation in an acute SCI model.  
Taken together, our results demonstrate that immunosuppressive monotherapy with 
Tacrolimus was not sufficient to provide long-term survival of human iPSC-derived NPCs 
transplanted into contused mouse spinal cord, and demonstrate the importance of studies 
involving combined immunosuppression or/and reduction of immunogenicity of 
transplanted cells prior to implementation of iPSC-based therapy into clinical practice.  
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7 Summary and Conclusions  
In the present study, we investigated the effect of (i) Nrf2 gene transfer, (ii) IL-33 
pharmacological treatment and (iii) transplantation of iPSC-derived neural progenitors on 
recovery from contusion SCI. Special focus was placed on assessing the 
immunomodulatory properties of recombinant IL-33 and role of Nrf2 in protection from 
secondary injury. In addition, we studied the response of endogenous Nrf2 and IL-33 to SCI. 
The main results of this thesis can be summarized as follows: 
 
 
I 
Contusion SCI induced sustained activation of the Nrf2-ARE pathway. Deletion of the Nrf2 
gene substantially exacerbated secondary damage leading to impaired functional recovery. 
Proper Nrf2 function was important for regulation not only of classic target genes, but also 
genes involved in inflammation, apoptosis, and tissue repair. These results provide new 
insights into the essential role of Nrf2 in acute CNS injuries. Nrf2 gene transfer with a 
lentiviral vector resulted in strong, long-term overexpression of the transgene in astrocytes 
and neurons. The side effect of gene therapy manifested as impaired motor function. An 
increased amount of delivered Nrf2 gene prevented locomotor impairment but did not 
provide extra benefit compared to normal activation of Nrf2 after contusion SCI. These 
results suggest the development of an inflammatory response after gene transfer and 
underline the importance of the optimal titer of the virus vector used for gene therapy after 
SCI. 
 
II 
Contusion SCI induced endogenous IL-33 expression in astrocyte nuclei. The results 
suggest the involvement of intracellular IL-33 in the SCI-induced immune response. 
Recombinant IL-33 ameliorated secondary injury and dramatically improved functional 
recovery. The neuroprotective effect of IL-33 was mediated through the modulation of the 
inflammatory response in the spinal cord and in the periphery. Sustained polarization of 
microglia/macrophages to the anti-inflammatory M2 phenotype in spinal cord was 
associated with decreased expression of cytotoxic TNF and a tendency to reduced T-cell 
infiltration. The beneficial effects of IL-33 in spinal cord were accompanied by elevation of 
anti-inflammatory IL-10 and suppression of the Th1 response in the peripheral tissues. The 
results indicate that IL-33 is a novel promising treatment for SCI. 
 
 
III 
The transplantation of human iPSC-derived neural progenitor cells was safe and grafted 
precursors had the potential to differentiate into neuronal cells in vivo. Subacutely 
transplanted into the contused spinal cord, the human iPSC-NPCs exhibited limited 
survival and did not facilitate functional recovery when the calcineurin inhibitor 
Tacrolimus was used to prevent graft rejection in doses commonly used in preclinical 
transplantation studies. The results suggest that contusion SCI is a particularly challenging 
condition to achieve effective and long-term immunosuppression and highlight the 
importance of additional studies involving combined immunosuppressive strategies to 
prevent rejection of human iPSC-derived cells.  
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In conclusion, we have for the first time demonstrated that recombinant IL-33 is an 
attractive candidate to modulate inflammation and promote functional recovery after 
contusion SCI. Despite the fact that Nrf2 plays crucial and multifaceted roles in protection 
from secondary injury, even strong Nrf2 overexpression in neurons and astrocytes with 
gene transfer technology may not offer extra benefit. Special attention should be paid to 
vector-associated toxicity issues in the future. Tacrolimus treatment is not sufficient to 
promote survival of human iPSCs subacutely transplanted into contused spinal cord. 
Achieving efficient and long-term immunosuppression is especially challenging in SCI. 
Additional studies are warranted to find an optimal regimen of immunosuppression to 
gain the potential beneficial effect of iPSC therapy after contusion SCI. 
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Spinal cord injury (SCI) is a 
catastrophic condition resulting 
in loss of sensation, motor, and 
autonomic function. There is no 
effective therapy for SCI. This thesis 
demonstrates that interleukin-33 is a 
promising novel therapeutic approach 
for acute SCI. Special attention is 
paid to the protective role of the 
transcription factor Nrf2 in SCI. 
The thesis also evaluates potential 
therapeutic avenues in the utilization 
of Nrf2 gene transfer and stem cell 
therapy for SCI.
